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Abstract 
Tools  that  allow  cost-effective  screening  of  the  susceptibility  of  cell  lines  to  operating 
conditions  which  may  apply  during  full-scale  processing  are  central  to  the  rapid 
development of robust processes for cell-based therapies. In this study, an ultra scale-down 
(USD) device has been developed for the characterization of the response of human cell 
lines to membrane-based processing, using just a small quantity of cells that is often all that 
is available at the early discovery stage. Key operating conditions investigated were cross-
membrane flow rate, cell age prior to processing and cell concentration (viscosity). The 
impact was evaluated by cell damage on completion of membrane processing as assessed 
by trypan blue exclusion and release of intracellular lactate dehydrogenase (LDH). Similar 
insight was gained from both methods and this allowed the extension of the use of the LDH 
measurements to examine cell damage as it occurs during processing by a combination of 
LDH appearance in the permeate and mass balancing of the overall operation.  
The  main  cell  line  studied  was  a  clinically  relevant  human  fibroblast.  As  expected, 
increased shear rates led to significant increases in rate and extent of cell damage. Cells 
aged (21°C hold for 24 hours) before processing led to a doubling of the extent of damage. 
Increased  cell  concentration  from  1x10
6  to  100x10
6  cells  mL
-1  gave  no  change  in  the 
proportion of cells damaged. Preliminary studies showed that increased shear stress also led 
to morphological changes and the appearance of apoptotic cells post-processing. 
Two other human cell lines were also tested briefly for cell damage; a neural stem cell line 
and a prostate cancer cell line. These appear to be less robust than the fibroblasts with, for 
example ~0%, ~18% and ~42% damage being observed at the lowest shear stress (~44 Pa) 
conditions for fibroblasts, prostate cells and neural stem cells respectively. The effects of 
increasing shear rate, age of cells or concentration varied for each of the cell lines studied.  
Overall, this work suggests how membrane processing may be used for the recovery  of 
human cells for therapy and how USD studies can speed the route to manufacture.    iv 
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Chapter 1.  Introduction 
1.1  Thesis overview 
This thesis will have the following structure: 
Chapter 1 presents a review of the literature of the cell-based therapy bioprocessing 
sector. It covers the advantages and hurdles identified for a range of topics such as types 
of cell-based therapies  and bioprocessing steps. It also highlights the importance of 
understanding the biological characterization of the product. 
Chapter 2 provides a detailed outline of the experimental techniques developed and 
adopted  throughout  this  body  of  work.  Standard  operating  procedures  as  well  as 
equipment and materials used will be presented to allow future execution of these tests 
if required. 
Chapter  3  aims  to  characterize  the  physical  impact  of  USD  membrane  separation 
parameters such as disc speed, cell ageing and cell concentration upon a model human 
fibroblast cell line. 
Chapter 4 describes the translation of a selection of the techniques developed for the 
original cell line for the evaluation of a second and a third cell line (a neuronal stem cell 
line and a prostate carcinoma cell line). 
Chapter 5 presents the evaluation of the effect of cell concentration on recovery of cells 
post-processing using once again the fibroblast cell line. 15 
 
Chapter 6 provides some final concluding remarks and proposes ways forward for the 
project. 
1.2  Introduction to therapeutics 
Historically, therapeutic drugs have played a major role in increasing life expectancy as 
well as improving quality of life around the world. Various types of drug therapies have 
been developed to prevent, eradicate or mask symptoms and diseases.  
Traditional therapies such as insulin hormone for the absorption of glucose in diabetic 
patients or the antibiotic penicillin commonly used for prevention or treatment of some 
bacterial infections, have been available since the 1920s. More contemporary therapies 
include a modern recombinant vaccine to prevent Human Papillomavirus (HPV) types 
16  and  18  under  the  commercial  names  of  Gardasil®  and  Cervarix®  (Bayas  et  al. 
2008);  successful  clinical  transplantation  of  bioengineered  airway  with  the  patient’s 
own  cells  (Macchiarini  et  al.  2008);  or,  even  more  recently,  an  upcoming  cellular 
regeneration therapy, currently in phase II of clinical trials, that aims to reverse the 
functional deficits in stroke patients (Pollock et al. 2006). 
These examples not only target very different diseases but were derived in completely 
different  ways:  microorganisms  (penicillin  and  recombinant  insulin),  virus  (HPV 
vaccine) and human cells (trachea transplant and stroke therapy), and may vary greatly 
in their method of production and administration. 16 
 
1.3  Cell-based therapies 
Contrary to the term ‘regenerative medicine’ which incorporates any methods and/or 
molecules  to  regenerate  cells  or  tissues,  ‘cell-based  therapies’  involve  the  direct 
application  of  cells.  Traditionally,  cells  would  act  as  a  host  or  production  vector 
(producers) for proteins and often undergo total disruption to obtain these products. 
Now the cells themselves have become the product (effectors) and their applications 
vary greatly.  
The U.S. Food and Drug Administration (FDA) defines cell therapy as “the prevention, 
treatment, cure or mitigation of disease or injuries in humans by the administration of 
autologous,  allogeneic  or  xenogeneic  cells  that  have  been  manipulated  or  altered 
ex-vivo” (U.S. Food and Drug Administration 1993). The first cell-based therapy was a 
successfully performed bone marrow transplant between twins in the 1950s and since 
then, different cell therapies have been widely used in modern medicine. More recently, 
in the last quarter of a century, these have experienced a rapid boost, creating a new 
emerging healthcare sector (Kemp 2006; Mason et al. 2011; Nerem 2010). For example, 
ChondroCelet® is a cartilage regeneration cell therapy where the patient’s own cartilage 
cells are biopsied, grown and expanded in the laboratory and then used to treat cartilage 
defects in knees (Saris et al. 2008). It is one of the first examples of a cell-therapy to be 
widely available after completion of the entire development, from research to clinical 
approval, all the way to commercialization.  
Another example is Provenge®. Provenge® is a cellular immunotherapy indicated for the 
treatment  of  asymptomatic  or  minimally  symptomatic  castrate-resistant  hormone 17 
 
refractory  prostate  cancer  (Kantoff  et  al.  2010).  Immune  antigen-presenting  cells 
(APCs) are retrieved from the patient, cultured ex-vivo with a recombinant antigen and 
become fully matured APCs. Once re-injected into the patient, the fully matured APCs 
induce  T  cell  proliferation.  Activated  T  cells  are  able  to  then  recognize  and  attack 
prostatic acid phosphatase (PAP) antigen expressed in prostate cancer cells, resulting in 
an immune response against them (Ward et al. 2002). 
These two examples show just how wide the ranges of methods of action, as well as 
types of cells are encompassed by the term ‘cell-based therapies’. There are four main 
categories of cell-based therapies; 1) cell replacement, such as blood transfusion from 
one or multiple donors into the circulatory system of a patient; 2) tissue engineering 
such as previously mentioned ChondroCelet®, skin grafts grown from skin stem cells to 
treat  patients  who  suffered  extensive  burn  damage  or  the  previously  mentioned 
transplants of fully engineered tracheas with the patient’s own cells (Macchiarini et al. 
2008); 3) stem cell based therapies, such as adult blood stem cells and bone marrow 
transplants  (Thomas  et  al.  1977)  or  more  recently  post-stroke  rehabilitation  therapy 
ReN001 (Pollock et al. 2006); to 4) fully differentiated cell-based therapies, such as 
whole-cell  cancer  vaccines  including,  amongst  others,  immunotherapy  Provenge® 
(Kantoff et al. 2010; Ward et al. 2002).  
The different nature of each cell-based therapeutic application can determine the source, 
classifying all therapies into two broader categories; allogeneic (cells from a donor) and 
autologous (patient’s own cells). 
1.3.1 Allogeneic versus autologous therapies 18 
 
An allogeneic cell therapy is where a patient receives cells from a donor, i.e. not the 
patient’s own cells. Human leukocyte antigens (HLAs) are found on the surface of all 
types of cells and identify whether an object is foreign or known to the body. If the 
object is foreign, then the immune system is alerted to neutralize the perceived threat. 
For this reason, for an allogeneic therapy to be successful, it needs a degree of genetic 
match or similarity and immunosuppressants unless the immune response is what is 
needed. 
On the other hand, autologous refers to cells or tissues that are re-implanted back into 
the individual from which the original tissue or cell type was sourced; in effect being 
one’s own ‘donor’. This this type of treatment is therefore preferred in certain cases for 
various  reasons,  for  example,  the  fact  that  there  is  no  need  to  provide 
immunosuppression products because the therapy is immune compatible. A common 
example of autologous choice for a therapy is when dealing with solid tumors as is the 
case with whole-cell cancer vaccines (Provenge® and OncoVAX®). 
Both types of therapies have several advantages and drawbacks that make them more or 
less suitable for specific applications. For example, for autologous therapies, the amount 
of  cells  required  and  the  high  economic  costs  incurred  by  the  patient  specific 
bioprocessing are great challenges yet to be addressed (Mason and Hoare 2006). With 
allogeneic therapies however, the main issue lies on the fact that the donor used in the 
transplant has to present a close genetic match to the patient and as a result the number 
of potential donors is limited.   19 
 
Over the past few decades both autologous and allogeneic cell therapies have become 
rapidly evolving fields. As life expectancy in developed countries increases, the need 
for  replacement  body  tissues  as  well  as  the  search  for  disease  eradication  is 
ever-growing. Currently, much of these forms of therapies are under investigation either 
in the laboratory or in clinical trials. Several treatments are being put into practice such 
as the previously mentioned clinical transplantation of tissue-engineered airways with 
the patient’s own cells (Macchiarini et al. 2008) and autologous serum for treatment of 
ocular disorders (Liu et al. 2005).  The potential of cell-based therapies is slowly being 
unmasked,  but  to  fully  understand  the  different  therapies,  it  is  important  to  first 
understand the hierarchy of cells and their characteristics. 
1.3.1  Cell hierarchy 
There are hundreds of different types of fully differentiated cells (such as skin, blood or 
brain) which have specific functions and characteristics that make them suitable for 
their  specific  roles.  For  example,  skin,  blood  or  brain  cells  all  have  very  different 
morphologies  (i.e.  elongated  without  spikes,  round,  and  elongated  with  spikes 
respectively).  
The different types of fully differentiated cells arise through cellular differentiation of 
less specialized adult stem cells. Adult stem cells are themselves the product of cellular 
differentiation of embryonic stem cells. Embryonic stem cells are the product of cellular 
differentiation of the zygote and blastocysts. This “hierarchy” of development is based 
on the cell’s ability to differentiate into different cell types; from totipotent (cells that 20 
 
can  differentiate  into  all  cell  types  that  make  an  organism)  to  unipotent  cellular 
organisms (those that can only give rise to one specific cell lineage).  
Figure 1.1 was adapted from Quante and Wang (2009) and shows the different stem cell 
hierarchies and differentiation potential of various types of cells - including those cell 
lines used in this study. Cells removed from the embryo up to (and including) the eight 
cell stage are known as totipotent cells, as they hold the capacity to develop into any 
form of human tissue including the trophectoderm. The trophectoderm comprises the 
placenta and umbilical cord. Cells removed from the inner cell mass of the blastocyst, 
i.e. past this eight cell stage, are known as pluripotent as they can differentiate into any 
of  the  three  main  germ  layers  (mesoderm,  ectoderm  and  endoderm).  Mesoderm 
comprises muscle, blood and bone lineages; ectoderm includes skin, ocular and neural 
lineages and the endoderm comprises internal and reproductive organs. Adult stem cells 
found within the tissue of these three germ layers hold potential to differentiate into 
cells of that specific germ layer only. Finally, in the past decade, induced pluripotent 
stem  cells  (iPS  cells)  have  emerged  as  an  alternative  renewable  supply  from 
reprogrammed somatic cells (Takahashi et al. 2007). 
The vast number of cell types and stages of differentiation means the mode of action 
and types  of cell-based therapies  will vary  greatly on the cells  used.  The next  few 
sections explain the mode of action of cell-based therapies based on the three main 
categories previously outlined; whole-cell cancer vaccines, stem cell based therapies 
and tissue engineering. 
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Figure  1.1:  Potency  hierarchies  and  differentiation  potential  of  various  types  of  cells  including 
those cell lines used in this study. Adapted from Quante and Wang (2009). 
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1.3.2  Whole-cell cancer vaccines 
Tumours may harbour many hundreds of different mutations which may be specific to 
tumour type or to an individual tumour (Haber and Settleman 2007). In light of the 
emergence of this data, the mechanisms used by the immune system to fight tumour 
cells  are  being  understood.  Therapies  targeting  a  single  antigen  are  slowly  being 
replaced  with  multi-valent  therapeutic  strategies  (Copier  et  al.  2007).  For  example, 
whole tumour cells could act as potent vehicles to target many antigens at once and 
therefore may offer a potential solution. Many vaccines focused on treating existing 
cancer have started to emerge, such as melanoma,  colorectal, ovarian  (Copier et al. 
2007; Gruijl et al. 2008) and prostate carcinoma, as is the case of Onyvax-P vaccine 
(Onyvax Ltd) which includes one of the cell lines used in this study. 
The increased potential shown by whole-cell cancer vaccines is due to the fact that these 
are made from actual cancer cells which act by enhancing the anti-tumor immunity over 
an extended period of time, by continuously secreting target antigens for the immune 
system to respond to (Ward et al. 2002). Whether an allogeneic or autologous approach 
is preferred, the method of action of the vaccine is essentially the same.   
The immune system has two lines of defense that work in a highly cooperative manner; 
innate and adaptive immune system. The innate immune system is a non-specific set of 
disease-resistance  mechanisms  that  act  as  the  first  line  of  defense  and  generally 
eradicates  most  of  the  microorganisms  encountered  by  an  individual.  The  adaptive 
(specific)  immune  response  is  triggered  by  the  innate  immune  system  if  a 
microorganism is not cleared by the non-specific mechanisms. Both lines of defense are 23 
 
composed of several types of cells and proteins that will trigger reactions to deal with 
foreign threats (Goldsby et al. 2007). 
Potentially,  the  immune  system  can  therefore  be  triggered  by  “mimicking”  threat 
signals. For instance, Natural Killer (NK) cells are a type of lymphocyte of the innate 
system that if activated with specific ligands found in tumour cells, can generate potent 
immunity  that  could  be  used  for  whole  cell  vaccination  (Diefenbach  et  al.  2001). 
Therefore, adjuvants administered or actions of NKs, act as a “danger” trigger signal 
(for  example  in  the  form  of  inflammatory  cytokines)  that  is  perceived  by  antigen-
presenting cells (APCs). APCs incorporate the antigen and migrate to the lymphoid 
tissue, where thanks to the conditioning and cross priming of T helper cells, anti-tumour 
cytotoxic T-lymphocytes (CTL) are created. An attack on the specific antigen from 
tumour cells by CTLs is triggered after the latter have been released from the lymphoid 
tissue. 
The key element of these vaccines is therefore the potency. The vaccine can present an 
array of antigens, in the case of Onyvax-P, provided by a combination of tumour cell 
lines  at  different  stages. The production challenges  therefore lie on maintaining the 
quality of the cells that comprise the vaccines to ensure the potency is not compromised. 
1.3.3   Stem cell therapies 
The unique regenerative capabilities of stem cells offer a promising alternative for the 
treatment  of  genetic  and  immunological  diseases.  Their  capacity  for  self-renewal, 
immortality and ability to differentiate into the entire range of lineages means stem cells 24 
 
can provide an endless and renewable source of cells for therapies (Ameen et al. 2008; 
Choumerianou et al. 2008). As was described in section 1.3.1, stem cells include adult, 
hESCs’ and iPS cells.  
Fetal and adult stem  cells  are used in  treatments  in  which they  may be  induced to 
differentiate into the specific cell types required to repair damaged or destroyed cells or 
tissues. This is the case of the previously mentioned post-stroke rehabilitation therapy 
ReN001, currently in Phase II of the clinical development. It is the first fetal neural stem 
cell-based treatment that consists of the transplantation of a conditionally immortalized 
clonal  neural  stem  cell  line  derived  from  human  somatic  stem  cells,  CTX0E03, 
(ReNeuron Group plc.) and administered into the patient’s brain (Pollock et al. 2006). 
Other examples of stem cells as potential sources for therapies include hematopoietic 
transplantation  and  reconstitution  (Farge  et  al.  2010;  Passweg  et  al.  2013), 
mesenchymal stem cells for bone repair (e.g. Oeteocel® from NuVasive® Inc.) and 
autologous  ocular  (limbal  epithelial)  stem  cell  expansion  and  transplantation 
(O'Callaghan and Daniels 2011). 
hESCs’  longevity  and  the  capacity  to  produce  a  wide  range  of  cells  make  them  a 
promising source of cells for therapies for the future. Several biological challenges are 
yet to be addressed with hESCs’, such as tightly controlling the differentiation of the 
cells,  the  need  to  develop  adequate  methods  for  separating  differentiated  from 
non-differentiated cells whilst ensuring they are genetically stable or the need to ensure 
pluripotency is maintained.  25 
 
The iPS cells provide a potential alternative for a renewable supply of stem cells from 
reprogrammed  somatic  cells  (Takahashi  et  al.  2007).  Ethically  and  morally,  these 
present  a  much  better  alternative  to  the  destruction  of  an  embryo.  However,  their 
derivation efficiency remains very low and tight control of the differentiation is also an 
issue.  On  the  other  hand,  Geron  has  treated  5  patients  with  their  spinal  cord  trial 
regeneration and they displayed no adverse effects. 
However, many challenges still need to be addressed before stem cell-based therapies 
are feasible and safe to use in patients. For example, the pluripotency characteristic that 
makes stem cells ideal candidates for therapies, also proposes a major challenge. The 
unlimited differentiation has a carcinogenic propensity which is a major concern. From 
a more practical point of view, fully differentiated cells present several advantages to 
stem cells. With stem cells, the culture complexity increases, the cells grow in colonies 
and the growth rates are slower than for fully differentiated cells. For instance, a 1 into 
8 split of fully differentiated human fibroblasts takes the same time and yields 5 times 
more cells as a 1 into 2 split of hESCs’. Nevertheless, recent development of techniques 
to  grow  hESCs’  in  culture  are  aiding  scientists  to  expand  the  understanding  of  the 
pathways of cell differentiation and thus the horizon of likely therapeutic uses (Halme 
and Kessler 2006).  
1.3.4  Tissue engineering 
Tissue  engineering  refers  to  the  field  that  uses  a  combination  of  cellular  material, 
biocompatible resources to build a scaffold and biochemical (e.g. growth factors) and 
physical  (e.g. mechanical loading) factors to create tissue-like structures (Bell et al. 26 
 
1981). The cellular material may either be an autograft (redistribution of patient’s own 
tissue) or an allograft (implantation of tissue from another source). The scaffold (or 
matrix) replicates the biological and mechanical properties as well as the functions of 
human  body  tissues.  In  most  cases,  the  ultimate  goal  of  tissue-like  structures  is 
implantation of the tissue construct into the body to  repair an injury or replace the 
function (e.g. structural, biochemical or barrier and transport related functions) of a 
failing organ. 
The  first  cell-based  tissue-engineered  product  marketed  was  Epicel  (Genzyme, 
Cambrige, MA). Epicel consists of sheets of autologous keratinocytes that are used to 
cover patients suffering from severe cutaneous burn injuries who do not have enough 
viable  skin  remaining  to  be  treated  with  traditional  autografting  techniques.  Other 
similar  skin  graft  products  approved  by  the  U.S.  FDA  include  Integra  Dermal 
Regeneration Template (Burke et al. 1981), Apligraft® (Organogenesis, Canton, MA) 
and TransCyte (Smith & Nephew). However, tissue-engineering has not only focused 
on skin graft products. In the last decade, the first tissue-engineered whole trachea organ 
was  successfully  transplanted  into  a  patient  (Macchiarini  et  al.  2008).  This  led  to 
increased efforts and rapid advancements with other organs such as heart, liver and lung 
tissues  (Farge  et  al.  2010;  Saris  et  al.  2008;  Uygun  et  al.  2010).  Efforts  have  also 
focused on cartilage regeneration (TruFit, Smith & Nephew Endoscopy, San Antonio, 
TX). 
However,  despite  the  advancements  in  the  field  major  hurdles  still  prevail.  The 
complexity  of  tissue-engineering  means  deep  understanding  of  the  effect  of  myriad 27 
 
factors on the development as well as the sustainability of the tissues and organs is 
needed (Berthiaume et al. 2011). Issues still to overcome include provision of functional 
vascular  supply,  control  of  the  complex  arrangement  of  different  cell  types  in  3D 
structures, identification of reliable cell sources and scalability of the manufacturing 
process.  
1.4  Cell bioprocessing at full scale 
Bioprocessing refers to  the translation  from  a life-science discovery into a practical 
product.  It  is  the  critical  link  between  discovery  stages  (including  research  and 
development) and commercialization (manufacturing) (Zaborsky 1995). Depending on 
the  nature  of  the  cells,  different  therapies  will  require  different  bioprocessing 
techniques. However, all cell-based products have a similar process as shown in Figure 
1.2.A. It shows a simplified generic bioprocess flowsheet for a whole-cell therapy. It 
begins with the production of the cellular material (upstream) and continues with the 
recovery, purification and formulation (all downstream) of the final  product.  Figure 
1.2.B shows an example of a manufacturing process used by Onyvax Ltd for production 
of the cell line constituents of the Ony-P whole cell prostate cancer vaccine. For each 
batch  produced,  three  40-layer  cell  factories  were  harvested  at  ~70%  confluency, 
enzymatically  detached,  washed,  concentrated  and  formulated  following  the  process 
flow stream shown in Figure 1.2.B. 
The ability to provide cell-based therapies to a wide range of patients ultimately relies 
on the capacity of large scale bioprocessing to yield high number of cells of acceptable 
quality (Rowley et al. 2012c). However, the inherently complex nature of the biological  28 
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Figure 1.2: Process flowsheets for a generic bioprocess for a whole-cell therapy and therapy specific 
manufacturing process. 
 
Figure 1.2: Process flowhseet for (A) a generic bioprocess for a whole-cell therapy (Lapinskas 2010) 
and (B) therapy specific manufacturing process used by Onyvax Ltd for production of cell line 
constituents of the Ony-P prostate cancer vaccine.  
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material  makes  applying  current  Good  Manufacturing  Practice’s  (cGMP)  to  the 
bioprocess  a  challenging  task.  Cells,  as  living  organisms,  can  trigger  responses  to 
physical and chemical changes in the processing environment (Agashi et al. 2009; Al-
Rubeai et al. 1995; Kretzmer and Schügerl 1991). Therefore bioprocessing will impact 
the quality of the end product, rendering the process and product inseparable (Mason 
and Hoare 2007).  
Ideally, to facilitate cGMP-compliant manufacturing of cell-based therapies for clinical-
scale expansion, the entire process from cell culture to post-culture processing would be 
completely closed and automated (Rowley et al. 2012a). Moreover, if the automated and 
closed system delivers a product suitable for storage and ready for use or administration 
in  a  clinical  setting,  the  risk  of  variability  and  microbial  contamination  would  be 
reduced significantly (Rowley et al. 2012a).  For this reason, adopting a Quality by 
Design (QbD) approach has become essential for cell-based products that are in the 
development process. A critical component of QbD is to understand what the product 
needs to do in order to create a Target Product Profile (TPP) as well as to identify the 
needs of the patient. TPP characteristics may include composition and dose (such as cell 
types  and  formulation),  function  (for  example  immunomodulary,  surgical 
implementation or targeting) and logistics (shell life and cold chain supply). Therapy 
specific  cell  quality  attributes  (CQAs)  to  do  with  clinical  safety  and  efficacy  are 
established in order to easily identify potential areas of significant change in cell quality 
(Arora et al. 2009). QbD approach can be maintained throughout the lifecycle of the 
product to ease innovation and encourage continuous improvement.  30 
 
1.4.1  Upstream processing 
The production of the cellular material (upstream processing) depends on the nature of 
the  therapy.  Various  techniques  are  currently  used  and  some  of  the  issues  will  be 
addressed in this section.  
1.4.1.1  Cell line selection 
Cell line selection will vary according to the type of therapy.  Immunogenicity, cell 
function, availability, proliferation potential and whether the therapy will be autologous 
or allogeneic are some of the factors to consider during cell line selection. If a specific 
cell  line  demonstrates  suitability  for  a  therapy  but  its  fragility  during  processing 
compromises its ability to function, it may be deemed as unusable.  
The cell source can vary greatly depending on location of the biopsy, cell type (stem 
cells,  fully  differentiated,  tumour  cells,  etc)  and  even  surgical  practitioner.  The 
characteristics  of  different  sources  of  cells  will  impact  on  their  susceptibility  and 
adaptability to processing. In this study, three different cell lines were used; human 
neonatal  foreskin  fibroblasts  for  skin  graft  translational  purposes  (HCA2),  an 
immortalized clonal neural stem cell line (CTX0E03, ReNeuron Group plc) derived 
from human somatic stem cells and a fully differentiated early stage prostate carcinoma 
cell line (P4E6, Onyvax Ltd.). Factors such as ease of culture (assessed on criteria such 
as  colony  formation  and  need  for  a  feeder  layer),  concentration  of  viable  cells  at 
harvest, robustness during processing and relevance to the cell-based therapy industry 
were considered when choosing the cell lines for this study (Table 1.1).   31 
 
 
Table 1.1: Comparison of cell lines used in this thesis (HCA2, P4E6 and CTX0E03) and other 
relevant cell types used in the industry (MSCs and hESCs). The information for this table was 
gathered from various sources in collaboration with Dr. Lawrence and Longster, UCL  (Acosta-
Martinez et al. 2010; Delahaye 2013; McCoy et al. 2010).  
  P4E6  HCA2  MSC  CTX0E03  hESC 
Therapeutic relevance  Cancer 
vaccine 
Tissue 
engineering 
Autologous 
therapies 
Post-stroke 
repair 
Allogeneic 
therapies 
Mean cell diameter 
in suspension 
15µm  15µm  15µm  15µm  15µm 
Culture complexity  ***  ***  ****  ****  ***** 
Surface attached  Yes  Yes  Yes  Yes  Yes 
Ability to differentiate  No  No  Multipotent  Multipotent  Pluripotent 
Control of 
differentiation 
N/A  N/A  √  √√  √√√ 
Purify differentiated  
from non-differentiated? 
N/A  N/A  Yes  No  Yes 
QC analysis: 
  Cell viability 
  Cytokine 
expression 
  Surface markers 
 
 
√ 
 
√ 
 
√ 
 
 
√ 
 
√ 
 
√ 
 
 
√ 
 
√ 
 
√ 
 
 
√ 
 
√ 
 
√ 
 
 
√ 
 
√ 
 
√ 
Susceptibility to stress  ***  ***  TBD  TBD  TBD 
Telomere activity  Finite  Finite  Indefinite  Indefinite**  Indefinite 32 
 
1.4.1.2  Cell culture and growth methods 
Anchorage dependent or adherent cells are those cells that require a surface to attach in 
order to grow and proliferate. These cells are usually derived from organ tissues and 
therefore are immobile and embedded in connective tissue. The following sections will 
review some of the platforms available for adherent cell culture 
1.4.1.2.1  Two-dimensional platforms 
Traditional  two-dimensional  manufacturing  platforms  refer  to  planar  tissue-
culture-treated  surfaces  (such  as  plates  or  flasks).  Tissue-culture  flasks  (T-flasks) 
surface areas range from approximatedly 5 to 175 cm2, yielding different number of 
cells depending on the cell line used. Generally, for a surface area of 175 cm2, around 
20x106 cells will be harvested at 80% confluency for cell lines such as the HCA2 and 
P4E6. For the neural stem cells, CTX0E03, approximately 10x106 will be harvested for 
the same surface area and confluency. Multilayered flasks or cell factories have been 
used for larger-scale expansion of adherent  cells to progress  allogeneic cell therapy 
products into mid to late clinical development (Rowley et al. 2012c). Good examples of 
these include Cell Cube and the CellSTACK (Corning, New York, USA) as well as the 
Cell Factory (Nunc, Thermo, Strasbourg, France). These platforms increase the number 
of growth surfaces available by stacking layers on top of each other, offering surface 
growth areas up to 25,000 cm2 (Brandenberger et al. 2011). However, commercial lot 
sizes for allogeneic “off-the-shelf” therapies based would require  ~1010 – 1012 cells 
(Brandenberger  et  al.  2011).  This  means  large  clean  rooms  or  even  entire  clean 33 
 
buildings would be needed as well as a large number of operators or robotic platforms 
(Rowley et al. 2012c). 
Cell culture in these two-dimensional platforms is labour intensive, not contained and 
operator dependant. On top of this, due to the inherent variability of cells, fluctuations 
in  the  culture  medium,  materials  or  operating  conditions  can  have  an  effect  on  the 
quality  of  the  cells  harvested.  Automation  of  cell  culture  decreases  the  number  of 
operators needed, removes the operator variability and allows for cell cuclture to happen 
in a closed environment. Several autoamted cell culture platforms are commercially 
available  such  as  CellmateTM  and  SelecT  (The  Automation  Partnership,  Sartorius 
Stedim, UK). CellmateTM
 was developed in the late 1980’s to work with 20 up to 1,000 
flasks and roller bottles with 10 different cell lines in parallel (Kempner and Felder 
2002). SelecT system is a more recent version of a fully automated cell culture system 
which includes a robotic arm which can access an incubator of a capacity of 90 T-175 
flasks. The system can also incorporate an automated cell counting machine within the 
laminar  flow  safety  cabinet  (Thomas  et  al.  2009).  However,  automated  cell  culture 
platforms have not been extensively used due to the high capital investment and their 
complexity with respect to cell line adaptation.  
Attempts  have  been  made  to  culture  anchorage  dependant  cells  in  more  contained 
three-dimensional  platforms  which  would  yield  higher  numbers  of  clinically  viable 
cells,  such  as  bioreactors  with  suspension  microcarries  and  hollow  fibre  perfusion 
cultures. 
1.4.1.2.2  Three-dimensional platforms 34 
 
Stirred  tank  bioreactors  (STRs)  are  generally  associated  with  traditional  industrial 
processes such as fermentation (Wendt et al. 2009). However, over the last decade, the 
importance to shift two-dimensional cell culture into three-dimensional platforms has 
gained increased recognition. Conventional STRs are well defined and characterized 
systems with highly effective monitoring and performance control (Want et al. 2012). 
However, cell culture within three-dimensional platforms introduce an array of new 
scientific and technical challenges associated with the complex nature of human cells 
(Wendt et al. 2009). Want et al. (2012) presents a review of the efforts to grow human 
pluripotent  stem  cells  in  three-dimensional  platforms  compared  to  two-dimensional 
traditional culture. He also gives an overview of the hurdles that these technologies face 
in order to provide standardized, scalable and efficient processes in terms of number of 
clinically  relevant  cells  produced  (i.e.  cells  that  maintain  critical  biological 
functionality).  
Unlike  some  selected  cell  lines  such  as  hESCs,  most  adherent  cells  do  not  form 
agglomerates (embryoid boides) when in culture. Most therapeutic cell lines in fact, 
require  a  growth  substrate  such  as  microcarriers.  Microcarriers  are  small  particles, 
usually spherical, made of either natural (e.g. collagen or gelatin) or synthetic (such as 
polyethylene or glass) matrices that offer an increased surface-area-to-volume ratio over 
traditional static cultures, increasing the cell density at harvest and reducing the overall 
footprint (Rowley et al. 2012c). Microcarriers can present a solid or porous structure 
(such as CytodexTM and Cultispher® S respectively) to which the cells attach to in order 
to grow. The use of bioreactors with suspension microcarries for cell culture also allows 
increased  online  control  and  automation  of  the  culture’s  environment.  Kehoe  et  al. 35 
 
(2010) described various modes in which scalable STRs can be employed to cultivate 
hESCs, human iPSCs and various stem cell  applications to date  which have shown 
promising results (Serra et al. 2010). 
However,  major  concerns  for  cell  culture  in  STRs  still  prevail.  These  include  cell 
damage  due  to  the  stress  induced,  wether  the  stress  is  from  the  energy  released  as 
bubbles burst or the high levels of agitation resulting in intense hydrodynamic forces 
(Al-Rubeai et al. 1995; Hu et al. 2011), due to bead to bead collisions (Fernandes et al. 
2007), harvesting issues (Varani et al. 1985) and seeding consistency from bead to bead 
(Ng et al. 1996). 
Commercially available and attractive closed systems alternative to microcarrier STRs 
include  wave  bag  technology  (Sartorius  BIOSTAT®  Cultibag),  perfusion  reactors 
(Aastrom  Replicell,  (Bartel  et  al.  2012)  and  hollow  fibre  perfusion  culture 
(QUANTUM® Cell expansion system). Small scale research tools are also available for 
three-dimensional cultures including ambrTM micro bioreator (Glen et al. 2013). 
1.4.2  Downstream processing 
Following cell culture, the harvested cells require downstream processing to become a 
suitable therapeutic product for delivery. Downstream processing includes a wash step 
for removing unwanted residual culture components, a volume reduction  step and a 
buffer  exchange  step  to  formulate  cells  ready  for  direct  administration  or  storage 
(Rowley et al. 2012b). Ideally, all these steps are performed within an aseptically closed 
system that it is simple to automate and scale, that minimizes mechanical disruption of 36 
 
the cells and ensures high cell quality and unperturbed function (Brandenberger et al. 
2011; Pattasseril et al. 2013).  
The  following  sections  will  address  the  major  techniques  traditionally  used  for 
downstream  processing  (centrifugation  and  filtration),  and  a  most  recent  technique 
known as continuous centrifugation (KSep®, KBI Biopharma, Durham, North Carolina, 
USA).  
1.4.2.1  Centrifugation 
Centrifugation is a crucial and widely applied technique both in research as well as 
industrially  for  the  processing  of  biologicals  and  biopharmaceuticals.  In  cell-based 
therapies from pilot to industrial scale, it is commonly used batchwise in several stages 
of the bioprocess for the separation of cells from solution. For instance, during harvest, 
the cells are separated from media or detachment enzyme or further downstream from 
cryopreservants or buffers. Due to its popularity within the industrial sector,  efforts 
have focused on providing small scale tools to predict the impact of key processing 
conditions (Delahaye 2013; Hutchinson et al. 2006; Tait et al. 2009; Zoro et al. 2009). 
Centrifugation  has  remained  popular  mainly  due  to  its  low  running  costs, 
straightforward process development and desired operating robustness (Axelsson 2002). 
However, it presents several downfalls, especially for the cell-based therapy industry. It 
is  a  poorly  contained  processing  step,  heavily  operator  dependent  and  prone  to 
contamination.  In  fact,  in  view  of  the  literature,  centrifugation  has  proven  to  be  a 
difficult step to automate while maintaining sterility (Mason and Hoare et al., 2006).  37 
 
When dealing with cell-based therapies, it is not uncommon to expect concentration 
factors in the region of 25 fold, ideally with the least possible number of purification 
steps to decrease the mechanical manipulation. As volumes and lot sizes increase, going 
from lab to clinical trials and commercial scale, tens of litres of cellular suspensions will 
need  to  be  handled  downstream  (Pattasseril  et  al.  2013).  For  the  traditional  batch 
centrifuge, this would require an increased number of iterations with several operators 
to process larger volumes (Pattasseril et al. 2013). To accommodate the demands of the 
industry and hoping to provide a suitable alternative, several technologies combining 
principles from centrifugation and filtration have emerged. 
1.4.2.2  Continuous centrifugation 
Continuous centrifugation techniques for the downstream processing of whole cells for 
therapy, potentially offer a low shear and contained alternative to batch centrifugation. 
These alternatives include systems such as Elutra® Cell Separation System (Gambro 
BCT,  Lakewood  CO,  USA),  CARR  UniFuge®  (PneumaticScaleAngelus,  Barry-
Wehmiller,  St  Louis,  Missouri,  USA)  and  kSep®  (KBI  Biopharma,  Durham,  North 
Carolina, USA).  
KSep® in particular offers a low shear, closed, scalable and continuous system capable 
of processing high volumes of cell harvest while maintaining critical quality parameters 
(Pattasseril et al. 2013). The capital expense to place a system like kSEP® for cGMP 
operation can range from US$200,000 to US$700,000. High capital cost, coupled with 
high  costs  for  process  development  due  to  the  large  number  of  cells  required  for 38 
 
meaningful development runs (Pattasseril et al. 2013), mean that the success of this 
development even though promising, is still under scrutiny (James 2011). 
1.4.2.3  Filtration 
Filtration offers an alternative away from centrifugation altogether. It has been widely 
used in many industries and forms an integral part of the biopharmaceutical sector. Its 
uses range from the separation of whole cells (and fragments of cells) from the target 
protein within the liquid phase to viral clearance for mammalian cell processes viral 
clearance step (Wang 2001). Filtration works on the principle of physical separation of 
solid particles from a fluid-solid mixture according to size, by forcing the fluid through 
a filter-medium (Doran 1995). If the driving pressure differential is held constant, then 
the  rate  of  filtration  will  decrease  with  time  as  the  resistance  to  flow  through  the 
membrane increases with progressive fouling (Perry and Green 2008). If the flux is kept 
constant then the transmembrane pressure (TMP) will increase as a result of progressive 
fouling (Perry and Green 2008). Therefore, the performance of a filtration process is 
governed by the fouling of the membrane. Fouling occurs when solids are deposited on 
the  filter  (i.e.  cake  formation)  or  due  to  adsorption  and  clogging  within  the  pore 
structure  (i.e.  pore  blocking,(Doran  1995)  and  is  largely  dependent  on  the  type  of 
operation of the filtration. Filtration is separated into two principal modes; normal flow 
filtration (NFF) and tangential flow filtration (TFF). 
NFF,  also  known  as  dead  end  filtration,  operates  with  the  slurry  flowing  into  the 
membrane (i.e. flow is perpendicular to the membrane, Figure 1.3.A). Particles and 
components which are smaller than the pores of the membrane will permeate through, 39 
 
whereas  those  larger  than  the  pores  will  be  retained.  NFF  is  typically  used  for 
suspensions with very low solid concentrations due to fouling of the filter. In the last 
decade, some studies have focused on the application of NFF to cell-based therapies. 
For instance, Sowemimo-Coker et al. (2009) described a NFF process for achieving 
volume  reduction  and  red  blood  cell  depletion  in  a  closed  and  sterile  manner.  The 
investigation focused on reducing the loss of haematopoietic stem and progenitor cells 
to a minimum. 
The second mode of operation is TFF, also known as cross-flow filtration. In TFF the 
fluid flow travels tangentially across the surface of the membrane (Figure 1.3.B) rather 
than into the filter. This can reduce the extent of surface fouling as the filter cake is 
constantly washed away during the process, increasing the length of time that a filter 
unit can be operational. Unlike NFF, TFF can be also operated in a continuous manner 
which can be of great advantage when dealing with large volumes of filtrate material 
(Pattasseril  et  al.  2013).  With  respect  to  the  cell  bioprocessing  industry,  TFF  is 
becoming  increasingly  popular.  Wash  phases  can  be  incorporated,  with  diafiltration 
using  volumes  of  wash  buffer  relative  to  the  initial  feedstock  volume  to  remove 
contaminants  carried  through  from  upstream  (cell  expansion  and  harvest  phases). 
Moreover, TFF can also incorporate the concentration of cellular material and buffer 
exchange, all into one enclosed step without the need of resuspension. Certain obstacles 
remain such as how to achieve high cell recovery, viability and functionality throughout 
this phase (Brandenberger et al. 2011). Successful and efficient TFF operation relies on 
finding  a  balance  between  increased  feed  flow  rates  to  maintain  performance  by 
reducing fouling and the creation of a high shear environment which can induce  40 
 
 
Figure 1.3: Schematic diagram of (A) normal flow filtration (NFF) and (B) tangential flow filtration 
(TFF) arrangements (Perry and Green 2008).   41 
 
secondary  flow  patterns  that  can  lead  to  considerable  cell  damage  (Maiorella  et  al. 
1991).  Rowley  et  al.  (2012a)  presented  a  method  for  aseptically  processing  live 
mammalian  cells  in  aqueous  medium  to  yield  a  cellular  suspension  of  a  final 
concentration of 5x106 cells mL-1 with at least 90% cell viability and 90% yield of 
starting cells. The method includes volume reduction using TFF whilst maintaining the 
TMP at less than about 5 psi, shear rate at less than 4,000 s-1 and transmembrane flux 
rates in between 50 and 100 LMH (Rowley et al. 2012a).  
Membrane selection will also play a vital role during filtration. Chemical interactions 
(such as electrical charge or hydrophobicity repulsion) and pore size of the membrane 
are some of the characteristics to take into account. The membranes are typically flat 
discs or bundles of porous hollow fibres within a cartridge (Chang and Fane 2002) and 
are usually made from materials such as polyethersulfone, polysulfone or polypropylene 
(van Reis  and Zydney  2001).  However, filtration has  evolved mainly  as  a practical 
exercise rather than strictly from theory (Perry and Green 2008). Therefore, unless exact 
data is available, small-scale tests must be performed to aid in the selection of filter 
material  and  to  determine  the  size  needed.  Established  systems  (such  as  GE 
Healthcare’s  ÄKTAcrossflow™  unit)  facilitate  the  lab-scale  development  of  these 
techniques. 
1.4.2.3.1  Theory of flow through filters and transmission 
At any given point during filtration, the rate of filtration is mathematically described by: 
?? =
 󱑽
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where ‘𝑣’ is the velocity of flow through the filter, ‘𝑎’ is the filter area, ‘∆?’ is the 
pressure drop across the filter, ‘𝜇’ is the dynamic viscosity of the filtrate, ‘𝗼’ is the 
average specific cake resistance, ‘?’ is the total mass of solids in the cake and ‘𝑟’ is the 
filter medium resistance. From this equation a basic understanding of the instantaneous 
mass transfer across the filter (rate of filtration per unit area) as a function of the driving 
force  and  the  combined  resistances  can  be  obtained  (Doran  1995;  Perry  and  Green 
2008).  
For  cell-based  products,  the  cells  themselves  are  the  end  product  which  means  the 
filtration step often focuses on the removal of contaminants. For this study in particular, 
the release of a specific intracellular protein will be measured to assess cell damage. 
Therefore, understanding the transmission of this protein through the membrane into the 
permeate will be crucial. Transmission at any given time ‘𝑡’ is given by: 
𝑇(𝑡) = 
[?](𝑡)
[?](𝑡)          Equation 1.2  
where ‘𝑇(𝑡)’ is the transmission of the protein investigated at time ‘𝑡’ and ‘[?](𝑡)’ and 
‘[?](𝑡)’ are the concentrations of the protein in question at time ‘𝑡’ in the permeate and 
the retentate respectively. Therefore, 100% transmission means equal concentrations of 
the protein in both the retentate and the permeate, i.e. all the protein is permeating 
through and none is being rejected or retained by the membrane. Equation 1.2 will be of 
particular interest as transmission can vary depending on the operating conditions. For 
example, lower shear rates can lead to higher deposition of solids on the membrane 
which can lower transmission. 43 
 
1.4.2.3.2  Bioprocessing stresses during TFF 
At this stage, the basic theory of TFF and its applicability to cell-based therapies has 
been presented and reviewed. In this section, the nature of the most common stresses 
encountered during processing are presented and reviewed with a focus on how these 
can impact critical cell quality attributes (CQAs). Careful identification, understanding 
and control of these factors must be put in place to ensure successful delivery of safe 
and efficient therapeutic products. 
A recurring topic in the cell bioprocessing industry is the importance of preserving cell 
quality,  functionality,  viability  and  yield  throughout  the  production  of  a  cell-based 
therapy (Brandenberger et al. 2011). Hydrodynamic stresses experienced by the cellular 
material throughout the various processing steps may destroy cells completely or induce 
physiological responses such as programmed cell death without any obvious physical 
damage (Chisti 2001; Veraitch et al. 2008; Zoro et al. 2008). Parameters such as shear 
rate, critical shear stress (Acosta-Martinez et al. 2010), average wall shear rate (Ma et 
al. 2010) and specific power dissipation have been used to predict and understand the 
nature of the forces affecting cell quality. Flow behavior is what will ultimately define 
the stresses encountered by the cellular material and flow behavior is governed by the 
viscosity of the fluid.  
Viscosity is defined as the fluid’s resistance to flow (Doran 1995) and it is a parameter 
of  particular  relevance  to  TFF.  This  is  because  as  the  concentration  of  the  cellular 
suspension increases, the viscosity of the fluid also increases, constantly changing the 
shear stress experienced by the cells. To further understand this concept, consider the 44 
 
development of laminar flow between two parallel plates not far from each other. When 
the lower plate is moved steadily whilst the upper one remains stationary, a steady 
Couette flow profile is  attained  (Doran 1995).  The force applied to  move the plate 
divided by the area of the plate is defined as shear stress: 
𝜏 =
?
𝑎          Equation 1.3    
where ‘𝜏’ is the shear stress (Pa), ‘?’ is the shear force (kg m s-2) responsible for the 
motion of the plate and ‘𝑎’ is the area of the plate. Shear stress is therefore the gradient 
described by: 
𝜏 ∝ ? ∝
𝑑𝑣
𝑑𝑦        Equation 1.4 
where  ‘
𝑑𝑣
𝑑𝑦’  is  called  the  shear  rate,  usually  denoted  as  ‘𝗾’  (s-1).  Therefore,  the 
proportionality given in equation 1.4 is represented by Newton’s law of viscosity: 
𝜏 = −𝜇
𝑑𝑣
𝑑𝑦        Equation 1.5 
where ‘𝜇’ is the proportionality constant or dynamic viscosity (Pa s). Specific equations 
derived for the device used in this study derived using computational fluid analysis will 
be  presented  and  reviewed  in  Section  1.5.1  to  assess  the  hydrodynamic  forces 
experienced at the various different operating conditions during membrane separation. 
1.4.3  Storage and delivery 
After formulation into the appropriate storage or delivery buffer, the final stage in the 
processing of cell-based therapies requires a scalable and reproducible technique for 45 
 
freezing and storing of cells. Like with any other processing step, cell quality attributes 
and  functionality  of  the  cells  must  be  maintained  during  storage  and  during 
transportation to the site of administration.  
Depending on the nature of the therapy, storage will vary. Traditionally, mechanical 
freezers  (-80˚C)  are  acceptable  for  short  term  storage  (-80˚C)  whereas  for  longer 
periods, liquid nitrogen (-196˚C) or vapour nitrogen (-135˚C) are preferred. However, 
some therapies such as tissue engineered scaffolds (e.g. Epicel) cannot be stored in the 
frozen state as they are part of a complex structure. These types of therapies usually 
have a short shelf life and are stored in special medium (e.g. AedestaTM). 
Cryopreservation of cells remains a challenging task for the cell-based industry. This 
has led to many efforts focusing on the effect of concentration, volume, rate of freezing 
and  buffer  composition  (De  Loecker  et  al.  1998;  Fuller  and  Devireddy  2008;  Pegg 
1981) in the hope of improving and understanding this crucial stage post-processing. 
Traditionally, to minimize the damage caused by freezing and thawing, the industry has 
used  controlled  cryoprocedures.  These  include  protective  agents  such  as  dimethyl 
sulfoxide (DMSO) or glycerol as well as controlled freezing rates (Fuller and Devireddy 
2008). However, toxicity has commonly been attributed to products containing DMSO 
and therefore its use has become a matter of concern. Commercially available storage 
buffers, such as Hypothermosol® (BioLife Solutions) for 2-8˚C storage and CryoStor® 
2%,  5%  and  10%  DMSO  (BioLife  Solutions)  for  -70˚C  to  -196˚C  storage,  have 
attempted to reduce the level of DMSO into a safe limit. 46 
 
Other aspects that need special consideration but are beyond the scope of this thesis are 
the logistical operations related to cold chain supply and adequate product labelling 
(crucial for autologous therapies,(Woods 2010). 
1.4.4  Scalability of cell-based therapies 
For any cell therapy, the manufacturing process has to be scaled from lab to clinic 
whilst maintaining at all stages critical cell quality attributes (CQAs) specific to the 
therapy in question (such as potency, yield, purity and cell viability). The production 
challenges  for  cell-based  therapies  differ  depending  on  the  source  (allogeneic  or 
autologous), method of administration to the patient (injection, surgical or other), scale 
(number of cells needed, volume of cells to process) and the type of cells used (i.e. 
some will be more susceptible to processing environments than others). Gaining in-
depth knowledge of cell-process interactions will help understand how scalability of the 
processing  steps  will  impact  cellular  material  both  physically  and  biologically 
(Delahaye 2013; McCoy et al. 2009). 
There are two main strategies for scaling cell-based therapies and both aim to increase 
the  level  of  production;  scale-out  and  scale-up.  Scale-out  refers  to  an  addition  of 
small-scale operations carried out in parallel to each other increasing the manufacturing 
output  by  increasing  the  number  of  batches.  Scale-up  refers  to  increasing  the 
manufacturing output by increasing the volume or number of cells processed for each 
batch (Hourd et al. 2014a). 47 
 
Both strategies have their advantages and disadvantages. For example, on the one hand, 
in  scaling-out,  there  are  no  connections  between  one  reactor  and  another  (with  the 
exception for the control systems -(Mason and Hoare 2006) and there is no need for re-
validation  because  the  manufacturing  process  stays  the  same.  However,  the  costs 
associated  with  scale-out  are  considerably  larger  due  to  the  number  of  operators, 
equipment and working space required. On the other hand, with scaled-up products, 
manual labor is reduced and more material can be produced per batch reducing utilities 
costs and the process footprint. However, the processing steps are not always easily 
scalable and there is usually a limit to the size of the equipment. Moreover, changing 
processing platforms will require  re-validation and  a processing failure will incur  a 
higher economic loss (Hourd et al. 2014b). 
Currently, many companies choose to scale-out instead of developing new technologies 
to scale-up as their small-scale processes are already validated. However, the nature of 
scalability of the process will inevitably depend on the type of therapy. A therapy that is 
patient-specific will require production on an individual basis and ideally at the point of 
care (Kirouac and Zandstra 2008). This type of therapy will need a smaller volume of 
cellular material than a therapy that is “off-the-shelf” and targets a larger number of 
patients  with  every  batch  produced.  Therefore,  scale-out  is  more  suited  for  patient-
specific therapies whereas scale-up is beneficial for “off-the-shelf” solutions.  
Irrespective of the strategy used for scaling a cell-based therapy, the need to understand 
and characterize the processing environment remains of utmost importance to facilitate 
scalability of the manufacturing process.  48 
 
1.5  Ultra-scale down (USD) technologies 
Efforts have been made to develop early stage, low cost process development predictive 
tools that can accurately mimic the performance of large-scale equipment using small 
amounts  of  material  (Titchener-Hooker  et  al.  2008).  Historically,  scaling  down  any 
process meant using a pilot plant or few litres scale. However these options remain 
costly because of the need for large amounts of biological material (Tait et al. 2009). 
More recently, ultra-scale down (USD) tools have been developed to cover an array of 
techniques within cell bioprocessing and Titchener-Hooker et al. (2008) presents an 
overview of these techniques.  
USD devices have been investigated as predictive tools for several different large-scale 
bioprocessing  steps  such  as  chromatography  columns  (Hutchinson  et  al.  2006; 
Titchener-Hooker et al. 2008), centrifugation (Delahaye 2013; Hutchinson et al. 2006; 
McCoy et al. 2009) and membrane separation (Ma 2009; Ma et al. 2010). For example, 
Hutchinson et al. (2006) combined the use of a rotating disc device and a laboratory-
scale  test  tube  centrifuge  to  successfully  predict  the  separation  characteristics  of 
industrial  scale  disc  stack  centrifuges  and  investigated  the  effect  of  operating  with 
different feed zones using milliliter quantities of biological material. 
Due  to  the  small  volumes  of  material  needed,  high  throughput  experimentation  is 
possible when using USD devices and therefore the scope for investigation is large. 
This feature is of particular importance for the cell-based industry, where the cellular 
material  is  expensive  to  produce.  Therefore,  identifying  and  understanding  both 
mechanical and biological responses of candidate cells to processing stimuli at an early 49 
 
stage will allow the design of robust bioprocesses to deliver reproducible and efficient 
therapies  and  to  reject  inappropriate  candidates  at  early  stages,  prior  to  clinical 
manufacturing. Recent studies have used USD tools to investigate the impact on surface 
markers,  growth  rates  and  retention  of  membrane  integrity  of  varying  processing 
conditions during downstream operations for cell-based therapies (Acosta-Martinez et 
al. 2010; Delahaye 2013; McCoy et al. 2010). In this thesis, the interest is in the effect 
of processing conditions on cell quality during membrane separation. 
1.5.1  USD membrane separation device 
Several  attempts  to  mimic  the  processing  environment  during  filtration  have  been 
reported by various authors. Chandler and Zydney (2004) published work on membrane 
screening using a small scale high-throughput multi-well filtration plate that allows to 
simultaneously test 96 different conditions. Ghosh and Cui (2000) proposed for the first 
time an ultrafiltration rotating disc device of ~15 mL capacity. This device consisted of 
a magnetically driven flat impeller which constantly stirs the retentate chamber. Based 
on this model, Ma et al. (2010) designed a USD device with a rotating disc to mimic 
cross-flow microfiltration with ~10-fold less working volume than what Ghosh and Cui 
(2000) had presented (volume of the retentate is ~1.7 mL). 
An optimized version of the latter USD device (fabricated at the Rapid Design and 
Fabrication  Facility,  RDFF,  in  the  Department  of  Biochemical  Engineering  at 
University  College  London,  UCL)  will  be  used  in  this  study.  The  most  important 
parameter of this device is the shear rate at the membrane surface, parameter which is 
normally responsible for the rate of fouling of the membrane. The device is designed 50 
 
such that it can be run in dead end mode but mimicking shearing conditions from a 
cross-flow model. This feature allows the decoupling of shear rate and pressure drop.  
Ma et al. (2010) used powerful computational fluid dynamics (CFD) software as an 
additional design tool for the analysis of shear forces in the USD membrane separation 
chamber. Dr. Spyridon Gerontas kindly adapted the CFD simulations to show the minor 
design changes that the device has undergone through the various optimization cycles. 
Figures  1.4.A  and  1.4.B  show  the  magnitude  of  the  shear  rate  experienced  by  the 
material  present  in  the  retentate  chamber  at  various  different  locations  as 
three-dimensional and two-dimensional heat maps (assuming a viscosity of water of 
0.99 g cm-3 at 21±1°C). From this figure it is evident that the highest shear experienced 
is at the edges of the rotating disc (red areas in Figures 1.4.A and 1.4.B).  
Figure  1.5  shows  shear  rate  as  a  function  of  viscosity.  By  keeping  the  disc  speed 
constant, and increasing the viscosity of the fluid, the shear rate experienced by the 
material  in  the  retentate  chamber  decreases.  Table  below  Figure  1.5  shows  the 
maximum shear rates experiences at the two disc speeds and viscosities reported in this 
study.  
1.6  Disruption  of  cell  homeostasis:  identification  and  assessment  of  cell 
quality attributes (CQAs) of the target cell population 
Cells maintain a steady state or internal equilibrium by adjusting their physiological 
processes. They require exchanges with their surrounding environment and dynamic 
adjustments in order to maintain the status quo (Kumar et al. 2007; Kuo et al. 2010). 51 
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Figure 1.4: A computational fluid dynamic (CFD) simulation displaying the shear rate experienced 
at various locations of the USD membrane device (kindly provided by Dr Spyron Gerontas). (A) 
Three-dimensional and (B) two-dimensional heat maps showing the increase in magnitude of shear 
rate by color change (from blue to red). 
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Figure 1.5: Shear rate at the bottom of the USD  membrane separation device as a function of 
rotational speeds of 6,000 (dashed lines) and 10,000 (continuous lines) rpm for varying viscosity 
values. Kindly provided by Dr Spyron Gerontas. 
 
           
    Average  Maximum 
Disc speed 
(rpm) 
Viscosity 
(mPa s) 
Shear rate 
(s-1) 
Shear stress 
(Pa) 
Shear rate 
(s-1) 
Shear stress 
(Pa) 
10,000 
1  37,000  37  116,000  116 
1.5  31,000  46  98,000  147 
2  27,000  55  88,000  176 
2.5  25,000  63  84,000  210 
3  23,000  70  79,000  237 
6,000 
1  14,000  14  44,000  44 
1.5  12,000  18  40,000  59 
2  11,000  21  38,000  76 
2.5  10,000  25  36,000  91 
3  9,000  28  33,000  99 
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When the equilibrium of a parameter or component is disturbed there is a readjustment 
giving rise to a stimulus. This homeostasis or equilibrium keeps the cell functioning 
properly and in a constant state of balance between waste products excreted and the 
nutrients  received.  The  plasma  membrane  and  membrane  proteins  are  the  main 
structures which help maintain this state and therefore the disruption of the membrane 
or mal-regulation of proteins can serve as indicators of cell health (Kumar et al. 2007).  
Exposed to a range of mechanical and physiochemical stresses during processing, living 
organisms such as cells intended for therapies are in a continual strive to adjust to the 
changes in the surrounding environment (Figure 1.6). Therefore a major challenge to 
successful  commercializing  of  cell-based  therapies  is  the  development  of  scalable 
manufacturing processes while maintaining CQAs (such as potency, purity, viability) of 
the final live cell product (Carmen et al. 2012). However, each individual therapy will 
have its own unique criteria that lead to assays that can be used to characterize the cells. 
Each product will require a customized procedure that measures potency (or as the FDA 
defines  it,  “appropriate  biological  activity”).  More  often  than  not,  it  is  not 
straightforward to determine what this should encompass, incurring high development 
costs and lengthy assays. Moreover, it remains the responsibility of the manufacturer to 
guarantee product safety and efficacy throughout bioprocessing of the cells as well as 
post-administration  to  the  patients.  For  this  reason,  the  best  practices  in  process 
development will rely strongly on cell characterization and a thorough understanding of 
the cell-based product (Carmen et al. 2012).  
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Figure 1.6: Stages in the cellular response to stress and injurious stimuli. Adapted from Kumar et 
al. (2007). 
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This section aims to provide an understanding of what defines CQAs for a generic 
cell-based therapy and provide an insight into some of the methods used to analyze the 
specific biological requirements.  
1.6.1  Membrane integrity 
The word integrity is derived from the Latin word “integer” which translates to “intact”. 
Integrity is defined as “the state of being whole and undivided” (Oxford Dictionaries). 
The integrity of a cell membrane is said to be compromised when there is a breakage of 
the lipid bilayer and intracellular components are released or extracellular components 
can enter the cell without being appropriately regulated. Should the integrity of the 
plasma membrane be disrupted, cell quality is immediately affected; cell  death may 
occur if there is no rapid restoration of the membrane (McNeil and Steinhardt 2003) as 
it compromises its functional role as a barrier (Kumar et al. 2007). 
Therefore, membrane integrity is used as an initial analysis of cell quality (also referred 
to  as  cell  viability).  Viability  assays  can  be  based  on  one  of  two  characteristic 
parameters; metabolic activity (achieved by measuring an indicator for healthy cells in 
cell populations) or cell membrane integrity of intact cells (accomplished by directly 
counting the number of cells that do not have a compromised or broken membrane). 
The  latter,  viability  as  measured  by  exclusion  dyes  or  release  of  intracellular 
components, is by far the most common assessment criteria used due to its ease in 
measurement and the fact that it does not need large quantities of material (Acosta-
Martinez 2011; McCoy et al. 2010; Wlodkowic et al. 2011). In this thesis, trypan blue 56 
 
exclusion and release of intracellular lactate dehydrogenase (LDH) enzyme are the two 
measurements presented to assess cell viability and death. 
1.6.1.1  Trypan blue exclusion dye as a measure of cell viability 
Exclusion dye techniques are normally excluded from the inside of a healthy cell due to 
a functioning intact plasma membrane.  Several different dyes are available, such as 
trypan blue and propidium iodide, and all have slightly different measuring techniques 
and  characteristics.  However,  the  principle  is  the  same  for  all  dye  exclusion 
measurements. If the cell membrane has been disrupted, the dye can freely cross the 
membrane staining the intracellular components of the cell. The dead cells distinctively 
appear colored in blue (trypan blue) or red (propidium iodide) under a microscope and 
thus the distinction can be made. 
For the purpose of this study, the term cell viability will therefore be a quantitative 
assessment of “intact” cells in a sample as measured by trypan blue exclusion dye. 
However,  with  trypan  blue  staining,  it  is  possible  that  the  cell  viability  has  been 
compromised in a way that the dye might not detect (such as its capacity to grow or 
expression of programmed cell death proteins) due to retention of membrane integrity. 
Research suggests that fluorometric dyes, such as propidium iodide, are more accurate 
indicators as  even small  amounts  of dye taken-up by injured cells  will show under 
fluorescent  microscopes  whereas  it  might  be  hard  to  see  with  trypan  blue  dye. 
Nevertheless, trypan blue remains more commonly used due to its rapidity and ease of 
use (Altman et al. 1993).  57 
 
1.6.1.2  Lactate dehydrogenase (LDH) release as a measure of cell death 
Several standard assays have been developed in order to provide sensitive, quantitative, 
reliable  and  accurate  methods  for  the  quantification  of  cellular  death.  These  assays 
measure intracellular proteins which are only released when membrane integrity is lost 
or cells are completely lysed. For example, lactate dehydrogenase (LDH) is a stable 
cytoplasmic enzyme widely reported to measure cell death. Its rapid release into the cell 
culture supernatant upon damage of the plasma membrane makes it an ideal candidate 
to  measure  cell  number  and  viability  (Markert  1984).  It  has  been  used  in  various 
systems, ranging from microwell plates (Wolterbeek and van der Meer 2005) to flask 
cultures (Racher et al. 1990) to perfusion reactors (Goergen et al. 1993; Herold et al. 
2009; Wagner et al. 1992).  
LDH has also been studied for filtration systems (Nema and Avis 1993). Nema and 
Avis  (1993)  investigated  the  loss  of  LDH  activity  during  membrane  filtration  by 
looking at the transmission of the protein using different membrane materials and pore 
sizes. Their investigation concluded polycarbonate and polyvinylidene fluoride (PVDF) 
filters showed low loss of protein with the exception of 5 µm PVDF filters. Even though 
this  study  did  not  use  cells  as  a  source  of  LDH,  the  observations  are  relevant  to 
membrane selection. The biggest pore size investigated by Nema and Avis (1993) with 
low loss of LDH activity was 0.65 µm PVDF membrane and this will be the membrane 
used in this study. 
Like trypan blue exclusion, LDH release does not differentiate between non-viable cells 
and  completely  lysed  cells  or  between  different  cell  death  pathways  (necrosis  or 58 
 
apoptosis). Therefore, once it is determined whether integrity has been compromised, 
further studies can be made to look at attributes such as changes in protein expression, 
morphology and size. 
1.6.2  Protein expression for cell death 
Analysis that focuses on the function and biological state of the cell population is an 
added measure of cell quality that may not be evident from the physical measurement of 
cell  damage.  For  example,  harsh  processing  conditions  can  trigger  cells  to  produce 
unwanted  proteins  or  impede  the  creation  of  necessary  ones  (Agashi  et  al.  2009). 
Therefore, an indication of the quality and state of cellular products is the level of 
expression of specific proteins.  
This  is  the  case  for  programmed  cell  death  protein  expression  (Darzynkiewicz  and 
Pozarowski 2007). Cell death biological assays will identify the two primary types of 
death; apoptosis and necrosis. These two categories are different in their morphology, 
mechanisms and roles in the programmed cell death pathways (Dive et al. 1992). The 
biological assays used to measure programmed cell death are based on the detection of 
caspase  –  a  key  molecule  in  the  apoptotic  mechanism  and  induction  of  apoptosis 
(Darzynkiewicz and Pozarowski 2007; Smolewski et al. 2002). Even though the caspase 
sub-type  involved  may  vary  from  one  tissue  to  another,  caspase-3  is  known  as  a 
universal caspase which functions in almost all tissues and is an indicator that the cell is 
committed to irreversible cell death processes and therefore most assays work on the 
activation of caspase-3 (Darzynkiewicz and Pozarowski 2007; Smolewski et al. 2002). 
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live;  early  apoptotic  cells  which  show  apoptotic  related  activity  but  no  loss  of 
membrane integrity; late apoptotic cells which show both apoptotic related activity as 
well  as  loss  of  membrane  integrity;  and  necrotic  cells  which  did  not  undergo  an 
apoptotic pathway prior to loss of membrane integrity.   
Therefore, expression of caspase-3 is  a  widely  used and reliable way  of measuring 
apoptosis.  In  addition,  by  inspection  of  the  morphology  of  cells,  some  preliminary 
observations can be made in order to assess cell health.  
1.6.3  Cell morphology post-processing 
Cell physical classification and identity can serve as an indication of cell health. Cells 
can  change  shape,  size  or  physical  appearance  after  being  exposed  to  stresses  (Al-
Rubeai  et  al.  1995;  Kretzmer  and  Schügerl  1991)  and  this  can  be  an  indication  of 
underlying  changes  in  structural  remodelling  (membrane  channels  changing 
conformation)  or  metabolic  pathways.  Size  change  can  be  a  sign  of  the  leaking  of 
internal components into the extracellular environment (if size is reduced) or swelling if 
extracellular fluids are permeating into the cell (Al-Rubeai et al. 1995; Kumar et al. 
2007).  
Morphological  changes  can serve as indicators  of specific  cell death  pathways.  For 
instance, necrosis often leads to inflammation of the cell as a host reaction to leakage of 
internal components due to a damaged membrane. On the other hand, apoptosis is often 
characterized by shrinkage of the  cell with  an intact  cell membrane  and membrane 
protrusions known as blebbing (Kumar et al. 2007). Even though the most reliable way 60 
 
of measuring programmed cell death is by measuring changes in protein expression, as 
was  previously  described,  morphological  changes  can  act  as  an  indicator  of 
programmed cell death. The clear advantage of morphological analysis is that it can be 
retrospectively performed from the images obtained by the automated haemocytometer.  
1.6.4  Cell growth rate post-processing 
The use of processed cell populations to inoculate further cultures can help assess the 
impact of specific processing steps or conditions upon a cell population. For successful 
cell division,  a chain  of events  must be completed in  an orderly and unidirectional 
manner. Changes in the rate of cell growth and doubling times can de-regulate this 
crucial chain of events (Kumar et al. 2007) and can serve as indicators of the state of 
cell  health  and  its  suitability  for  use  as  a  whole  cell  product  (Agashi  et  al.  2009; 
Kretzmer and Schügerl  1991).  However, for  growth rate studies,  it  is  essential that 
numerous influential factors for cell growth (media composition, dissolved oxygen, pH, 
surface material for attachment, seeding density, etc) are kept constant. 
1.7  Thesis aims and objectives 
The  successful  processing  of  adherent  cells  requires  a  deep  understanding  of 
time-dependent relationship of cell-cell interactions and cell-surface interactions such 
that processing environments are not destructive of the cells themselves. Understanding 
how operating conditions impact cell recovery, cell integrity and cell quality is crucial 
for the successful processing of human cells. However, as important is having tools that 
will monitor and indicate key CQAs. 61 
 
This study aims to develop and explore the use of a novel USD membrane separation 
technique to help understand the relationship between operating conditions, cell line 
selection and membrane (material) selection  required for the successful recovery of 
human  adherent  cells  for  therapeutic  use.  The  aim  within  this  investigation  is  to 
quantify  the impact  of  processing upon cell-based  therapies, identifying mainly cell 
damage  by  loss  of  membrane  integrity  and  lysis  (as  measured  by  both  trypan  blue 
exclusion  and  LDH  release).  It  also  provides  a  glance  into  other  key  cell  quality 
attributes such as cell morphology, programmed cell death and growth post-processing. 
The focus in this study lies on providing a consistent and reproducible tool to assess cell 
damage  in  response  to  the  bioprocessing  environment  without  intervening  with  the 
actual cell suspension. Human fibroblasts were utilized to develop the measurements of 
cell damage as assessed by both trypan blue and LDH. By selecting extreme processing 
conditions, it is hoped that mechanistic hypotheses can be established as to the source of 
cell responses.  
Its reproducibility and suitability for cell damage assessment was subsequently tested 
under different operating conditions and then used to translate the impact of the same 
processing conditions to more expensive cell therapy candidate cell lines (tumour cells 
and neural stem cells). The method provides a way to assess cell damage that will be 
adaptable to any other filtration study and cell line as long as minimum transmission 
studies are carried out to ensure the underlying assumptions of the method apply with 
the new filtration characteristics.  62 
 
Lastly, the research also aims to create a fundamental understanding of how cell-cell 
interactions occur in concentrated suspensions in shear conditions and how these affect 
cell  integrity (membrane integrity)  and  cell-related loss (cell damage by  lysis). The 
ability  to  work  with  microscale  quantities  of  cells  within  the  bioprocess  mimics, 
especially for the studies on concentrated suspensions, will offer a novel means of early 
selection of membrane separation and other methods for cell recovery.  
With the range of tests carried out, the study will present a generic evaluation of cell 
damage over time of operation that is envisaged to be applicable to a wide range of 
current and future cell therapies with varying thresholds for different cell lines. Using 
our  USD  membrane  separation  device  facilitated  the  study  of  a  range  of  operating 
conditions in a cost and time effective manner using relatively small amounts of cellular 
material. 
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Chapter 2.  Materials and methods 
2.1  Introduction 
Changes in cell properties during exposure to various operating conditions, relevant to 
the use of cross-flow membrane processes operations at preparative scale, were studied. 
This chapter will outline the operating procedures adopted for cell handling (including 
cryopreservation, culture and harvesting), cell processing (including detailed operation 
of the device and operating conditions) as well as cell analytics (including evaluation of 
cell health, morphology and proliferation post-processing). 
2.2  Cell lines 
Three cell lines were used in this research for the development of an ultra scale-down 
tool. 
2.2.1  HCA2 cell line 
HCA2 cells (provided by Prof David Kipling, University of Cardiff, UK) are human 
neonatal foreskin fibroblasts and are used for skin grafting applications. These cells had 
previously been immortalized using an amphotropic retrovirus expressing hTERT, the 
catalytic protein subunit of human telomerase. The retrovirus was constructed and used 
for infection of the HCA2 normal human fibroblasts (Stephens et al. 2003; Wyllie et al. 
2000).  
2.2.2  P4E6 cell line 
P4E6 cell line (provided by Onyvax Ltd, St George’s Hospital, London) is one of three 
cell lines used in a human prostate whole-cell cancer vaccine. It is derived from an early 64 
 
prostate  cancer  biopsy.  It  is  a  prostate  carcinoma  cell  line  (Maitland  et  al.  2001) 
immortalized by transfection of a retroviral construct (PLXSN16E6) expressing human 
papilloma virus (HPV) type 16 E6 gene (Halbert et al. 1992). The cell line maintains 
epithelial characteristics and the ability to express both prostate specific antigen (PSA) 
and androgen receptor (AR). 
2.2.3  CTX0E03 cell line 
CTX0E03 neural stem cell line (provided by ReNeuron Group plc., London) is a human 
clonal cell line developed to aid regeneration of human brain tissue post-stroke. It is 
derived by genetic modification of foetal brain tissue using a conditional immortalizing 
gene,  c-mycERTAM  (Pollock  et  al.  2006).  Incorporation  of  c-mycERTAM  gene  was 
performed  using  a  retroviral  vector  pLNCX-2  encoding  for  the  c-mycERTAM  gene 
(Pollock et al. 2006). Cell proliferation takes place only in the presence of 4-hydroxy-
tamoxifen (4-OHT) and, upon removal  of 4-OHT, the  cells  stop  dividing. Tests  on 
rodent models demonstrated that the use of c-mycERTAM provides a necessary safeguard 
switch to prevent against inappropriate cell division or tumour formation (Pollock et al. 
2006). The human foetal cortex was obtained from first trimester foetal human brain 
following  normal  termination  and  in  accordance  with  nationally  (UK  and/or  USA) 
approved ethical and legal guidelines.  
2.3  Cell culture 
The  cell  banks  were  tested  for  sterility  and  mycoplasma  infection  prior  to  the  cell 
culture work. All cell handling was carried out in a class II biological safety cabinet 
(Walker, Derbyshire, UK) using sterile techniques. 65 
 
2.3.1  Growth media 
All three cell lines were grown in different complete growth media (CGM). 
HCA2 cells were grown in Dulbecco’s Modified Eagles Medium (DMEM, Invitrogen, 
Paisley, UK), supplemented with 10% (v/v) foetal calf serum (PAA Laboratories, Linz, 
Austria) and 2 mM of glutamine (Invitrogen, Paisley, UK). The supplemented medium 
will be referred to as hCGM. 
P4E6 cells were grown in keratinocyte serum-free medium (Gibco-Invitrogen, Paisley, 
Scotland, UK) supplemented with 5μg L-1 of epidermal growth factor (EGF; Gibco-
Invitrogen,  Paisley,  Scotland,  UK)  and  2%  (v/v)  foetal  calf  serum  (FCS;  PAA 
Laboratories, Linz, Austria). The supplemented medium will be referred to as pCGM. 
CTX0E03 cells were grown in reduced modified medium which comprised DMEM:F12 
(Invitrogen,  Paisley, UK) supplemented with human serum albumin (HSA; 0.03% v/v; 
Octopharma, Manchester, UK), L-Glutamine (2 mM; Invitrogen, Paisley, UK), human 
transferrin (100 µg/mL; Millipore, Hertfordshire, UK), putrescine dihydrochloride (16.2 
µg/mL;  Sigma-Aldrich,  Ayrshire,  UK),  human  insulin  (5  µg/mL;  Sigma-Aldrich, 
Ayrshire,  UK),  progesterone  (60  ng/mL;  Sigma-Aldrich,  Ayrshire,  UK),  sodium 
selenite  (40  ng/mL;  Sigma-Aldrich,  Ayrshire,  UK),  basic  fibroblast  growth  factor 
(bFGF;  10 ng/mL;  Invitrogen, Paisley, Scotland, UK) and EGF (20 ng/mL;  Sigma-
Aldrich, Ayrshire, UK). This medium formulation was referred to as cCGM. Before use 
for  cell  culture,  4-hydroxy-tamoxifen  (4-OHT;  Sigma-Aldrich,  Ayrshire,  UK)  was 
added to the cCGM (referred to as cCGM:4-OHT) to a final concentration of 100 nM. 66 
 
2.3.2  Cryopreservation of cell lines 
HCA2 cell line: A cell bank for future expansion was created in-house by collaborative 
efforts within our group. It consisted of frozen aliquots of 1 mL containing 5x106 cells 
in freezing medium (foetal calf serum, FCS; Thermo Fisher Scientific, Northumberland, 
UK)  supplemented  with  10%  (v/v)  dimethyl  sulfoxide  (DMSO;  Sigma-Aldrich, 
Ayrshire,  UK)  and  stored  in  liquid  nitrogen.  HCA2  cells  were  cultured  between 
passages  11 and  25 counted from  frozen state  (passage 11). The minimum  seeding 
density was approximately 2x104 cells cm-2. 
P4E6 cell line: A cell bank for future expansion was created by Onyvax, consisting of 
frozen aliquots of 1 mL containing 5x106 cells in freezing medium as described for 
HCA2 cell line. P4E6 cells were used between passages 51 and 60 counted from frozen 
state (passage 50). The minimum seeding density was approximately 4x104 cells cm-2. 
CTX0E03 cell line: A cell bank, from an aliquot provided by ReNeuron, was derived 
in-house by Dr Kate Lawrence, consisting of frozen aliquots of 1 mL containing 5x106 
cells  in  freezing  medium  (cCGM,  supplemented  with  10%  (v/v)  DMSO;  Sigma-
Aldrich,  Ayrshire,  UK)  and  stored  in  liquid  nitrogen.  CTX0E03  cells  were  used 
between passages 24 and 37 counted from frozen stage (passage 24), in accordance with 
ReNeuron  manufacturing  protocol.  The  minimum  seeding  density  used  was 
approximately 2x104 cells cm-2. 67 
 
2.3.3  Revival of cell lines 
A cell line was revived from frozen state by placing one aliquot of cells in a 37°C 
waterbath for 2 minutes, then slowly transferring the defrosted sample into a 15 mL 
centrifuge tube and adding 9 mL of the cell’s appropriate CGM. The removal of the 
freezing medium was facilitated by centrifugal spin (Thermo, Strasbourg, France) for 5 
minutes at 500 x g. The cells were then resuspended in 18 mL of appropriate CGM and 
transferred to a  T75  tissue culture flask  (Cellstar, Greiner  Bio-One,  Germany). The 
flasks were kept in an incubator (Sanyo, Osaka, Japan) maintained at a controlled gas 
environment (5% CO2, 95% air) and temperature (37°C). 
2.3.4  Cell preparation for recovery studies 
Cell  line  specific  culture  protocols  are  described  in  this  section.  It  also  includes 
information  for  the  three  cell  lines  such  as  the  average  diameter  of  the  cells  in 
suspension or days taken to reach confluency. The protocols outlined in this section 
describe cell culture in T175 flasks; Table 2.1 shows the volumes needed for wash 
buffer, detachment enzyme and CGM for all flasks used in this study (i.e. T75, T175 
and triple flasks). 
2.3.4.1  HCA2 and P4E6 cell lines 
Cells  were  passaged  when  70-80%  confluency,  as  assessed  by  light  microscopy 
inspection,  was  reached.  To  dissociate  the  cells  from  the  T175  tissue  culture  flask 
(Cellstar,  Greiner  Bio-One,  Germany),  the  spent  medium  was  aspirated,  cells  were 
washed with 15 mL of Dulbecco’s Phosphate Buffered Saline (DPBS; Sigma-Aldrich, 
Ayrshire, UK) and enzymatically detached using 5 mL TrypLETM Select (Invitrogen,  68 
 
Flask type 
 
Area for cell culture   DPBS  TrypLETM Select  CGM 
(cm2)  Volume (mL) 
T75  75  7  3  18 
T175  175  15  5  42 
Triple flask  525  40  25  110 
 
Table 2.1: Volumes used of reagents for different sizes of cell culture flasks.  Minimum seeding 
densities for HCA2 and CTX0E03 was approximately 2x104 cells cm-2 and 4x106 cells cm-2 for P4E6 
cell line. 
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Paisley, UK)  for 4-8 minutes at  37°C. To quench the enzyme, an equal  volume of 
appropriate CGM was introduced into the flask. The cells were then transferred to a 15 
mL centrifuge tube and centrifuged (Thermo, Strasbourg, France) for 3 minutes at 500 x 
g at 21±1°C. The supernatant was removed by aspiration and the pellet was loosened 
from the tube wall by gently flicking the centrifuge tube. The cells were subsequently 
manually resuspended in 42 mL of appropriate CGM using a Pipetboy (IBS, Integra 
Biosciences, Zizers, Switzerland), counted, transferred into a new tissue culture flask at 
a  cell  density  determined  by  the  desired  split  and  placed  in  the  incubator  to  allow 
proliferation.  A  1  in  6  split  and  1  in  4  for  HCA2  and  P4E6  respectively,  take 
approximately 4 days to reach 70-80% confluency, as assessed by light microscopy 
inspection. 
2.3.4.2  CTX0E03 cell line  
Prior to seeding of the cells, each cell culture flask was pre-treated with 15 mL of 
laminin (10 µg/mL; AMS Biotechnology) in DMEM:F12 (Invitrogen, Paisley, UK) and 
placed in the incubator (Sanyo, Osaka, Japan) at 5% CO2, 95% air and 37°C for at least 
one hour. The addition of laminin provides a coated membrane component to assist cell 
attachment, growth and proliferation. Prior to cell inoculation, the laminin solution was 
removed by aspiration and the flasks washed with DMEM:F12.  
Cells  were  passaged  when  70-80%  confluency,  as  assessed  by  light  microscopy 
inspection, was reached. To dissociate the cells, the spent medium was removed by 
aspiration  and  the  cells  were  washed  with  15  mL  of  Hanks’  balanced  salt  solution 
(HBSS;  Sigma-Aldrich,  Ayrshire,  UK).  The  cells  were  then  enzymatically  detached 70 
 
using 5 mL TrypZean (Lonza, Slough, UK), for 5 minutes at 37°C. To quench the 
enzyme, an equal volume of defined trypsin inhibitor (DTI; Invitrogen, Paisley, UK) 
supplemented with a final concentration of 20 units per mL of benzonase (Benz; Merck, 
Nottingham,  UK)  was  introduced  into  the  flask.  The  cells  were  then  centrifuged 
(Thermo, Strasbourg, France) for 5 minutes at 800 x g, at 21±1°C. The supernatant was 
aspirated off and the pellet was loosened from  the tube wall by gently flicking the 
centrifuge tube. The cells were subsequently resuspended in cCGM:4OHT, counted, re-
seeded  at  varying  cell  densities  depending  on  the  desired  split  and  placed  in  the 
incubator to allow proliferation. A 1 in 2 split takes approximately 4 days to reach 70-
80% confluency, as assessed by light microscopy inspection. 
2.4  Membrane separation rotating disc shear device 
2.4.1  Technical details 
The rotating disc shear device used (Figure 2.1) is similar to the one described by Ma et 
al. (2010) and was built by the Rapid Design and Fabrication Facility (RDFF) at UCL. 
It consists of a sealed Perspex chamber of internal diameter of 21 mm and a fixed total 
volume  of  1.7  mL.  The  chamber  had  a  centrally  mounted  conical  disc,  15  mm  in 
diameter  with  a  4º  conical  cross-section,  with  an  accompanying  shaft  assembly 
fabricated in stainless steel (Figure 2.1).  The shaft was fitted to a high speed motor with 
a feedback loop (Outrunner Motor, 920Kv Park 400, Champaign, Illinois, USA) driven 
by a portable power-pack also built by the RDFF. The rotating disc can be set to run at 
fixed speeds of 6,000 ± 50, 8,000 ± 50 and 10,000 ± 100 rpm.  71 
 
 
Figure 2.1: Image of the ultra scale-down membrane filtration device set-up. (A) Attached to a 
syringe pump and (B) inside of the chamber, (C) schematic representation of the device and (D) 
schematic representation of full set-up of the device, including pressure measurement and syringe 
pump. 
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A  25  mm  diameter  polyvinylidene  fluoride  Durapore®  membrane  (Millipore, 
Hertfordshire, UK) with an area of 4.91  cm2 and 0.65 µm  pore size, was  mounted 
between the bottom of the shear cell and an O-ring seal of 25 mm outer diameter that 
sits on the permeate port (Figure 2.1.C). Due to the width of the O-ring, the effective 
area of the membrane is 3.64 cm2. The gap between the membrane and the rotating tip 
was designed at 1 mm (Figure 2.2.A). Three ports were drilled into the upper half of the 
chamber to allow for filling, sampling, emptying the device as well as measurement of 
the chamber pressure.  
A  correlation  for  the  surface  averaged  shear  rate  as  a  function  of  the  speed  of  the 
rotating disc, was developed by Ma et al. (2010) using CFD simulations and were used 
in this study: 
𝗾 = 2.12 × 10−6𝜇−1.375𝜔1.5      Equation 2.1 
where ‘𝗾’ is the shear rate (s-1), ‘𝜇’ is the viscosity of the fluid (Pa s) and ‘𝜔’ is the 
rotational speed of the disc (revolutions per minute, rpm). Assuming a viscosity like 
that of water at 21±1°C, the averaged shear rates for the three fixed rotating disc speeds 
are of 13,000 s-1, 20,000 s-1 and 28,000 s-1 respectively. As was explained in section 
1.5.1, the maximum shear rate is experienced at the edges of the rotating disc (Figure 
1.3). For this study, maximum shear rate values will be reported instead of average ones 
for the two disc speeds and varying viscosities investigated. These values were obtained 
from Figure 1.4, also in section 1.5.1 and are summarized in the table below it. 
An inline pressure sensor can be fitted into one of the sampling ports and operates 
within the 0-7 bar range (±0.07 bar; 40PC100G2A, Honeywell Sensors and Control,  73 
 
 
Figure 2.2: Cross-sectional view of the chamber from (A) the side and view of (B) the inside of the 
chamber from below.   74 
 
Golden Valley, USA) and was built by the RDFF. This pressure device was composed 
of an amplified pressure gauge sensor (RS Components Ltd, Northants, UK) connected 
to  a  multifunction  data  acquisition  device  (National  Instruments  Corporation  Ltd, 
Berkshire, UK) and powered by a power-pack also built by the RDFF. The pressure 
readings  acquired  were  logged  using  LabVIEW  software  (National  Instruments 
Corporation Ltd, Berkshire, UK) and were in the form of mV at 1 second intervals. The 
pressure  device  was  calibrated  in  collaboration  with  Alex  Chatel  using  the  ÄKTA 
Crossflow system (GE Healthcare, Uppsala, Sweden) as a reference (Figure 2.3). 
This was done by running water through a 50 kDa membrane filter at different fluxes 
while recording the readings from the pressure sensor as well as the ÄKTA Cross-flow 
system. A correlation was then established (R2=1.00) to convert the reading from mV to 
bar given by:  
? = 1.676 (??) + 1.380      Equation 2.2 
where ‘?’ is pressure (in bar) and ‘??’ is the voltage reading (in mV) from the custom 
pressure sensor. Accurate monitoring of the resultant absolute pressure in the chamber 
was  possible.  The  transmembrane  pressure  (‘𝑇??’)  was  then  calculated  using  the 
following equation: 
𝑇?? = ?? − ??        Equation 2.3 
where ‘??’ is the pressure in the retentate and ‘??’ is the pressure in the permeate (bar). 
The pressure in the permeate is atmospheric pressure, therefore 𝑇?? = ??. 
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Figure 2.3: Calibration curve correlation obtained for the pressure sensor built by the RDFF by 
using the built-in pressure sensor in the ÄKTA cross-flow system. The equation obtained (R2= 
1.00) was ?? = ?.???(?󳡽) + ?.𝛑??, where ‘??’ is pressure and ‘?󳡽’ the reading from the pressure 
sensor built by the RDFF. 
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A 100 mL disposable syringe driven by a Harvard syringe pump PHD 4400 (Harvard 
Apparatus Ltd, Kent, UK) was connected to the USD membrane device and was used to 
feed the buffer (diafiltration mode) into the device at an accurate and fixed flow rate 
(‘?’) of 0.5 mL min-1 flow rate (equivalent membrane flux rate of 82 LMH. 
2.4.2  Operation of the device 
5 mL of cell suspension at the desired concentration (1x106 cells mL-1 to 100x106 cells 
mL-1)  was  prepared  for  each  experiment.  After  placing  a  membrane  into  the  USD 
device, as described in section 2.4.1, it was then filled with cell suspension using a 5 
mL  plastic  syringe.  The  chamber  was  filled  with  1.7  mL  of  cell  suspension  taking 
special care to ensure any air bubbles could escape by keeping another port open. The 
chamber was then sealed by closing the open port (taking care not to introduce any air) 
and connected to the syringe pump. All experiments were carried out in constant flux 
mode and pressure was monitored throughout.  The permeate was collected every  5 
minutes and the retentate was collected from the chamber using a clean syringe once the 
experiment finished. The 5 mL plastic syringe used to fill the device was discarded after 
emptying the remaining 3.3 mL of unused cellular suspension in a microfuge tube. This 
is the non-sheared control for the duration of the experiment (referred to as control). 
Following  processing  in  the  USD  membrane  device,  analysis  such  as  membrane 
integrity  by  trypan  blue  exclusion  dye  exclusion  and  LDH  protein  release,  for  the 
cellular suspension fed into the device (referred to as ‘?(0)’), the control (‘?(60)’ and 
the retentate (‘?(60)’) were carried out. Everything was maintained at 21 ± 1 ºC except 
for the feed and permeate samples collected for LDH analysis which were held on ice. 77 
 
2.4.2.1  Mode of operation 
Diafiltration mode was used to operate the device and is detailed below (Figure 2.4). A 
typical diafiltration run consisted of filling the device as previously described. The cell 
suspension  was  then  sheared  in  the  USD  device  for  60  minutes  and  maintained  at 
21±1ºC while flushing with CGM at a fixed flow rate of 0.5 mL min-1 (82 LMH) as 
seen in Figure 2.4.A. The permeate was collected at 5 minute intervals and immediately 
placed on ice ready for subsequent LDH analysis.  
2.5  Cell analysis 
In  this  study,  two  main  techniques  were  used  to  assess  cell  damage;  automated 
haemocytometer and LDH assay. The automated haemocytometer is based on a trypan 
blue exclusion dye technique which provides a measure of cell size, total and viable cell 
concentrations and percentage viability based on membrane integrity. The LDH assay is 
a technique that measures the amount of LDH present in the supernatant and allows 
calculation of the number of intact cells lost due to processing by measuring the number 
of whole cells in the feed, retentate and control samples. 
Both measurements complement each other; for instance, if a proportion of cells were 
fully  lysed  during  processing,  the  automated  haemocytometer  would  not  be  able  to 
account for those missing cells but LDH would. On the other hand, LDH would not be 
able to distinguish non-viable cells from completely lysed, but trypan blue exclusion 
would. 
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Figure 2.4: Schematic representation of the experimental set-up. The USD membrane device was 
fed the cellular suspension  and then connected to a syringe pump that pumps CGM only in a 
diafiltration mode. 
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2.5.1  Membrane integrity, concentration and size 
Membrane  integrity,  viable  and  total  cell  concentrations  and  size  distributions  were 
measured in quadruplicate, using the trypan blue exclusion method carried out in an 
automated system (Vi-CELL XR™, Beckman Coulter, Fullerton, CA, USA).  
Cell sizing is carried out by using video imaging through a quartz flow cell. The range 
of  detection  of  concentration  of  the  Vi-Cell  XR™  is  between  1x104  and  5x107 
cells mL-1,  therefore  samples  were  diluted  with  DPBS  accordingly  to  ensure  the 
concentration  of  the  sample  was  within  range.  In  order  to  achieve  statistically 
significant counts, the device takes fifty images per sample (each image being 10 µL of 
the  total  sample,  therefore  taking  a  minimum  of  100  cells  per  count).  Analytical 
settings, such as cell size in suspension and declustering degree, for each cell type were 
optimized within the lab in collaboration with Dr Kate Lawrence and Mr Longster. 
2.5.2  Cell damage 
Applying mechanical or chemical stresses on cells can lead to damage or injury which 
can cause cell death (Carmen et al. 2012; Chisti 2001; Goergen et al. 1993). Cell death 
can be manifested by the loss of membrane integrity and the subsequent uncontrolled 
release  of  cytoplasmic  products  into  the  supernatant,  by  a  change  in  the  rate  of 
proliferation  or  through  “cell  suicide”,  expressed  by  changes  in  morphology  and 
expression  of  proteins  (referred  to  as  “programmed  cell  death”)  prior  to  loss  of 
membrane integrity.  80 
 
Cell  damage  analysis  assay  by  LDH  release  was  used  for  the  majority  of  the 
experiments. Cell growth and proliferation and programmed cell death assay (FLICA® 
assay) were used in specific experiments to gain a more in-depth insight into the effect 
of processing (see Chapter 3, section 3.3.4). 
2.5.2.1  Cell damage analysis by LDH release 
LDH is a stable cytosolic enzyme that is released upon cell lysis. LDH was measured 
using  a  colourimetric  assay  (CytoTox-96®  Non-Radioactive  Cytotoxicity  Assay, 
Promega  UK,  Southampton,  UK)  that  quantitatively  measures  LDH  released  in  the 
supernatant by using a 30 minute coupled enzymatic assay which converts a tetrazolium 
salt (INT) into a red formazan product. The amount of product formed is proportional to 
the amount of LDH as seen from the reaction below: 
LDH 
NAD+ + lactate → pyruvate + NADH 
 
Diaphorase 
NADH + INT → NAD+ + formazan (red) 
The assay was carried out as indicated by the protocol provided by manufacturer and 
detailed below.  
Once  the  retentate  was  collected  from  the  USD  membrane  separation  device  after 
operation, cells were aliquoted at a range of 10,000 to 20,000 cells per well in 100 µL of 
CGM into eight wells of a 96-well round-bottom plate (Nalgene Nunc International, 81 
 
New York, USA). The same was done for the non-sheared control sample and the feed 
sample (placed on ice at the start of the experiment). A total of 10 μl of lysis solution 
(9% (v/v) Triton® X-100) was added to four wells for each sample, in order to measure 
the “total LDH release” (i.e. maximum release from sample). A total of 10 μl of CGM 
was added to the remaining four wells for each sample to correct for volume, these 
wells were used to measure the “external LDH release” (i.e. release from non-viable and 
already lysed cells). The permeate samples that were collected at 5 minute intervals, on 
ice, were plated in four wells at 50-100 µL per well. CGM was added to correct for the 
volume difference bringing all wells to a total volume of 110 μl. The plate was then 
incubated for 45 minutes in a humidified chamber (37°C, 5% CO2) and subsequently 
centrifuged at 250 x g for 4 minutes. 50 μl of the supernatants were transferred from all 
wells to a fresh 96-well flat-bottom enzymatic assay plate (Nalgene Nunc International, 
New York, USA). The Assay Buffer (contents not disclosed by Promega) was thawed 
in a waterbath, protected from light and 12 mL was added to a bottle of Substrate Mix 
(contents  not  disclosed),  referred  to  as  reconstituted  Substrate  Mix.  50  μl  of  the 
reconstituted  Substrate  Mix  was  added  to  each  well  of  the  plate.  The  plate  was 
incubated at 21 ± 1ºC and protected from light for 30 minutes. Lastly, 50 μl of Stop 
Solution (1 M acetic acid) was added to each well and absorbance was recorded at 
490 nm (reference wavelength 690 nm if one needed). Results were read within one 
hour after the addition of Stop Solution. 
The assay was previously optimized for all cell lines producing standard curves for cell 
numbers varying from 5,000 to 40,000 to assess the linearity range of the assay (refer to 
Chapter 3, section 3.4 Optimizing lactate dehydrogenase assay). To obtain a reliable 82 
 
signal the number of cells per well was kept between 10,000 and 20,000. Four intra 
assay replicates were performed on each single sample obtained from processing and a 
background control was run for each experiment.  
2.5.2.2  Cell growth and proliferation analysis for HCA2 cell line 
For in-depth analysis of the growth, proliferation and morphology of cell populations, 
both processed and control samples were cultured and counted every 24 hours post 
seeding, for 76 hours.  
Cells were processed at 25x107 cells mL-1 under low and high disc speeds and Vi-CELL 
XR™ counts were carried out post-processing. 6 well plates were seeded with 2x105 
viable cells per well for each sample (processed and control for both experiments) and 
incubated for 72 hrs at 37ºC, 5% CO2. 
Cell  counts  using  Vi-Cell  XR™,  as  well  as  light  microscopy  imaging  of  the  wells 
(Eclipse TE2000-U, microscope camera DS-Fi1, Nikon, Japan) were carried out every 
24  hours  to  monitor  the  attachment,  cell  number  proliferation  and  morphological 
changes, if any. Growth curves and rate constants were established and morphological 
analysis  was  carried out using  an image analysis software (see section  2.5.3  Image 
processing - morphology). 
2.5.2.3  Cell death by apoptosis for HCA2 cell line 
Detection of cell death by apoptosis in whole cells can be identified by measuring the 
activity  of  caspase.  Cell  death  analysis  was  conducted  using  the  CaspaTag™  Pan-
Caspase In Situ assay kit, Fluorescein (Millipore, Watford, UK) for the HCA2 cell line 83 
 
only.  The  assay  consists  of  a  membrane-permeant,  fluorescent  labelled  inhibitor  of 
caspase (FLICA®) which bonds covalently to the activated caspase enzymes. FLICA® 
reagents are cell permeable and non-cytotoxic markers and once they enter the cell, they 
covalently bind to active caspase (Ekert et al. 1999). 
The  cell  suspensions  were  processed  in  the  USD  membrane  separation  device  (as 
described in section 2.4.2 Operation of the device) and the processed samples were held 
for 2 hours post-processing to allow increase of expression of apoptotic markers if any. 
Cells were then adjusted to 5x106 total cells in 300 µL of hCGM using Vi-CELL XR™ 
data retrieved for each processed sample. The lyophilized FLICA® reagent supplied was 
reconstituted with 50 µL of DMSO and mixed until completely dissolved. 7 µL of 30X 
FLICA®  reagent  were  added  to  the  samples  and  subsequently  flicked  to  mix.  The 
sample tubes were covered in tin foil to protect them from light and incubated for 1 
hour  in  a  37ºC,  5%  CO2  incubator,  gently  agitating  the  tubes  twice  during  the 
incubation  time  to  resuspend  settled  cells.  The  wash  buffer,  supplied  as  a  10X 
concentrate was diluted to create a 1X solution by using deionised water. 2 mL of 1X 
wash buffer was added to each tube and gently mixed before samples were centrifuged 
for 5 minutes at 400 x g. The supernatant was removed and cell pellets were loosened 
from the tube. A further wash step using 1 mL of 1X wash buffer was carried out. The 
cell samples were finally resuspended in 300 µL of 1X wash buffer and 1.5 µL of 
propidium iodide (PI) was added to each tube. A wash step was performed using 500 
µL of DPBS and spun as previously described. The supernatant was removed and the 
cells  were  resuspended  in  mounting  medium  (VECTASHIELD®  Mounting  Media, 
Vector  Laboratories,  Peterborough,  UK)  containing  4',6-diamidino-2-phenylindole 84 
 
(DAPI). 10 µL of each sample were placed on microscope slides and covered with a 
cover slip. 
An apoptotic control was carried out by adding an inducer of apoptosis to growing 
HCA2  cells.  A  stock  of  1  mM  staurosporine  (STA;  Sigma-Aldrich,  Ayrshire,  UK) 
solution in DMSO stored at -20ºC was diluted in hCGM to create the 10 µM and 20 µM 
working  concentrations.  The  hCGM  was  replaced  by  5  mL  of  hCGM  with  added 
working STA and incubated for ~ 6 hrs at 37ºC, 5% CO2. The cells were subsequently 
harvested  using  the  enzymatic  detachment  method  as  previously  described  (section 
2.3.4.1 HCA2 and P4E6 cell lines), immediately prior to application of the staining 
procedure as described above for the processed samples. 
Images  were  collected  using  fluorescent  microscope  (Okolab  enclosed  microscope 
camera DS-Fi1, Nikon, Japan). FLICA® emission was measured at 518 nm, PI emission 
at 620 nm and DAPI emission at 460 nm. 
2.5.3  Image processing - morphology 
Software  for  image  processing  was  developed  using  MATLAB  Image  Processing 
Toolbox  (MathWorks,  Cambridge,  UK)  by  Nicolas  Jaccard  in  the  Biochemical 
Engineering Department at UCL. 
Image analysis enables rules to be set to classify cells depending on their morphological 
characteristics. This can be especially important post-processing when the cells might 
change morphology due to the exposure to harsh operating conditions (Kretzmer and 
Schügerl 1991). 85 
 
The  image  processing  algorithms  implemented  using  the  script  created  by  Nicolas 
Jaccard, operates in  three steps. Firstly, it  detect  the objects  on the image;  then it 
corrects and allocates each object detected into a category, using rules based on decision 
flow chart shown in Figure 2.5; lastly, it outputs the results in an excel file.  
Figure 2.6.A shows an example of a raw image as obtained from Vi-CELL XR™ and 
Figure 2.6.B an output from the script after classifying the cells based on morphology. 
Counts provided by the image processing algorithms were compared against manual 
counts to verify the accuracy of the software. 
2.5.4  Rheology studies 
Rheology  studies  were  carried  out  using  a  cup-and-bob  rheometer  (LVDV-II+, 
Brookfield, MA, USA). Both the control and the processed samples were exposed to 
shear rates ranging from 37.5 s-1 to 1,500 s-1 in seven increments in both increasing and 
decreasing sweeps. The viscometer was allowed to complete 5 revolutions at each speed 
before taking a measurement. The temperature was maintained at 21 ± 1°C using a 
waterbath and a peristaltic recirculation pump. Two spindles were used depending on 
the apparent viscosity of the sample, CP-40 (cone angle 0.8°C and sample volume 0.5 
mL) and CP-42 (cone angle 1.565° and sample volume 1 mL). Both spindles used were 
calibrated using both water and low viscosity (~5 mPa s) silicone oil standard (RT5, 
Cannon Instrument Company, PA, USA). The measurement error was found to be less 
than 4%.         
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Figure  2.5:  Decision  flow  chart  used  by  the  image  processing  algorithms  implemented  using 
MATLAB  Image  Processing  Toolbox  (MathWorks,  Cambridge,  UK)  to  categorize  cells  by 
morphology. 
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Figure 2.6: Sample image obtained of cellular suspension after processing. (A) ViCell XR™   raw 
image  and  (B)  script  created  by  Nicolas  Jaccard  using  MATLAB  Image  Processing  Toolbox 
(MathWorks, Cambridge, UK). See Figure 2.5 for explanation of object identification.   88 
 
2.6  Transmission of LDH using the HCA2 cell line 
Knowledge on transmission was used to develop an understanding of retention of LDH 
in the USD membrane separation device which was then followed by a confirmation of 
the observed phenomena with an empirical study of transmission during usage of the 
membrane  and  modeling  of  the  retentate  during  operation.  All  experiments  in  this 
section were carried out using the USD membrane separation device in diafiltration 
mode, connected to the syringe pump that flushed hCGM for 60 minutes (although 
some specified shorter times of operations), at a disc speed of 10,000 rpm at a 0.5 mL 
min-1 rate. All of these parameters potentially impact on the transmission of LDH. 
2.6.1  Mass balancing of LDH during processing 
This section outlines the equations and assumptions used to determine the concentration 
of soluble LDH present in the retentate of the USD membrane separation device based 
on measurements of the permeate (output stream) and hence the determination of the 
total soluble LDH released during processing.  
Figure 2.7 shows the block diagram for the experimental set-up. From left to right, a 
buffer feed, ‘?’, is supplied to the USD membrane separation device at a constant flow 
rate,  ‘Q’.  The  permeate  stream,  ‘?’,  exiting  the  USD  membrane  separation  device 
(‘Block USD device’) is pooled over 5-minute intervals, where ‘i’ denotes the interval 
number, ‘i’ = 1 to 12. The average concentration of extracellular LDH present in the 
retentate for any given time interval (‘∆𝑡𝑖’) is estimated using: 
[?]𝐿?HEXT(∆𝑡𝑖) =
[?]???(∆𝑡𝑖)
𝑇(𝑡)       Equation 2.4 89 
 
   
Figure 2.5: Block diagram for the experimental set-up used to derive the amount of soluble LDH 
present during ‘∆ti’.    90 
 
where ‘𝑇(𝑡)’ is the LDH transmission at time ‘𝑡’ and ‘[?]𝐿??(∆𝑡𝑖)’ is the measured 
concentration of LDH present in the permeate collected over interval ‘∆𝑡𝑖’ and subscript 
‘ ?𝑋𝑇’ refers to extracellular component. The transmission measured is at the end of 
the run, ‘𝑡 = 𝑡?’: 
𝑇(𝑡?) =
[?]???(𝑡?)
[?]???_?𝑋𝑇(𝑡?)         Equation 2.5 
where ‘[?]𝐿??(𝑡?)’ is the concentration of extracellular LDH present in the permeate 
collected over the period ‘𝑡? − 1 min’ to ‘𝑡?’ and ‘[?]𝐿???𝑋𝑇(𝑡?)’ is the measured 
concentration of extracellular LDH in the retentate. Assuming ‘𝑇(𝑡)’ is constant and 
equal to ‘𝑇(𝑡?)’ throughout the experiment, the average concentration of extracellular 
LDH present in the retentate for any given time interval is given by: 
 [?]𝐿???𝑋𝑇(∆𝑡𝑖) =
[?]???(∆𝑡𝑖)
𝑇(𝑡?)    Equation 2.6 
The total amount, ‘?’, of extracellular LDH present in the system given in Figure 2.7 
after any interval ‘∆𝑡𝑖’ is: 
∴ ?𝐿???𝑋𝑇(∆𝑡𝑖) = ?? × [?]𝐿???𝑋𝑇(∆𝑡𝑖) + ∑ ? × ∆𝑡𝑖 × [?]𝐿??(∆𝑡𝑖) 𝑖
𝑖=1  Equation 2.7 
or from Eq 2.6: 
?𝐿???𝑋𝑇(∆𝑡𝑖) = ?? ×
[?]???(∆𝑡𝑖)
𝑇(𝑡?) + ∑ ? × ∆𝑡𝑖 × [?]𝐿??(∆𝑡𝑖) 𝑖
𝑖=1    Equation 2.8 
where ‘??’ is the volume of retentate (fixed). Lastly, the amount of intracellular LDH 
present in the retentate after any given time interval ‘∆𝑡𝑖’, is given by: 
?𝐿????𝑇(∆𝑡𝑖) = ?? × [?]𝐿????𝑇(0) − ?𝐿???𝑋𝑇(∆𝑡𝑖)    Equation 2.9 91 
 
where ‘[?]𝐿????𝑇(0)’ is the concentration of LDH present in the intact cells  in the 
retentate at ‘𝑡 = 0’ (and is given by ‘[?]𝐿????𝑇(0) = [?]𝐿??𝑇?𝑇(0) − [?]𝐿???𝑋𝑇(0)’). 
All of the membrane studies to test the effect of disc speed, cell concentration and cell 
ageing were carried out over a period ‘𝑡?’ = 60 min. To test the assumption that ‘𝑇(𝑡)’ 
is  constant  and  equal  to  ‘ 𝑇(𝑡? = 60) ’  (i.e.  the  membrane  is  not  changing  its 
transmission characteristics) experiments were carried out for varying values of ‘𝑡?’ and 
‘𝑇(𝑡?)’ recorded in each case.  
The raw data for these experiments are given in Table B and Figure 2.8. An average 
transmission coefficient of 0.80 was recorded for ‘𝑡?’ values ranging from 15 to 60 min 
with no significant trend noted with varying ‘𝑡?’.  
Lastly, Figure 2.9 shows the transmission coefficients obtained during the last minute of 
a  60  min  operation  for  varying  concentrations  of  intact  cells  fed  into  the  USD 
membrane separation device as measured by trypan blue exclusion and analyzed by 
ViCell XRTM. Three repeats were carried out at 6 different concentrations of intact cells 
fed. Figure 2.9 shows an average of the three repeats at each concentration, showing by 
the  use  of  x-errors  bars,  the  range  of  concentrations  of  intact  cells  fed  that  each 
averaged point covers. It appears that after the first two low concentration points which 
lie  around  transmission  coefficient  of  0.80,  a  plateau  at  around  0.87  transmission 
coefficient seems to occur when going to higher concentrations of intact cells fed. 
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B.   ‘??’ 
 
(min) 
‘[?]𝑳??(?󵑭)’ 
 
µU mL-1 
‘[?]𝑳????𝑻(?󵑭)’ 
 
µU mL-1 
‘𝑻(?󵑭)’ 
1st repeat 
(×) 
15  0.38 ± 0.03  0.56 ± 0.03  0.69 
30  0.30 ± 0.01  0.34 ± 0.01  0.87 
45  0.33 ± 0.06  0.39 ± 0.08  0.83 
60  0.60 ± 0.01  0.84 ± 0.06  0.72 
2nd repeat 
(+) 
15  0.26 ± 0.02  0.34 ±0.14  0.76 
30  0.35 ± 0.07  0.41 ± 0.02  0.87 
45  0.44 ± 0.09  0.56 ± 0.02  0.78 
60  0.74 ± 0.01  0.84 ± 0.02  0.88 
 
Figure 2.6: Effect of processing time, ‘?󵑭’, on the measured transmission of LDH. Two repeats of 
four experiments carried out for set times, ‘?󵑭’ showing (A) transmission coefficient (‘𝑻(?󵑭)’) as a 
function of ‘?󵑭’. Dashed line is for mean of ‘𝑻(?󵑭 = ??)’ values. Table (B) shows the raw data (n = 
2) for each of the four separate experiments and both repeats which were carried out under the 
same operating conditions with two separately prepared cell suspensions (‘Q’= 0.5 mL min-1, ‘VR’= 
1.7 mL, ‘N’= 10,000 rpm, ‘[?]𝑻?_𝑻?𝑻(?)’= 2.0×106 cells mL-1).    
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Figure 2.7: Transmission coefficient (‘𝑻(??)’) based on the last minute of ‘[?]𝑳??(?󵑭’ )’ over the 
‘[?]𝑳????𝑻(??)’ for HCA2 cell line with varying numbers of intact cells fed mL-1 into the USD 
membrane  separation  device.  Dashed  line  shows  an  average  of  0.87  which  appears  to  be 
independent of intact cells fed concentration (‘[?]𝑻?????𝑳𝑳(?)’). Error bars show ± 1 s.d. (n = 3).   94 
 
Chapter 3.  The impact of processing on loss of intact cells 
3.1  Introduction 
With cell-based therapies, careful bioprocessing of cell populations is of the utmost 
importance because the cells are the product (Mason and Hoare 2006). It is therefore 
important to ensure that cell homeostasis is not disrupted and this can be achieved by, 
for  example,  preventing  increases  in  necrotic  or  apoptotic  populations,  avoiding 
changes  in  morphology  (Fernandez-Pol  1978)  or  changes  in  growth,  metabolism  or 
surface  proteins  (Lee  et  al.  2009).  However,  different  cell  lines  have  different 
characteristics, different resistances to shear forces (Acosta-Martinez et al. 2010) and 
varying mechanical strengths (Stamenovic 2008) making bioprocessing complex and 
cell line specific. 
In addition, current processing techniques suffer from drawbacks when applied to cell 
manufacturing. For example, most cell-based therapies to date use batch centrifugation 
for washing, buffer exchange and concentration of the cellular suspension. However, 
centrifugation has proven to be a difficult step to operate while maintaining sterility 
(Mason and Hoare 2006). With the current processing set-up, processing large volumes 
of cells require multiple rounds of centrifugation with several operators, becoming not 
only operator dependent but very time consuming (Pattasseril et al. 2013). Therefore if 
these  therapies  are  to  be  commercialized  at  an  industrial  scale,  the  processing 
bottlenecks will shift to the downstream steps and will need to be addressed (Pattasseril 
et al. 2013; Rowley et al. 2012b). The industry faces major challenges according to 
Pattasseril et al. (2013). One of these challenges is to have the capacity downstream to 
manufacture  and  process  large  volumes  of  cells  in  suspension  (100  to  1,000  litres) 95 
 
whilst achieving high cell concentration and high percentage viability within acceptable 
limits. Current potential alternatives to batch centrifugation include continuous flow 
centrifugation systems such as kSep from KBI Biopharma or tangential flow filtration 
(TFF) units such as Uniflex from GE Healthcare. These can potentially allow for more 
contained  and  less  labour-intensive  processing  than  is  achieved  using  batch 
centrifugation  (Pattasseril et al. 2013).  
TFF  has  been  studied  for  many  years.  However,  due  to  the  complexity  of  this 
processing step, to translate findings from large-scale clarification of mammalian cell 
cultures (Roach et al. 2008) to the production of cells for therapy, a number of operating 
parameters will need to be optimized. Ultra scale-down (USD) tools might offer a cost-
effective  solution  for  the  need  to  study  large  numbers  of  operating  variables.  USD 
devices  allow  for  the  investigation  of  several  manufacturing  hydrodynamic 
environments (McCoy et al. 2009; McCoy et al. 2010; McQueen et al. 1987; Zoro et al. 
2009) and geometries (Acosta-Martinez et al. 2010) using relatively small amounts of 
process material. In this way, the throughput of the experimental phase is significantly 
increased  in  an  efficient  manner  making  USD  tools  suitable  for  rapid  screening  of 
manufacturing  processes  and  identifying  potential  areas  of  damage.  The  USD 
membrane separation device in particular allows for the investigation of the effect of 
altering independently parameters such as shear rate and flux rate.  
This chapter investigates the use of the USD membrane separation device to create and 
populate  a design space by identifying bioprocessing conditions  associated with  the 
wash  and  buffer  exchange  steps  within  the  filtration  process.  Mapping  relevant 96 
 
operating conditions such as shear rate (disc speed), cell ageing and cell concentration 
(and hence also viscosity) will help identify the sources of stress and resulting product 
quality loss. It is important to bear in mind that the USD membrane separation device is 
not a direct mimic of a full-scale TFF system, but rather facilitates the assessment of the 
impact of processing at full-scale using scalable parameters.  
All experiments presented in this chapter were carried out using the diafiltration set-up, 
with hCGM being pumped into the system for 60 minutes at a flow rate of 0.5 mL min-1 
(≈ 82 LMH). The disc speed was set to either 6,000 rpm (‘γ’ = 44,000 s-1) or 10,000 rpm 
(‘γ’ = 116,000 s-1) and the concentration of the feed material was ~2x106 cells mL-1. The 
cells  that  are  referred  to  as  “fresh”  cells,  essentially  had  zero  hours  hold  prior  to 
processing. Future changes will address different cell concentrations and ages. 
3.2  Calculations 
Due to the need to collect material for analysis over a period of ‘∆𝑡’, it is necessary to 
record performance as an average over a particular time interval, ‘∆𝑡𝑖’. One method of 
characterizing the effect of any operating condition is to monitor the proportion, ‘ɷ’, of 
intracellular LDH remaining versus time: 
𝜔(∆𝑡𝑖) =
??????𝑇(∆𝑡𝑖)
??????𝑇(0)      Equation 3.1 
where ‘?𝐿????𝑇(∆𝑡𝑖)’ is a caclulated average amount of intracellular LDH (that of intact 
cells)  remaining  in  the  retentate  in  the  USD  membrane  separation  device  over  the 
interval ‘∆𝑡𝑖’ and ‘?𝐿????𝑇(0)’ is the calculated amount of intracellular LDH present in 97 
 
the USD membrane separation device at the start of the experiment (i.e. in the retentate 
at ‘𝑡 =  0’): 
?𝐿????𝑇(0) = ?𝐿??𝑇?𝑇 (0) − ?𝐿???𝑋𝑇(0)     Equation 3.2 
where ‘?𝐿??𝑇?𝑇(0)’ and ‘?𝐿???𝑋𝑇(0)’  are the measured total and external amounts of 
LDH present in the USD membrane separation device at the start of the experiment, at 
‘𝑡 = 0 min’.  
The following relationships depend on the assumption that the total amount of LDH is 
the system (retentate and permeate) remains constant throughout the duration of the 
membrane shear study. For any particular interval, ‘∆𝑡𝑖’, ‘?𝐿????𝑇(∆𝑡𝑖)’ is given by: 
?𝐿????𝑇(∆𝑡𝑖) = ?𝐿????𝑇(0) − (∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 + ?𝐿???𝑋𝑇(∆𝑡𝑖))   Equation 3.3 
where ‘∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’ is the sum of the amounts of LDH recorded in the permeate 
stream  collected  from  the  start  of  the  experiment  to  the  end  of  interval  ‘∆𝑡𝑖’  and 
‘?𝐿???𝑋𝑇(∆𝑡𝑖)’ is the calculated average amount of extracellular LDH present in the 
retentate during interval ‘∆𝑡𝑖’.  
The concentration ‘[?]𝐿??_?𝑋𝑇(∆𝑡𝑖)’ is given by: 
[?]𝐿???𝑋𝑇(∆𝑡𝑖) =
[?]???(∆𝑡𝑖)
𝑇(𝑡?)     Equation 3.4 
where  ‘[?]𝐿??(∆𝑡𝑖)’  is  the  concentration  of  extracellular  LDH  measured  in  the 
permeate  collected  over  interval  ‘∆𝑡𝑖’  and  ‘𝑇(𝑡?)’  is  the  transmission  of  LDH  as 
measured from the retentate and permeate concentrations of LDH at the end of  the 98 
 
experiment. Therefore the average amount of extracellular LDH present in the retentate 
over interval ‘∆𝑡𝑖’ is given by: 
?𝐿???𝑋𝑇(∆𝑡𝑖) =
[?]???(∆𝑡𝑖)
𝑇(𝑡?) × ??     Equation 3.5 
where ‘??’ is the permeate volume over interval ‘∆𝑡𝑖’ (equal to ‘? × ∆𝑡𝑖’). Hence from 
equation 3.3 and 3.5: 
?𝐿????𝑇(∆𝑡𝑖) = ?𝐿????𝑇(0) − ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 − (
[?]???(∆𝑡𝑖)
𝑇(𝑡?) × ??)    Equation 3.6 
Using values measured experimentally, equation 3.6 becomes: 
?𝐿????𝑇(∆𝑡𝑖) = [?]𝐿????𝑇(0) × ?? − ∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 − (
𝑉?×[?]???(∆𝑡𝑖)
𝑇(𝑡?) )         
Equation 3.7 
where ‘??’ is the volume of the retentate, hence: 
    𝜔(∆𝑡𝑖) =
[?]?????𝑇(0)×𝑉𝑅−∑ ([?]???(∆𝑡𝑖)×?×∆𝑡𝑖) 𝑖
𝑖=1 −(
𝑉?×[?]???(∆𝑡𝑖)
𝑇(𝑡?) )
[?]?????𝑇(0)×𝑉𝑅
  Equation 3.8 
This parameter is calculated at 5-minute intervals using the LDH readings from the 
permeate. Therefore the decrease of intracellular amount of LDH in the USD membrane 
separation device as a proportion of the initial amount of intracellular LDH can be 
investigated over time. 
3.3  Effect of disc speed (shear rate) on HCA2 fibroblasts 
The effect of low and high disc speeds 6,000 and 10,000 rpm (or shear rates of 44,000 
and 116,000 s-1 respectively) on cell damage on the HCA2 cell line was assessed by the 99 
 
release of LDH, by evaluation of cell membrane integrity (trypan blue exclusion) and 
by generation of post-processing growth curves and measurement of apoptotic markers. 
3.3.1  Physical impact as measured by LDH release 
Five repeats at each of the two disc speeds using freshly harvested cells each time were 
carried out on different occasions. The raw data and calculations for an example run at 
high disc speed will be used to demonstrate how the figures and tables for the LDH data 
for  each  repeat  were  generated.  For  all  other  runs  the  raw  data  is  included  in 
Appendix A.1. 
The LDH data for the first study at high disc speed is given in Tables 3.1, 3.2 and 3.3. 
Table 3.1.A gives the average concentration and amount of extracellular LDH in the 
permeate collected over 5-minute intervals and over the final minute of operation (‘𝑡?’). 
The amount is based on the concentration measured and the volume collected. The 
concentration of total and extracellular LDH was measured for each of (a) the retentate 
pre-processing  (i.e.  starting  point,  ‘[?](0)’),  (b)  control  (i.e.  non-sheared  sample, 
‘[?](60)’) held at 21 ± 1ºC in a centrifuge tube concurrently for the duration of the 
experiment and (c) retentate post-processing (i.e. end point, ‘[?](60)’) samples and the 
results are given in Table 3.1.B.  
The amounts of total, extracellular and intracellular LDH for each of (a) the retentate 
pre-processing  (‘ ?(0) ’),  (b)  control  (‘ ?(60) ’)  and  (c)  retentate  post-processing 
(‘?(60)’) samples were evaluated using the measured concentrations and are given in 
Table 3.2.A along with (d) the total LDH measured in the permeate (from Table 3.1.A).  100 
 
 
 
 
 
 
 
Table 3.1: Tables (A) and (B) show the raw LDH data for the first study at high disc speed (‘N’ = 
10,000  rpm,  ‘Q’  =  0.5  mL  min-1,  ‘VR’  =  1.7  mL,  ‘[?]𝑻?𝑻?𝑻(?)’  =  2.05×106  cells  mL-1).  Values 
reported to 2 decimal places (n = 4).   
A. 
  
Time  
‘∆???’ (min) 
‘[?]𝑳??(∆???)’ 
(µU mL-1; n = 4) 
?𝑳??(∆???) = 
[?]𝑳??(∆???) × ? × ∆???’ (µU) 
     
0  0  0 
     
0-5  0.76 ± 0.037  1.91 ± 0.092 
     
5-10  0.52 ± 0.061  1.29 ± 0.153 
     
10-15  0.33 ± 0.024  0.82 ± 0.061 
     
15-20  0.11 ± 0.023  0.27 ± 0.058 
     
20-25  0.10 ± 0.015  0.26 ± 0.038 
     
25-30  0.07 ± 0.025  0.17 ± 0.062 
     
30-35  0.20 ± 0.012  0.50 ± 0.031 
     
35-40  0.09 ± 0.012  0.22 ± 0.030 
     
40-45  0.04 ± 0.007  0.09 ± 0.017 
     
45-50  0.12 ± 0.027  0.31 ± 0.067 
     
50-55  0.26 ± 0.004  0.64 ± 0.011 
     
55-59  0.23 ± 0.026  0.47 ± 0.052 
    59-60  0.26 ± 0.008  0.13 ± 0.004 
‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’   
7.08 ± 0.230 
B. 
  
[LDH] µU mL-1 ± 1 s.d. (n = 4) 
Disc speed   10,000 rpm 
Process stream  Notation  Total 
(‘LDH_TOT’) 
Extracellular 
(‘LDH_EXT’) 
Pre-processing   ‘[?](0)’   14.18 ± 0.93  0.65 ± 0.18 
Control   ‘[?](60)’  14.68 ± 0.32  1.01 ± 0.15 
Post-processing   ‘[?](60)’  9.39 ± 0.24  0.32 ± 0.09 101 
 
 
 
 
Table 3.2: Table (A) shows the amount of LDH calculated for each stream (‘N’ = 10,000 rpm, ‘Q’ = 
0.5 mL min-1, ‘VR’ = 1.7 mL, ‘[?]𝑻?𝑻?𝑻(?)’ = 2.05×106 cells mL-1). Box diagram (B) of the USD 
membrane separation device showing process streams. Values reported to 2 decimal places (n = 4). 
   
A.      LDH µU ± 1 s.d. (n = 4) 
   Disc speed  10,000 rpm 
Process 
stream  Notation  Total 
(‘LDH_TOT’) 
Extracellular 
(‘LDH_EXT’) 
Predicted 
internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  24.10 ± 1.58  1.11 ± 0.3  22.98 ± 1.61 
Control  (b) ‘?(𝑡?) = [?](60) × ??’  24.96 ± 0.55  1.73 ± 0.26  23.23 ± 0.61 
Post-processing  (c)  ‘?(𝑡?) = [?](60) × ??’  15.97 ± 0.4  0.54 ± 0.16  15.43 ± 0.43 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  7.08 ± 0.12       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’   23.05 ± 0.19  7.62 ± 0.19  15.43 ± 0.43 102 
 
A. 
  
[LDH] µU mL-1 ± 1 s.d. (n = 4) 
[?]𝑳??(?󵑭) (measured)  0.26 ± 0.01 
[?]𝑳????𝑻(??)(measured)  0.32 ± 0.09 
𝑻(?󵑭) = [?]𝑳??(??) [?]𝑳????𝑻(??) ⁄   0.80  
 
 
 
 
 
 
 
 
 
 
Table 3.3: Concentrations of soluble LDH measured in the retentate and permeate streams. Table 
(A) shows the concentration of soluble LDH measured at ‘?󵑭’ for the retentate and the permeate 
used to calculate the transmission. Table (B) shows the average amounts of extracellular LDH 
predicted in the retentate, ‘?𝑳????𝑻(∆???)’, the average amount of intracellular LDH remaining in 
the retentate, ‘?𝑳????𝑻(∆???)’, and the proportion of intracellular LDH remaining, ‘𝝎(∆???)’, in the 
USD membrane separation device over each of the 5-minute intervals. Values rounded to 2 decimal 
places (n = 4).   
B.       
Time 
‘∆???’ 
(min) 
‘?𝑳????𝑻(∆???) =
??×[?]𝑳??(∆???)
𝑻(?󵑭) ’ 
(µU) 
‘?𝑳????𝑻(∆???) =
 ?𝑳????𝑻(∆???−?) −
?𝑳????𝑻(∆???)’  
(µU) 
‘ ) ( i t   ’ 
0  0.00  22.98  1.00 
0-5  1.61  21.37  0.93 
5-10  1.09  20.28  0.88 
10-15  0.70  19.58  0.85 
15-20  0.23  19.35  0.84 
20-25  0.22  19.13  0.83 
25-30  0.15  18.99  0.83 
30-35  0.42  18.57  0.81 
35-40  0.19  18.38  0.80 
40-45  0.08  18.30  0.80 
45-50  0.26  18.04  0.78 
50-55  0.54  17.50  0.76 
55-60  0.40  17.10  0.74 103 
 
The  total  amount  of  LDH  present  after  processing  in  (c)  the  retentate  and  (d)  the 
permeate is also given in Table 3.2.A. A box diagram of the USD membrane separation 
device and process streams is shown in Table 3.2.B and aims to aid the interpretation of 
the  mass  balance  by  outlining  the  process  streams  (labelled  (a)  to  (d)).  Important 
information may be acquired from the interpretation of this mass balance and is outlined 
below. 
For example, there is no significant difference in the total LDH present in the retentate 
pre-processing  (‘?𝐿??𝑇?𝑇(0)’, labelled ‘a’)  and the non-sheared control  held for  60 
minutes (‘?(60)’, labelled ‘b’). This is in agreement with previous studies which have 
reported LDH in serum to be stable for at least three days at room temperature (Berger 
and Tietz 1976) and confirms that there should not be any loss of LDH activity by 
merely holding the sample without processing.  
Moreover, there is good agreement in the amount of total LDH in the retentate stream 
pre-processing (‘?𝐿??𝑇?𝑇(0)’, labelled ‘a’ in the diagram) and that after processing by 
the sum of the two output process streams; retentate post-processing (‘?𝐿??𝑇?𝑇(60)’, 
labelled ‘c’) and permeate (‘∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’, labelled ‘d’).  Therefore, all of the LDH 
mass is accounted for. 
Using the data in Tables 3.1.A and 3.1.B, ‘𝑇(𝑡?)’, ‘?𝐿????𝑇(∆𝑡𝑖)’ and ‘𝜔(∆𝑡𝑖)’ values 
were  calculated  and  are  given  in  Tables  3.3.A  and  3.3.B.  Table  3.3.A  shows  the 
concentration  of  extracellular  LDH  present  in  the  permeate  collected  over  the  last 
minute  of  processing,  ‘ [?]𝐿??(𝑡?) ’  obtained  from  Table  3.1.A,  to  be 104 
 
0.26 ± 0.002 µU mL-1.  This  value  is  in  agreement  with  the  concentrations  of  LDH 
measured in the permeate stream during the last 10 minutes of operation, which vary 
from  0.23  to  0.26  µU mL-1.  Moreover,  the  standard  error  for  the  concentration  of 
extracellular  LDH  in  the  retentate  post-processing 
(‘[?]𝐿???𝑋𝑇(60)’ = 0.32 ± 0.09 µU mL-1, Table 3.2.A) gives confidence of the accuracy 
of this value as an estimate of the population mean. The transmission coefficient is 
heavily depends on both ‘[?]𝐿??(𝑡?)’ and ‘[?]𝐿???𝑋𝑇(60)’ so the above considerations 
are relevant to gain confidence on the value for the transmission coefficient. The value 
obtained which will be used to model the entire run, also shown in Table 3.3.A, is 0.80 
± 0.04. As will be discussed later, this value is in agreement with the those obtained for 
the four remaining runs.  
The  impact  of  disc  speed  on  retention  of  intact  cells  as  measured  by  remaining 
intracellular LDH is shown by plots of ‘𝜔(∆𝑡𝑖)’ with time in Figure 3.1 (where the 
information given in Table 3.3.B is shown in Figure 3.1.C). 
Each plot in Figure 3.1 shows both low and high disc speeds. Each of the four trends 
shown in Figures 3.1.A and 3.1.B are for a different cell harvest. For each of Figures 
3.1.C, 3.1.D and 3.1.E the trends shown for the two disc speeds are from the same cell 
harvest. As will be seen, even though there is variability at high disc speed, all repeats 
fall within one standard deviation. However, this was not the case at low disc speed, 
where Figure 3.1.B is evidently an outlier. Analyzing the raw data (Appendix A1) for 
this particular repeat, it was seen that the measured amounts of LDH in the permeate 
stream were unusually high compared to the other repeats. The amount of LDH  105 
 
 
Figure 3.1: Membrane processing of feed (0 hour cell ageing) HCA2 cells – effect on cell damage as 
measured by LDH at low (○) and high (▲) disc speeds of 6,000 and 10,000 rpm (‘𝜸’ = 44,000 s-1 and 
116,000 s-1 respectively).  Figures (A) to (E) are five repeats of the same conditions. Data shown in 
Table 3.3.B is plotted in figure 3.1.C (n = 4).   106 
 
collected in the permeate at low disc for the second repeat was 6.56 µU whereas the 
average of the remaining four repeats was 1.32 ± 0.25 µU. This is due to the higher 
concentration of total cells measured at the start of the experiment (3.71x106 cells mL-1 
as measured by trypan blue exclusion) compared to an average of ~2.0x106 total cells 
mL-1 for the remaining runs. Therefore, Figure 3.1.B (‘?’ = 6,000 rpm only) was set 
aside for separate analysis (see Chapter 5) from all other runs presented in Figure 3.1.  
Tables 3.4.A and 3.4.B summarize some of the key performance data for the two sets of 
runs  for  low  and  high  disc  speeds  respectively.  Column  2  presents  the  measured 
transmission of LDH through the membrane at the end of each of the 60 minute shear 
runs. These are the transmission values that are used for calculations. The mean value 
for LDH transmission is significantly lower at the low disc speed (0.78 ± 0.02 compared 
with 0.88 ± 0.04) probably due to the lower shear rate over the membrane surface.  
Column 3 examines the stability of LDH over the period of the membrane study for 
each run. On average for both cases, the cells might be considered stable for the length 
of the run. Even though run B, low disc speed (Table 3.4.A), showed several anomalies, 
it was decided to retain the results and assess later how best these are interpreted.  
Column 4 examines the total amount of LDH (extracellular and intracellular) measured 
- i.e. permeate plus retentate – and it is compared with total LDH at the start of the 
experiment.  This  helps  to  check  whether  all  LDH  is  recovered  (none  is  stuck  to 
membrane) and none is lost through denaturation. For both low and high disc speed 
there is a small, but not statistically significant, loss of ~4-7% of LDH which might be 
trapped in the membrane or may fall within experimental error.  107 
 
Column 5 is a second measure of accountability for LDH, comparing the total in the 
retentate and permeate to the control cells for the duration of the experiment. Again for 
high disc speed there is a small, but not statistically significant, loss of ~5% of LDH. 
For low disc speed, due the outlier Run B, the loss would be ~13% but excluding this 
outlier there is a ~9% loss which was not found to be statistically significant. 
Overall, it can be seen from Tables 3.4.A and 3.4.B that the averages are representative 
of  the  runs.  The  average  values  of  the  repeats  were  used  to  produce  Figure  3.2  to 
analyze the impact of low and high disc speed on cell damage as measured by LDH 
release.  Overall,  observing  the  LDH  results  in  Figure  3.2.A,  the  proportion  of 
intracellular  LDH  remaining  in  the  USD  membrane  separation  device  throughout 
operation decreased ~8% at a low disc speed and ~30% at a high disc speed. This 
finding  suggests  that  increasing  the  speed  of  the  disc,  causes  more  damage  to  the 
cellular population being processed.  
From Figure 3.2, Tables B and C, show the amount of total, external and internal LDH 
in each of the process streams for both low and high disc speeds. Mass balances for both 
disc speeds show that the amount of total LDH in the non-sheared controls held at 
21 ± 1ºC in a centrifuge tube concurrently for the duration of the experiment did not 
decrease. This leads to the conclusion that the changes seen at the two disc speeds can 
be fully attributed to processing conditions. Moreover, for both disc speeds (ignoring 
Run B at low disc speed) there is a small (~5%) and insignificant decrease in the total 
mass of LDH collected in the permeate plus the total amount collected in the retentate 
post-processing compared to pre-processing as was shown from Tables 3.4.A and 3.4.B.   108 
 
A.                                         6,000 rpm ± 1 s.e. (j = 5; n = 4) 
1. 
 
Run (‘?’) 
2. 
 
‘𝑻(?󵑭)’ 
3. 
 
‘?/?’ 
4. 
 
‘(? + ?)/?’ 
5. 
 
‘(? + ?)/?’ 
A  0.82 ± 0.07  1.08 ± 0.03  1.00 ± 0.02  0.88 ± 0.02 
B  0.75 ± 0.06  1.69 ± 0.08  1.14 ± 0.05  0.69 ± 0.01 
C  0.84 ± 0.04  0.98 ± 0.04  0.82 ± 0.03  0.85 ± 0.03 
D  0.73 ± 0.07  1.04 ± 0.04  1.01 ± 0.02  0.98 ± 0.02 
E  0.74 ± 0.09  0.92 ± 0.09  0.87 ± 0.07  0.95 ± 0.05 
Average  0.78 ± 0.02  1.01 ± 0.14  0.93 ± 0.06  0.91 ± 0.05 
 
B.                              10,000 rpm ± 1 s.e. (j = 5; n = 4) 
A  0.88 ± 0.08  1.11 ± 0.05  1.03 ± 0.04  0.93 ± 0.04 
B  0.91 ± 0.04  0.82 ± 0.01  0.81 ± 0.01  1.00 ± 0.02 
C  0.80 ± 0.04  1.01 ± 0.08  0.96 ± 0.06  0.92 ± 0.02 
D  0.78 ± 0.06  1.17 ± 0.12  0.95 ± 0.09  0.78 ± 0.02 
E  1.02 ± 0.06  0.96 ± 0.03  1.06 ± 0.04  1.10 ± 0.02 
Average  0.88 ± 0.04  1.01 ± 0.06  0.96 ± 0.04  0.95 ± 0.05 
 
Table 3.4: Membrane processing of feed (0 hour cell ageing) HCA2 cells – effect of disc speed on cell 
damage. (A) 6,000 and (B) 10,000 rpm cell damage as recorded by release of LDH. From left to right 
columns show; (1) run; (2) transmission coefficient; (3) ratio of intracellular LDH in the control to 
the intracellular LDH pre-processing in the retentate to evaluate stability of LDH in the cells without 
processing (where 1 equals to no loss in LDH activity); (4) ratio of the sum of the total LDH in the 
retentate  post-processing and permeate streams to the total LDH in the retentate pre-processing, to 
evaluate the mass balance agreement (where 1 equals to complete agreement, i.e. all LDH mass is 
accounted for); (5) ratio of the sum of the total LDH in the retentate post-processing and permeate 
streams  to  the  total  LDH  in  the  control,  to  evaluate  the  mass  balance  agreement  assuming  the 
processed cells change as with control. Run B for 6,000 rpm, shown in red in table A, was considered 
as an outlier due to an unusually high initial cell concentration with respect to the other runs.  109 
 
 
 
 B. 
  
LDH µU ± 1 s.e. (j = 5; n = 4) 
Disc speed   6,000 rpm 
Sample  Notation  Total 
(‘LDH_TOT’) 
Extracellular 
 (‘LDH_EXT’) 
Predicted 
internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  23.92 ± 2.96  0.76 ± 0.11  23.16 ± 2.89 
Control  (b) ‘?(60) = [?](60) × ??’  23.91 ± 2.50  0.79 ± 0.21  23.12 ± 2.70 
Post-processing  (c)  ‘?(60) = [?](60) × ??’  20.03 ± 2.94  0.41 ± 0.09  19.62 ± 2.93 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  2.02 ± 0.27       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’  
22.05 ± 2.95  2.43 ± 0.35  19.62 ± 2.93 
                
C.  Disc speed  10,000 rpm 
Sample  Notation  Total 
(‘LDH_TOT’) 
Extracellular 
 (‘LDH_EXT’) 
Predicted 
Internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  25.09 ± 0.91  0.73 ± 0.14  24.36 ± 1.03 
Control  (b) ‘?(60) = [?](60) × ??’  25.73 ± 1.78  1.06 ± 0.33  24.68 ± 1.75 
Post-processing  (c)  ‘?(60) = [?](60) × ??’  15.70 ± 1.08  0.62 ± 0.23  15.08 ± 1.05 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  8.37 ± 0.49       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’  
24.07 ± 1.17  8.99 ± 0.65  15.08 ± 1.05 
Figure 3.2: Membrane processing of feed (0 hour cell ageing) HCA2 cells – effect of disc speed on 
cell damage.  Recorded by (A) release of LDH. Tables (B) and (C) show mean LDH data for all 
streams including both external and total measurements at 6,000 and 10,000 rpm (‘𝜸’ = 44,000 and 
116,000 s-1 respectively). A non-sheared control held in a centrifuge tube concurrently, 21 ± 1ºC, for 
the duration of the experiment was used to  measure LDH pre and post-processing. Figure (A) 
shows the proportion of intracellular LDH remaining (‘ɷ’, Eq 3.8), for 6,000 rpm (○) and 10,000 
rpm  (▲)  at  a  concentration  of  2.1x106  total  cells  mL-1.  High  disc  speed  resulted  in  a  ~30% 
reduction of viable cells as measured by release of LDH. Data shown are mean values ± 1 s.e. (j = 5; 
n = 4). 
0.4
0.6
0.8
1
0 20 40 60
P
r
o
p
o
r
t
i
o
n
 
o
f
 
i
n
t
r
a
c
e
l
l
u
l
a
r
 
L
D
H
 
r
e
m
a
i
n
i
n
g
 
(
ɷ
)
Time (min)
6,000 rpm 10,000 rpm A.110 
 
3.3.2  Physical impact as measured by trypan blue exclusion 
Plots in Figure 3.3 show the trypan blue data for the five repeats at both disc speeds, 
with the concentration of total and viable cells on the left-hand side (column A) and the 
percentage  viability  on  the  right-hand  side  (column  B).  The  average  values  for 
concentrations and percentage viabilities for all repeats were calculated. Values that fall 
outside one standard deviation from the mean were evaluated and if considered to be 
outliers these were not used to produce the plots in Figures 3.4 and 3.5. For example, it 
is evident that the second repeat at low disc speed plotted in Figure 3.3.A.2, is an outlier 
since the concentration is considerably higher, almost double, than for all other repeats 
(note the y-axis in Figure 3.3.A.2 is the only one that shows 0 to 6 x 106 cells mL-1 
compared  to  0  to  3  x  106  cells  mL-1  for  all  other  repeats).  This  may  explain  the 
unusually high amount of LDH previously measured in the permeate  and shown in 
Figure  3.1.B,  reinforcing  the  experiment  can  indeed  be  considered  an  outlier.  Even 
though this repeat will be excluded for the analysis of the effect of low disc speed on 
cell  damage  investigated  in  this  section,  it  will  be  taken  into  consideration  when 
examining the effect of cell concentration on cell damage. 
The plots shown in Figures 3.4 and 3.5 were used to analyze the impact of low and a 
high disc speed on cell damage as measured by trypan blue exclusion. From the results 
in Figure 3.4, it appears that at a high disc speed there is a significant ~25% (p = 0.003) 
decrease in the population of viable cells compared to no decrease at a low disc speed. 
Analysis of Figure 3.5 shows that a high disc speed resulted in a significant ~10% (p = 
0.001) drop in percentage viability post-processing compared to no drop in percentage 
viability at a low disc speed.    111 
 
 
Figure 3.3: Membrane processing of feed (0 hour cell ageing) HCA2 cells – effect of low and high 
disc  speeds  (‘?’  =  6,000  and  10,000  rpm)  on  cell  damage  shown  by  total  and  viable  cell 
concentrations  pre  and  post-processing  (column  A)  and  percentage  viability  (column  B)  of  the 
cellular suspension as recorded by trypan blue exclusion. (1) to (5) are five repeats. Error bars 
show ± 1 s.d. and significant changes between non-sheared control and post-processing (*p<0.5, 
**p<0.01, ***p<0.001; n = 4).    112 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Membrane processing of feed (0 hour cell ageing) HCA2 cells – effect of disc speed on 
cell damage shown by total and viable cell concentrations pre and post-processing of the cellular 
suspension as recorded by trypan blue exclusion. Table below shows mean of raw data determined 
by trypan blue exclusion for concentration of total and viable cells. A non-sheared control held in a 
centrifuge tube concurrently, 21 ± 1ºC, for the duration of the experiment was used to measure 
trypan blue pre and post-processing for both 6,000 and 10,000 rpm (‘𝜸’ = 44,000 and 116,000 s-1 
respectively). Trypan blue exclusion indicates that processing at high disc speed, resulted in a ~25% 
reduction of viable cells. Low drop was observed in the viable cell concentration post-processing at 
a low disc speed. Significant changes between non-sheared control and post-processing (*p<0.5, 
**p<0.01, ***p<0.001). Data shown are mean values ± 1 s.d. (j = 5; n = 4).  
   
 
Concentration (x106 cells mL-1) ± 1 s.d. (j = 5; n = 4) 
   Total cells (‘TB_TOT’)  Viable cells (‘TB_VC’) 
Disc speed 
(rpm) 
Pre-
processing  Control  Post-
processing 
Pre-
processing  Control  Post-
processing 
6,000  2.07 ± 0.28  1.71 ± 0.24  1.79 ± 0.15  1.97 ± 0.20  1.67 ± 0.25  1.69 ± 0.15 
10,000  2.13 ± 0.07  1.98 ± 0.06  1.67 ± 0.19  2.06 ± 0.09  1.94 ± 0.06  1.44 ± 0.17 
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Figure 3.5: Membrane processing of feed (0 hour cell ageing) HCA2 cells – effect of disc speed on 
(A) percentage viability of the cellular suspension as recorded by trypan blue exclusion. Table (B) 
shows  mean of raw data determined by trypan  blue  exclusion for percentage viability. A non-
sheared control held in a centrifuge tube concurrently, 21 ± 1ºC, for the duration of the experiment 
was used to measure trypan blue exclusion pre and post-processing for both 6,000 and 10,000 rpm 
(‘𝜸’ = 44,000 and 116,000 s-1 respectively). Trypan blue exclusion indicates that processing at high 
disc speed, resulted in a ~10% drop in percentage viability post-membrane processing. Low drop 
was observed in percentage viability at a low disc speed. Significant changes between non-sheared 
control and post-processing (*p<0.5, **p<0.01, ***p<0.001). Data shown are mean values ± 1 s.d. 
(j = 5; n = 4).  
   
 
% ± 1 s.d. (j = 5; n = 4) 
   % Viability 
Disc speed  
(rpm)  Pre-processing  Control  Post-processing 
6,000  97.3 ± 0.2  97.2 ± 0.3  94.4 ± 1.5 
10,000  97.2 ± 0.5  97.0 ± 0.3  86.7 ± 2.1 114 
 
3.3.3  Average rate constants for cell damage 
To further understand and characterize the effect of each disc speed on cell damage, as 
measured by trypan blue and LDH, the average rate constants were calculated. The rate 
constant for any first order process is a numerical value that relates the rate at which a 
specific  reaction  takes  place  (in  this  case  the  “reaction”  is  cell  damage)  to  the 
concentration of reactants (in this case intact cells fed). Therefore, analysis of the data 
indicates that cell damage could be described as a first order process with respect to the 
concentration of intact cells fed to the USD membrane separation. Chapter 5, Section 
5.2  explains  the  reasoning  for  the  assumptions  made  and  outlines  the  calculations 
carried out to obtain the rate constants. However, in this section these calculations will 
not be shown because new terminology will be introduced in the next chapters that will 
form the basis of the calculations of the rate constants. The values obtained for each 
disc speed and method of assessment will however be discussed. 
As measured by LDH release, high disc speed leads to a rate constant of 0.30 ± 0.15 h-1 
compared to 0.06 ± 0.02 h-1 for low disc speed. For cell damage measured by trypan 
blue exclusion (loss of membrane integrity), high disc speed yielded a rate constant of 
0.15 ± 0.07 h-1 compared to 0.03 ± 0.01 h-1 for low disc speed. These values suggest that 
cell  damage  occurs  five  times  faster  at  high  disc  speed  than  at  low  disc  speed, 
suggesting the rate constant is strongly dependent on the magnitude of disc speed. It 
also appears that LDH release is twice more sensitive to cell damage than trypan blue 
exclusion. Lappalainen et al. (1994) also observed differences between the sensitivity of 
LDH  release  and  trypan  blue  exclusion  assays.  They  concluded  that  LDH  release 
appears to be a more sensitive indicator of earlier damage to the cell membrane than 115 
 
trypan blue exclusion, which stains only dead cells. It may be that LDH can be released 
before the membrane lesions are produced and therefore can serve as an indication of 
earlier  cytotoxicity.  In  fact,  Diederichs  et  al.  (1979)  investigated  the  mechanism  of 
release of LDH from isolated skeletal muscle and concluded that cell swelling, which is 
typical of necrotic cells, prior to membrane damage was connected with an increased 
LDH permeability. 
Apart  from  the  physical  impact  that  disc  speed  appears  to  have  on  the  cellular 
suspension, these processing conditions might have triggered biological responses such 
as programmed cell death (apoptosis) or might have compromised the metabolic activity 
of the cells in such a way that they cannot re-grow once plated after processing. The 
next sub-sections investigate the morphology of the cells pre-processing, immediately 
after  processing  and  after  a  2-hour  hold  post-processing  as  well  as  growth  curves 
post-shear and finally apoptotic markers. 
3.3.4  Cell morphology, growth and apoptosis analysis 
It  has  been  widely  reported  that  changes  in  the  rate  at  which  cells  grow,  physical 
appearance and morphology can occur after the cells are exposed to stresses (Al-Rubeai 
et al. 1995; Kretzmer and Schügerl 1991) and can serve as indicators of the state of cell 
health  (Agashi  et  al.  2009;  Kretzmer  and  Schügerl  1991).  For  instance,  both 
programmed cell death pathways, necrosis and apoptosis, can be indicated by specific 
morphological  changes  as  was  explained  in  Chapter  1,  Section  1.6.3.  Using  these 
processed  cells  to  inoculate  further  cultures  can  provide  an  insight  into  a  different 
impact of a particular processing condition upon the cell population.  116 
 
For  all  experiments  presented  in  this  section,  HCA2  cell  line  was  used.  The  USD 
membrane  separation  device  was  set-up  in  diafiltration  mode,  with  hCGM  being 
pumped into the system for 60 minutes at a flow rate of 0.5 mL min-1 (≈ 82 LMH). The 
disc speed was set to low (‘N’ = 6,000 rpm) and high (‘N’ = 10,000 rpm) and the 
concentration of total cells of the feed material was ~25x106 cells mL-1  and only fresh 
cells were used, i.e. no pre-processing hold time.  
After processing, cell populations were counted and split into two samples; one sample 
was held for 2 hours at 21 ± 1ºC and then re-counted and the other sample was seeded 
into tissue culture plates at a fixed seeding density of 2x104 viable cells per well. The 
seeded cells were cultured for a period of 72 hours. Light microscopy images of the 
attached cells were taken every 24 hours to observe if there were any morphological 
changes during culture and the cells were then detached to carry out trypan blue counts, 
also every 24 hours. For all the counts carried out in the automated haemocytometer, the 
samples  were  re-analysed  using  the  Matlab  script  to  classify  the  cells  into  cell 
populations based on morphology. 
3.3.4.1  Cell morphology analysis 
Within this section, the morphology and physical appearance of cells post-processing 
was investigated. Morphological analysis  was  carried out on the cellular suspension 
immediately post-processing and 2 hours post-processing. Further observations were 
carried  out  on  the  inoculated  post-processed  cells,  in  culture  (attached)  and  in 
suspension (immediately after detachment). Nonetheless, categorizing the state of cell 
health on physical appearance alone would not be sufficient. The next sections will 117 
 
therefore complement this analysis with the evaluation of growth profiles and apoptotic 
markers. 
Examples of the type of images obtained from the automated haemocytometer are given 
in Figure 3.6. For both low and high disc speeds (Figures 3.6.1 and 3.6.2 respectively) 
three time points are shown; pre-processed samples (images labelled A), immediately 
post-processing  (labelled  B)  and  2  hours  hold  post-processing  (labelled  C),  all  at 
21±1ºC. 
From Figures 3.6.1.A and 3.6.2.A, pre-processed samples for both low and high disc 
speeds,  it can be seen that most cells are round viable cells with sharply defined outer 
edges or clearly non-viable as stained positive for trypan blue exclusion. However, the 
appearance of elongated and ‘blebby’ cells is observed immediately post-processing 
(Figures 3.6.1.B and 3.6.2.B). ‘Blebs’ are membrane bound protrusions from the plasma 
membrane caused by weakness in the actin cytoskeleton which helps maintain cellular 
structure (Kumar et al. 2007). Literature reveals that ‘blebbing’ is a dynamic process 
and can resolve itself once the actin cytoskeleton is restored (Kumar et al. 2007) and in 
fact, images C, after 2 hours hold post-processing, reveal that a large portion of the 
‘blebs’ have disappeared and there are lower numbers of elongated cells. This trend 
seems  to  be more evident  at  high  disc speed (Figure  3.6.2) than at  low disc speed 
(Figure 3.6.1). 
These morphological characteristics identified were used as building blocks to define 
the different cell types for the Matlab script. Figure 3.6.D shows some examples for 
each of the cell types identified for image processing using the Matlab  118 
 
1.  Low disc speed    2. High disc speed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D. 
 
 
 
 
 
 
Figure 3.6: (1) Low and (2) high disc speeds (‘N’ = 6,000 and 10,000 rpm respectively) images of (A) 
pre-processing; (B) post-processing and (C) 2 hours hold post-processing. (D) Shows examples of 
HCA2 images from the cell image library created to facilitate the identification of cell phenotype in 
a given image. The cell library was constructed from images selected for each designated categroy. 
Each category was assigned paramteters (such as aspect ratio and intensity) and these were then 
used as rules for identification purposes for the Matlab script.  119 
 
script. The cells were classified into short elongated (SE), long elongated (LE), viable 
round (VR), non-viable (NV) and debris (DEBRIS). For example, parameters such as 
aspect  ratio  were  used  to  classify  cells  into  round,  short  or  long  elongated  cells; 
intensity was used to identify dead and alive and area was used to identify debris from 
cells. Originally, a degree of ‘blebbing’ for each cell type was going to be included as 
an  added  characteristic  to  each  cell  population.  However,  the  implementation  and 
incorporation of this parameter proved to be unreliable. The images from the automated 
haemocytometer were analyzed using the Matlab script and the proportions for each of 
the cell populations at the three given time points (pre-processing, immediately post-
processing and 2 hour hold post-processing) are shown in Figures 3.7.A and 3.7.B (low 
and high disc speeds respectively).  
At high disc speed in Figure 3.7.B, there is an increase in the proportion of dead cells 
and a reduction in the proportion of viable round cells immediately post-processing that 
remained the same after 2 hours hold. At both low and high disc speeds in Figures 3.7.A 
and 3.7.B respectively, there is an increase in the proportion of both short and long 
elongated  cells  immediately  post-processing  that  appears  to  return  to  pre-processed 
levels after the 2 hour hold. The apparent trend previously appreciated in Figure 3.6 is 
in agreement with the quantitative data in Figures 3.7. Therefore elongation may be a 
temporary change of morphology, at least whilst in suspension.  
The  morphology  of  the  HCA2  cells  was  also  investigated  post-processing  during 
attachment to the surface of a tissue culture well plate and the images obtained by light 
microscopy every 24 hours are shown in Figure 3.8. Apart from the evident difference 120 
 
in number of cells at the same time points between sheared and non-sheared samples 
(which is discussed in more detail in the following section), there appears to be no 
change in morphology or in extent of alignment. This implies that shearing the cells for 
a prolonged time did not cause a permanent change in morphology after inoculation 
post-processing  and  did  not  cause  a  directional  growth,  which  reinforces  that  the 
elongation was indeed a temporary change. Finally, the cells were detached for trypan 
blue  exclusion  measurement  at  the  24  hour  points,  analyzed  in  suspension  and  the 
proportion of each cell population is given in Figure 3.9. Both of the sheared samples 
show comparable proportions of cell populations to the non-sheared controls.  
3.3.4.2  Growth profiles and specific growth rate constants post-processing 
As active participants in their environment, cells continually adjust their structure and 
function to accommodate changing extracellular stimuli. If the extracellular stresses are 
aggressive  or  prolonged  enough,  cells  can  lose  their  normal  homeostasis  that 
encompasses a range of physiologic parameters. Compromising cell homeostasis can 
therefore impact cell division. For successful cell division, a chain of events must be 
completed in an orderly and unidirectional manner. Changes in the rate of cell growth 
and doubling times can de-regulate this crucial chain of events (Kumar et al. 2007) and 
therefore  serve  as  indicators  of  poor  cell  health  or  cell  injury  post-processing  (Al-
Rubeai et al. 1995; Veraitch et al. 2008). A way to monitor how fast cells are dividing is 
by calculating the specific growth rate constant: 
𝑑???(𝑡)
𝑑𝑡 = ? × ???(𝑡)        Equation 3.9   121 
 
Figure 3.7: Effect of disc speed on cell morphology after shear and after shear plus hold (software 
for image processing developed using Matlab Image Processing Toolbox (MathWorks, Cambridge, 
UK) by Nicolas Jaccard in the Biochemical Engineering Department at UCL). The cell categories 
correspond to libraries created for the Matlab script (Figure 3.6.D). The proportion of each cell 
type or population was compared to the total cells in the sample for pre-processing (■), immediately 
post-processing (■) and 2 hours hold post-processing (■).   122 
 
 
Figure 3.8: Phase contrast of HCA2 cells in culture after (A) low disc speed (‘N’ = 6,000 rpm, ‘γ’ = 
44,000 s-1), (B) high disc speed (‘N’ = 10,000 rpm, ‘γ’ = 116,000 s-1) and (C) non-sheared control. 
Control  cell  populations  were  cultured  in  parallel  with  populations  subjected  to  varying  disc 
speeds. These images show snapshot of cells in culture for (1) 24 hours, (2) 48 hours and (3) 72 
hours. The black bar scale represents 50 µm. 
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Figure  3.9:  Effect  of  growth  time  point  post-shear  on  cell  morphology.  Software  for  image 
processing developed using Matlab Image Processing Toolbox (MathWorks, Cambridge, UK) by 
Nicolas  Jaccard  in  the  Biochemical  Engineering  Department  at  UCL.  The  cell  categories 
correspond to libraries created for the Matlab script (Figure 3.6.D). The proportion of each cell 
type or population was compared to the total cells in the sample for 24 hours after seeding (■), 48 
hours after seeding (■) and 72 hours after seeding (■).    124 
 
where ‘?’ is the specific growth rate constant (h-1), ‘???(𝑡)’ is the number of intact cells 
in the retenate at time ‘𝑡’. Integrating between the limits of 0 to ‘𝑡’ and ‘???(0)’ which 
is the number of intact cells at the start (i.e. ‘𝑡 = 0 min’) to ‘???(𝑡)’ gives: 
? =
2.303
𝑡  × ??𝑔(
???(𝑡)
???(0))      Equation 3.10 
Because cell growth rates can vary as a result of several factors, ranging from the cell 
concentration  at  inoculation,  to  the  physiochemical  and  physical  environment,  all 
variables used to study cell growth rate were maintained constant.  In this section of the 
study,  the  growth  curves  and  specific  growth  rate  constants  of  processed  cell 
populations  were  investigated  to  help  gauge  the  impact  of  disc  speed.  This  allows 
identification of any harmful or irreversible changes to the cell population otherwise 
undetected by analysis using LDH release and trypan blue exclusion. 
Each data point shown in this section is the mean of three replicates. The HCA2 cell 
line was processed using the USD membrane separation device in diafiltration mode, 
with hCGM being pumped into the system for 60 minutes at a flow rate of 0.5 mL min-1 
(‘?’ ~82 LMH), i.e. ~18 diafiltration volumes. The disc speeds of 6,000 rpm and 10,000 
rpm  were  used  and  the  concentration  of  the  feed  material  was  fixed  at 
~25x106 cells mL-1 with essentially no hold time prior to processing. After processing in 
the USD membrane device, cell populations were counted and cells seeded onto tissue 
culture plates at a fixed density of  ~2x105 viable cells per well (i.e. 4.28x104 viable 
cells per cm2). Light microscopy images and trypan blue counts were recorded every 24 
hours and over a period of 72 hours after processing. 125 
 
By inspection of this preliminary set of results shown in Figure 3.10.A, even though 
cells were exposed to processing for a prolonged period of time, they can still grow and 
proliferate.  There  is  some  suggestion  of  slower  initial  growth  for  both  processed 
samples and lower overall growth for the processed sample at high speed compared 
with the control. However the results are preliminary and therefore not significant and it 
appears processed cells can grow similarly to unprocessed cells. 
3.3.4.3  Biological impact post-processing by cell death analysis 
Identifying potentially damaging operations and parameters can help minimize cell loss 
and maintain quality of the product to ensure efficacy and economic viability. It has 
been established that bioprocessing steps can expose the cells to severe stresses which 
can cause severe abnormalities and cell injury resulting in cell death (Agashi et al. 2009; 
Al-Rubeai et al. 1995; Augenstein et al. 1971; Born et al. 1992; Chisti 2001; Hu et al. 
2011). In fact, the images from previous sections have shown that processing may cause 
‘blebbing’ which has been reported to be a characteristic of cell death (Kumar et al. 
2007).  
Cell death biological assays can identify the two primary types of death; apoptosis and 
necrosis  which  are  different  in  their  morphology,  mechanisms  and  roles  in  the 
programmed cell death pathways (Dive et al. 1992). The biological assay used in this 
study was based on a cytometric technique (Dive et al. 1992) used for detection and 
categorization of both the mode and phase of programmed cell death. The biological 
assay  is  based  on  Fluorochrome-labeled  inhibitors  of  caspases  (FLICA).  These 
inhibitors have proven to provide the means for a convenient, sensitive and reliable way 126 
 
of  measuring  caspase  activation  –  a  key  molecule  in  the  apoptotic  mechanism  and 
induction of apoptosis (Darzynkiewicz and Pozarowski 2007; Smolewski et al. 2002). 
Even  though  the  caspase  sub-type  involved  may  vary  from  one  tissue  to  another, 
caspase-3 is known as a universal caspase which functions in almost all tissues and is an 
indicator that the cell is committed to irreversible cell death processes. Therefore assays 
that work on the activation of caspase-3 correlate well with the results obtained by 
FLICA reagents used in this study (Darzynkiewicz and Pozarowski 2007; Smolewski et 
al.  2002).  By  using  these  markers  in  conjunction  with  propidium  iodide  (PI  -  cell 
membrane integrity marker), the cell population can be segregated into four different 
categories (see Table 3.5). Cells which are live will be negative for both PI and FLICA; 
early  apoptotic  cells  will  show  apoptotic  related  activity  but  no  loss  of  membrane 
integrity, therefore will stain negative for PI but positive for FLICA; late apoptotic cells 
will show both apoptotic related activity as well as loss of membrane integrity, staining 
positive for both PI and FLICA; and necrotic cells will stain positive for PI but negative 
for  FLICA,  suggesting  that  no  apoptotic  processes  were  induced  prior  to  loss  of 
membrane integrity.  
This section attempts to identify if there is any degree of induction of programmed cell 
death for the HCA2 cell line, following the exposure to low and high disc speeds. The 
sheared samples were held on the bench at 21 ± 1ºC for 2 hours post-processing prior to 
the staining, to allow increased expression of apoptotic markers if any were present. The 
non-sheared control samples were also held on the bench at 21 ± 1ºC for the duration of 
the experiment, including the 2 hours hold post-processing and prior to the staining, to 
ensure these cells truly represent controls for the sheared samples.   127 
 
 
Figure 3.10: (A) Cell growth analysis of HCA2 cells following low (6,000 rpm, ○) and high (10,000 
rpm, ▲) disc speeds (‘𝜸’ = 44,000 s-1 and 116,000 s-1 respectively) as well as non-sheared control (×). 
(B) Specific growth rate constants, Eq 3.10, calculated every 24 hours for the growth curves shown 
in (A) for non-sheared control (■), low (■) and high (■) disc speeds. Cells were inoculated after 
processing  at  2x105  viable cells  per  well  and  trypan blue  exclusion  counts  performed  every  24 
hours. It appears that cells exposed to low and high disc speeds can grow post-processing although 
there is some evidence of a longer lag phase than non-sheared control by observation of the growth 
profiles and the specific growth rates. Specific growth rates for all three samples appear to be of 
similar magnitudes by the 48-72 hour time point. Data shown are mean values ± 1 s.d. (j = 3; n= 4).   
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Category  Description  FLICA  PI 
Live 
Fully functional cell without loss in membrane 
integrity or apoptotic related activity. 
N  N 
Early 
apoptotic 
Apoptotic related activity but no loss of 
membrane integrity. 
P  N 
Late 
apoptotic 
Apoptotic related activity and loss in 
membrane integrity. 
P  P 
Necrotic 
Apoptotic processes were not initiated prior to 
loss in membrane integrity. 
N  P 
 
 
Table 3.5: The assay allows the segregation of the cell population into four different categories by 
staining a combination of positive (P) and negative (N) for FLICA and PI dyes.  The categories 
identified are live, early apoptotic, late apoptotic and necrotic cells. 
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For Figures 3.11 to 3.14, image A refers to a normal light microscopy image of the 
cells; image B shows a DAPI stain that stains intact and non-intact cells containing 
DNA in blue; image C shows the caspase-3 expressing cells in green; and image D 
shows  a  PI  stain  which  stains  in  red  accessible  DNA,  i.e.  those  cells  with  only  a 
damaged outer membrane. 
Figure 3.11 shows the non-sheared controls for low and high disc speeds. As expected, 
there appears to be no induction of apoptosis (Figure 3.11.C) as well as no evident loss 
of  membrane  integrity  (Figure  3.11.D).  For  the  post-processing  sample  at  low  disc 
speed, the images displayed in Figure 3.12 show no induction of apoptosis in Figure 
3.12.C and no loss of membrane integrity in Figure 3.12.D. This appears to indicate 
promising results at low disc speed in terms of processing, where low levels of cell 
damage were measured by both LDH release and trypan blue exclusion (as shown in 
sections 3.3.1 and 3.3.2) as well as low induction of apoptosis. 
However, for the post-processed sample at high disc speed a degree of early apoptosis 
was  observed (Figures  3.13.C and 3.14.C). Moreover,  both  early  apoptotic  and late 
apoptotic cell populations were observed for the post-processed sample in the bottom 
half of Figures 3.14.C and 3.14.D respectively. It was a common occurrence to see late 
apoptotic cell populations stick together in clumps as seen in Figure 3.14 possibly due 
to the release of DNA (from cell fragmentation). On top of this, the process and time 
taken  to  do  the  staining  could  explain  the  appearance  of  late  apoptotic  populations 
within the data gathered.  
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Figure  3.11:  Fluorescent  microscopy  of  CaspaTag™  Pan-Caspase  staining  for  non-processed 
controls (A to D). Holding the cellular suspension on the bench at 21 ± 1ºC for the duration of the 
experiment,  including  the  2  hours  hold  post-processing,  does  not  induce  apoptosis  (no  positive 
FLICA staining in images C) or lead to loss of  membrane integrity (no positive PI staining in 
images D). Enhanced images shown.   131 
 
 
 
Figure  3.12:  Fluorescent  microscopy  of  CaspaTag™  Pan-Caspase  staining  for  post-processed 
retentate sample at low disc speed (‘?’ = 6,000 rpm). No induction of apoptosis (C) and no loss of 
membrane integrity (D) are seen post-processing at low disc speed. Images shown are enhanced 
images. 
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Figure  3.13:  Fluorescent  microscopy  of  CaspaTag™  Pan-Caspase  staining  for  post-processed 
retentate  sample  at  high  disc  speed  (‘?’  =  10,000  rpm).  At  high  disc  speed  early  apoptotic 
populations are induced post-processing (images C and D respectively). Enhanced images shown. 
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Figure  3.14:  Fluorescent  microscopy  of  CaspaTag™  Pan-Caspase  staining  for  post-processed 
retentate  sample  at  high  disc  speed  (‘?’  =  10,000  rpm).  At  high  disc  speed  late  apoptotic 
populations  are  also  induced  post-processing  (images  C  and  D  respectively).  Enhanced  images 
shown.   134 
 
This  observation  also  poses  a  question  regarding  previous  post-processing  growth 
profiles  in  section  3.3.4.2.  If  some  of  the  cells  are  committed  to  death  but  remain 
undetected via the trypan blue technique, this suggest that the trypan blue data used to 
determine the process volume used to seed the well cultures based on number of viable 
cells, may require adjustment prior to the inoculation of cell populations. If this is the 
case, it may explain the fact that after 24 hours there are less number of viable cells 
observed at high disc speed as some have undergone apoptosis. It may also mean that at 
high disc speed, the possibly longer lag phase previously (Figure 3.10.A and 3.10.B) 
observed may be justified by the rate of cell loss of “viable” cells, as stained by trypan 
blue, due to apoptosis. Literature reveals that the rate of cell proliferation within any 
population of cells depends on three parameters; the rate of cell division, the fraction of 
cells within the population undergoing cell division (growth fraction) and the rate of cell 
loss from the population due to terminal differentiation or cell death   (Kumar et al. 
2007). It might be that the fraction of viable cells undergoing cell division is lower as a 
result of exposure to high disc speed. 
3.4  Effect of cell age on HCA2 fibroblasts 
Cell  age  (also  referred  to  as  pre-process  hold  time)  is  often  encountered  during 
processing when harvesting large quantities of cells. Cell age prior to processing might 
have  a  negative  impact  on  cell  quality  affecting  the  percentage  viability  and  the 
robustness of the cellular suspension. It has been shown (Section 3.3) that processing 
fresh HCA2 cells (i.e. no pre-process hold time) at a low disc speed (‘?’ = 6,000 rpm) 
leads to a small but significant level of cell damage as measured by both LDH release 135 
 
and by trypan blue uptake (Figures  3.2 and 3.4 respectively). An investigation was 
carried out on the effect of cell age of 24 hours, on cell response to processing. 
3.4.1  Physical impact as measured by LDH release 
Five runs for each of fresh cells (aged 0 hours) and cells aged for 24 hours were carried 
out and the breakdown of each one is shown in Tables 3.6.A and 3.6.B. The results 
presented  in  Table  3.6.A  are  the  same  as  those  presented  in  Table  3.4.A  and  are 
reproduced for convenience. These tables summarize some of the key performance data 
for the two sets of runs. Each run, A to E, depends on preparation of a new batch of 
cells. Each time, enough cells were prepared to run one experiment with fresh cells and 
another one with cells aged for 24 hours at 21 ± 1˚C. Despite a constant method of 
preparation used, there will inherently be some variation between batches. 
Column 2 presents the measured transmission of LDH through the membrane at the end 
of each of the 60 minutes shear runs. These are the transmission values that are used for 
calculations. The mean values for LDH transmission for both fresh cells and aged for 24 
hours  were 0.78  ± 0.02  and 0.78 ± 0.07 respectively.  The similar mean values are 
probably due to the fact that both conditions have the same shear rate.  
Column 3 examines the stability of LDH over the period of the membrane study for 
each run. On average for both cases, the cells might be considered stable for the length 
of the run. Ageing of the cells for 24 hours was held the same way and conditions as the 
control during the membrane study and showed no loss of LDH compared to fresh cells. 136 
 
Column 4 examines the total amount of LDH (extracellular and intracellular) measured 
- i.e. permeate plus retentate – and it is compared with total LDH at the start of the 
experiment.  This  helps  to  check  whether  all  LDH  is  recovered  (none  is  stuck  to 
membrane) and none is lost through denaturation. For both aged and fresh cells there is 
a small, but not statistically significant, loss of ~7% of LDH which might be trapped in 
the membrane. 
Finally, column 5 is a second measure of accountability for LDH comparing the total in 
the retentate and permeate to the control cells for the duration of the experiment. For 
fresh cells there is a small (~9%), but not statistically significant, loss of LDH and there 
was no loss showed for aged cells.  
Overall, it can be seen from Tables 3.6.A and 3.6.B that the averages are representative 
of the runs. Therefore, the average values of the repeats were used to produce Figure 
3.15.A. This figure shows the proportion of intracellular LDH remaining with time. 
This proportion decreased by ~8% for fresh cells and by ~15% for cells aged for 24 
hours. These results suggest that by prolonging the cell ageing period, the cells appear 
to be twice as susceptible to damage during processing than fresh cells.  
From Figure 3.15, Tables B and C show the amount of total, extracellular and internal 
LDH in each of the process streams for 0 and 24 hours cell ageing respectively. The 
mass  balances  for  both  conditions  show  that  the  amount  of  total  LDH  in  the  non-
sheared controls held at 21 ± 1ºC in a centrifuge tube for the duration of the experiment, 
did not decrease. As with the disc speed investigation, any changes seen can therefore 
be fully attributed to processing conditions.  137 
 
A.                                     0 hours cell age ± 1 s.e. (j = 5; n = 4) 
1. 
 
Run (‘?’) 
2. 
 
‘𝑻(?󵑭)’ 
3. 
 
‘?/?’ 
4. 
 
‘(? + ?)/?’ 
5. 
 
‘(? + ?)/?’ 
A  0.82 ± 0.07  1.08 ± 0.03  1.00 ± 0.02  0.88 ± 0.02 
B  0.75 ± 0.06  1.69 ± 0.08  1.14 ± 0.05  0.69 ± 0.01 
C  0.84 ± 0.04  0.98 ± 0.04  0.82 ± 0.03  0.85 ± 0.03 
D  0.73 ± 0.07  1.04 ± 0.04  1.01 ± 0.02  0.98 ± 0.02 
E  0.74 ± 0.09  0.92 ± 0.09  0.87 ± 0.07  0.95 ± 0.05 
Average  0.78 ± 0.02  1.01 ± 0.14  0.93 ± 0.06  0.91 ± 0.05 
 
B.                           24 hours cell age ± 1 s.e. (j = 5; n = 4) 
A  1.03 ± 0.04  0.92 ± 0.02  0.84 ± 0.01  0.92 ± 0.02 
B  0.85 ± 0.08  0.91 ± 0.09  0.88 ± 0.05  0.98 ± 0.08 
C  0.68 ± 0.05  0.80 ± 0.09  0.97 ± 0.05  1.21 ± 0.04 
D  0.62 ± 0.04  0.88 ± 0.10  0.96 ± 0.10  1.10 ± 0.05 
E  0.71 ± 0.05  1.28 ± 0.12  1.00 ± 0.08  0.78 ± 0.03 
Average  0.78 ± 0.07  0.96 ± 0.08  0.93 ± 0.03  1.00 ± 0.07 
 
 
 
 
 
 
 
Table 3.6: Membrane processing of feed (‘N’ = 6,000 rpm, ‘γ’ = 44,000 s-1) HCA2 cells – effect of 
(A) 0 and (B) 24 hours cell age on cell damage as recorded by release of LDH. To note results 
presented in Table 3.6.A are as presented in Table 3.4.A. Box diagram (C) of the USD membrane 
separation  device  showing  process  streams.  From  left  to  right  columns  show;  (1)  run;  (2) 
transmission coefficient; (3) ratio of intracellular LDH in the control to the intracellular LDH pre-
processing in the retentate to evaluate stability of LDH in the cells without processing (where 1 
equals to no loss in LDH activity); (4) ratio of the sum of the total LDH in the retentate  post-
processing and permeate streams to the total LDH in the retentate pre-processing, to evaluate the 
mass balance agreement (where 1 equals to all LDH mass is accounted for); (5) ratio of the sum of 
the  total  LDH  in  the  retentate  post-processing  and  permeate  streams  to  the  total  LDH  in  the 
control,  to  evaluate  the  mass  balance  agreement  assuming  the  processed  cells  change  as  with 
control. Run B for 0 hour cell ageing, shown in red in table A, was considered as an outlier due to 
an unusually high initial cell concentration with respect to the other runs (j = 5; n = 4). 138 
 
 
 
 B.     LDH µU ± 1 s.e. (j = 5; n =4) 
   Cell age (hrs)  0 
Sample  Notation  Total 
(‘LDH_TOT’) 
Extracellular 
 (‘LDH_EXT’) 
Predicted 
internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  23.92 ± 2.96  0.76 ± 0.11  23.16 ± 2.89 
Control  (b) ‘?(60) = [?](60) × ??’  23.91 ± 2.50  0.79 ± 0.21  23.12 ± 2.70 
Post-processing  (c)  ‘?(60) = [?](60) × ??’  20.03 ± 2.94  0.41 ± 0.09  19.62 ± 2.93 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  2.02 ± 0.27       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’  
22.05 ± 2.95  2.43 ± 0.35  19.62 ± 2.93 
 
  C.  Cell age (hrs)  24 
Sample  Notation  Total 
(‘LDH_TOT’) 
Extracellular 
 (‘LDH_EXT’) 
Predicted 
internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  24.66 ± 0.89  0.94 ± 0.18  23.72 ± 0.77 
Control  (b) ‘?(60) = [?](60) × ??’  23.42 ± 1.66  1.13 ± 0.23  22.29 ± 1.47 
Post-processing  (c)  ‘?(60) = [?](60) × ??’  18.82 ± 1.02  0.78 ± 0.12  18.04 ± 0.95 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  4.19 ± 0.42       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’  
23.01 ± 1.19  4.97 ± 0.51  18.04 ± 0.95 
Figure 3.15: Membrane processing of feed ( ‘N’ = 6,000 rpm, ‘γ’ = 44,000 s-1) HCA2 cells – effect of 
cell ageing on cell damage as recorded by (A) release of LDH. Tables (B) and (C) show the mean 
LDH  data  for  all  streams  including  both  external  and  total  measurements.  To  note  results 
presented in Figure 3.15 (Table B) are as presented in Figure 3.2 (Table B). A non-sheared control 
held in a centrifuge tube concurrently, 21 ± 1ºC, for the duration of the experiment was used to 
measure  LDH  pre  and  post-processing.  Figure  (A)  shows  proportion  of  intracellular  LDH 
remaining (‘ɷ’, Eq 3.8), for 0 hours (○) and 24 hours (▲) at a concentration of ~2.0x106 cells mL-1. 
LDH release suggests that the cells are twice as weak, as reflected by damage during membrane 
processing, after 24 hours of cell ageing. Data shown are mean values ± 1 s.e. (j = 5; n = 4). 
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It also appears that for both fresh cells and cells aged for 24 hours, the total amount of 
LDH in the retentate pre-processing is ~5% less than the total amount of LDH collected 
post-processing in both the retentate and in the permeate. However, this does lie within 
experimental error and  is  not  statistically significant  as  previously shown in  Tables 
3.6.A and 3.6.B. 
3.4.2  Physical impact as measured by trypan blue exclusion 
The plots shown in Figures 3.16 and 3.17 were used to analyze the impact of cell age on 
cell damage as measured by trypan blue exclusion. The results presented for the fresh 
cells (i.e. 0 hours cell ageing) in Figures 3.16 and 3.17 are the same as those presented 
in Figures 3.4 and 3.5 for low disc speed (‘?’ = 6,000 rpm) and are reproduced for 
convenience. Figure 3.16 shows the concentration of total and viable cells for the pre-
processing, control and post-processing samples for fresh cells and cells aged for 24 
hours. There is no major difference between the two conditions investigated and no 
evident decrease of the population of viable or total cells after processing.  
Figure  3.17  shows  the  percentage  viability  for  pre-processing,  control  and 
post-processing samples for both fresh cells and cells aged for 24 hours. Analysis of this 
figure shows that cell age has no major impact on the drop of the percentage viability. It 
was expected that by ageing the cells for 24 hours (i.e. holding the cells at 21 ± 1ºC 
without processing) a lower percentage viability would be observed due to the fact that 
the cellular suspension was not held at optimum conditions. 
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Figure 3.16: Membrane processing of feed (‘?’ = 6,000 rpm, ‘𝜸’ = 44,000 s-1) HCA2 cells – effect of 
cell ageing on cell damage as shown by total and viable cell concentrations pre and post-processing. 
Table below shows mean of raw data determined by trypan blue exclusion for concentration of 
total and viable cells for pre and post-processing as well as a non-sheared control. To note results 
for fresh cells presented in this figure are as presented in Figure 3.4 for low disc speed.  A non-
sheared control held in a centrifuge tube concurrently, 21 ± 1ºC, for the duration of the experiment 
was used to measure trypan blue pre and post-processing for 0 and 24 hours cell ageing. Trypan 
blue exclusion indicates that there is no evident drop in concentration of total or viable cells after 
processing at a 0 and 24 hours cell ageing. Data shown are mean values ± 1 s.d. (j = 5; n = 4). 
   
 
Concentration (x106 cells mL-1) ± 1 s.d. (j = 5; n = 4) 
 
Total cells (‘TB_TOT’)  Viable cells (‘TB_VC’) 
Cell ageing 
(hours) 
Pre-
processing  Control  Post-
processing 
Pre-
processing  Control  Post-
processing 
0  2.07 ± 0.28  1.71 ± 0.24  1.79 ± 0.15  1.97 ± 0.20  1.67 ± 0.25 1.69 ± 0.15 
24  1.54 ± 0.31  1.39 ± 0.13  1.78 ± 0.21  1.49 ± 0.28  1.34 ± 0.12 1.69 ± 0.21 
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Figure 3.17: Membrane processing of feed (‘?’ = 6,000 rpm, ‘𝜸’ = 44,000 s-1) HCA2 cells – effect of 
cell ageing on the percentage viability of cellular suspension as recorded by trypan blue exclusion. 
Table below shows mean of raw data determined by trypan blue exclusion for percentage viability. 
To note results for fresh cells presented in this figure are as presented in Figure 3.5 for low disc 
speed. A non-sheared control held in a centrifuge tube concurrently, 21 ± 1ºC, for the duration of 
the experiment was used to measure trypan blue pre and post-processing for 0 and 24 hours cell 
ageing. Trypan blue exclusion indicates that there is no significant drop in percentage viability 
after processing at a 0 and 24 hours cell ageing. Data shown are mean values ± 1 s.d. (j = 5; n = 4). 
        % ± 1 s.d. (j = 5; n = 4) 
 
% Viability 
Cell ageing  
(hrs)  Pre-processing  Control  Post-processing 
0  97.3 ± 0.2  97.2 ± 0.3  94.4 ± 1.5 
24  97.2 ± 0.9  97.0 ± 0.8  96.0 ± 0.2 
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3.5  Effect of cell concentration on HCA2 fibroblasts 
As part of downstream processing operations, key requirements such as achieving a 
broad range of cell concentrations should be considered (Pattasseril et al. 2013). These 
concentrations could range from 1-2x106 cells mL-1 to 100x106 cells mL-1 (Pattasseril et 
al. 2013). This high concentration factor will have an impact on the properties of the 
cellular suspension, such as an increase in the viscosity. The change in fluid properties 
will therefore have an effect on key processing parameters such as shear stress or shear 
rate and these will vary according to the mathematical relationship previously described 
in Chapter 1, section 1.5. 
Ma et al. (2010) developed a specific CFD model for the USD membrane separation 
device to determine the relationship between fluid viscosity and rotating speed and the 
resultant shear rate. From these values, the average shear stress may be estimated as the 
product  of  shear  rate  and  viscosity.  This  simulation  was  run  and  adapted  by  Dr. 
Spyridon Gerontas at varying disc speeds and viscosities. He found that increasing the 
viscosity of the suspension decreased the average shear rate for a fixed rotating speed in 
the USD device. This is presumably due to the decreased recirculation rate or pumping 
effect of the rotating disc.  
In  this  section,  the  HCA2  cell  lines  were  processed  at  fixed  high  disc  speed 
(‘?’ = 10,000 rpm), using fresh cells and two concentrations; high cell concentration of 
~50 x 106 cells mL-1 which translates to a shear stress of 176 Pa (µ ≈ 2.03 mPa s) and 
shear rate of 88,000 s-1; and low cell concentration of approximately 2.0 x 106 cells 143 
 
mL-1 which translates to a shear stress of 116 Pa (µ ≈ 1.02 mPa s) and shear rate of 
116,000 s-1.  
3.5.1  Physical impact as measured by LDH release 
As with the disc speed and cell age experiments, five runs for each low and high cell 
concentration were carried out and the breakdown of each one is shown in Tables 3.7.A 
and 3.7.B. The results presented in Table 3.7.A are the same as those presented in Table 
3.4.B and are reproduced for convenience. These tables summarize some of the key 
performance data for the two sets of runs. Each run, A to E, depends on preparation of a 
new batch of cells. Despite a constant method of preparation used, there will inherently 
be some variation between batches. 
Column 2 presents the measured transmission of LDH through the membrane at the end 
of each of the 60 minutes shear runs. These are the transmission values that are used for 
calculations. The mean value for LDH transmission is significantly lower at the higher 
cell concentration (0.77 ± 0.04 compared with 0.88 ± 0.04) probably due to the lower 
shear rate over the membrane surface or due to the greater level of membrane fouling 
species. The average transmission value at high cell concentration and high disc speed 
is similar to the average transmission value at low cell concentration and low disc speed 
of 0.78 ± 0.02, which might be a reflection of the similarity in the average shear rates 
(11,000 s-1 and 13,000 s-1 respectively). 
Column 3 examines the stability of LDH over the period of the membrane study for 
each run. On average for both cases, the cells might be considered stable for the length 
of the run. There were two anomalies; Run C for the high cell concentration (Table 144 
 
3.7.B) and, to a lesser extent, Run D for low cell concentration (Table 3.7.A). Both 
these runs have slightly higher values of the LDH in the control than that in the retentate 
pre-processing. However, overall, the averages for low and high cell concentrations 
were  1.01 ± 0.06  and  0.97 ± 0.06  respectively  concluding  that  the  cells  might  be 
considered as stable for both cases. 
Column 4 examines the total amount of LDH (extracellular and intracellular) measured 
- i.e. permeate plus retentate – and it is compared with total LDH at the start of the 
experiment.  This  helps  to  check  whether  all  LDH  is  recovered  (none  is  stuck  to 
membrane) and none is lost through denaturation. For low cell concentration there is a 
small, but not statistically significant, loss of ~4% of LDH which might be trapped in 
the membrane or may fall within experimental error. For high cell concentration, there 
is no loss of LDH. 
Finally, column 5 is a second measure of accountability for LDH, comparing the total in 
the retentate and permeate to the control cells for the duration of the experiment. Again 
for low cell concentrations there is a small, but not statistically significant, loss of ~5% 
of LDH and no loss for high cell concentration. 
Overall, it can be seen from Tables 3.7.A and 3.7.B that the averages are representative 
of the runs. Therefore, the average values of the repeats were used to produce Figure 
3.18.A. This figure shows the proportion of intracellular LDH remaining with time. The 
trends seen in this figure show that at a high cell concentration, more cells are damaged 
than at a low concentration. However, the proportion of intracellular LDH remaining 
has decreased ~26 ± 1.7% for low cell concentration and ~19 ± 6.1% for high cell  145 
 
A.                                     Low concentration ± 1 s.e. (j = 5; n = 4) 
1. 
 
Run (‘?’) 
2. 
 
‘𝑻(?󵑭)’ 
3. 
 
‘?/?’ 
4. 
 
‘(? + ?)/?’ 
5. 
 
‘(? + ?)/?’ 
A  0.88 ± 0.08  1.11 ± 0.05  1.03 ± 0.04  0.93 ± 0.04 
B  0.91 ± 0.04  0.82 ± 0.01  0.81 ± 0.01  1.00 ± 0.02 
C  0.80 ± 0.04  1.01 ± 0.08  0.96 ± 0.06  0.92 ± 0.02 
D  0.78 ± 0.06  1.17 ± 0.12  0.95 ± 0.09  0.78 ± 0.02 
E  1.02 ± 0.06  0.96 ± 0.03  1.06 ± 0.04  1.10 ± 0.02 
Average  0.88 ± 0.04  1.01 ± 0.06  0.96 ± 0.04  0.95 ± 0.05 
 
B.                           High concentration ± 1 s.e. (j = 5; n = 4) 
A  0.65 ± 0.06  0.84 ± 0.04  1.11 ± 0.03  1.34 ± 0.05 
B  0.80 ± 0.03  0.95 ± 0.04  1.10 ± 0.02  1.15 ± 0.04 
C  0.85 ± 0.07  1.21 ± 0.09  1.03 ± 0.08  0.84 ± 0.03 
D  0.83 ± 0.09  0.87 ± 0.07  0.86 ± 0.06  0.96 ± 0.05 
E  0.71 ± 0.07  0.99 ± 0.05  0.89 ± 0.04  0.89 ± 0.01 
Average  0.77 ± 0.04  0.97 ± 0.06  1.00 ± 0.05  1.04 ± 0.09 
 
Table 3.7: Membrane processing of feed (‘N’ = 10,000 rpm) HCA2 cells – effect of (A) low and (B) 
high cell concentration on cell damage as recorded by release of LDH. To note results presented in 
Table  3.7.A  are  as  presented  in  Table  3.4.B.  From  left  to  right  columns  show;  (1)  run;  (2) 
transmission coefficient; (3) ratio of intracellular LDH in the control to the intracellular LDH pre-
processing in the retentate to evaluate stability of LDH in the cells without processing (where 1 
equals to no loss in LDH activity); (4) ratio of the sum of the total LDH in the retentate  post-
processing and permeate streams to the total LDH in the retentate pre-processing, to evaluate the 
mass balance agreement (where 1 equals to complete agreement, i.e. all LDH mass is accounted 
for); (5) ratio of the sum of the total LDH in the retentate post-processing and permeate streams to 
the total LDH in the control, to evaluate the mass balance agreement assuming the processed cells 
change as with control.  
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B.   LDH µU ± 1 s.e. (j = 5; n = 4) 
   Cell concentration  Low concentration 
Sample  Notation 
Measured 
total 
(‘LDH_TOT’) 
Measured 
external 
(‘LDH_EXT’) 
Predicted 
internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  25.09 ± 0.91  0.73 ± 0.14  24.36 ± 1.03 
Control  (b) ‘?(60) = [?](60) × ??’  25.73 ± 1.78  1.06 ± 0.33  24.68 ± 1.75 
Post-processing  (c)  ‘?(60) = [?](60) × ??’  15.70 ± 1.08  0.62 ± 0.23  15.08 ± 1.05 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  8.37 ± 0.49       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’  
24.07 ± 1.17  8.99 ± 0.65  15.08 ± 1.05 
Figure 3.18: Membrane processing of feed (0 hours cell ageing, ‘N’ = 10,000 rpm) HCA2 cells – 
effect of cell concentration on cell damage as recorded by (A) release of LDH. Tables (B) and (C) 
show the mean LDH data for all streams including both external and total measurements. To note 
results presented in Figure 3.18 (Table B) are as presented in Figure 3.2 (Table C). A non-sheared 
control held in a centrifuge tube concurrently, at 21 ± 1 ºC, for the duration of the experiment was 
used to measure LDH before and after processing. Figure (A) shows the proportion of intracellular 
LDH remaining (‘𝝎’, Eq 3.8), for low (~2x106 cells  mL-1, ○) and high (~50x106 cells  mL-1,  ▲) 
concentrations.  LDH  release  indicates  that  after  processing  the  same  proportion  of  intact  cells 
remain after processing at both concentrations. Data shown are mean values ± 1 s.e. (j = 5; n = 4).   
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 C.  Cell concentration  High concentration 
Sample  Notation 
Measured 
total 
(‘LDH_TOT’) 
Measured 
external 
(‘LDH_EXT’) 
Predicted 
internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  572.9 ± 33.0  20.4 ± 4.5  552.5 ± 34.2 
Control  (b) ‘?(60) = [?](60) × ??’  564.0 ± 50.4  26.3 ± 6.5  537.7 ± 44.5 
Post-processing  (c)  ‘?(60) = [?](60) × ??’  439.7 ± 22.0  12.1 ± 1.4  427.6 ± 22.9 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  111.9 ± 17.5       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’  
551.6 ± 5.2  124.0 ± 18.3  427.6 ± 22.9 147 
 
concentration. Taking into consideration the experimental errors, the values obtained for 
the decrease for both cell concentrations overlap. Therefore even though more cells are 
damaged at high cell concentration, the proportion of intact cells remaining in the USD 
device appears to be relatively constant and independent of cell concentration.  
From Figure 3.18.A, it can be also seen that even though the final proportion of intact 
cells remaining in the USD device appears to be the same for both concentrations, the 
profiles of decrease are dissimilar. On the one hand, high cell concentration follows a 
constant  decrease  of  ~2 ± 0.2%  every  five  minutes.  On  the  other  hand,  low  cell 
concentration has two different slopes of release of LDH into the permeate stream. 
During the first 15 minutes of processing, ~15% of the intracellular LDH is collected in 
the permeate. For the remaining 45 minutes of operation there is a ~1 ± 0.4% decrease 
in intracellular LDH every 5 minutes of operation.  
From Figure 3.18, Tables B and C show the amount of total, extracellular and internal 
LDH in each of the process streams for low and high cell concentration respectively. 
The results in Figure 3.18, Table B are the same as those presented in Figure 3.2, Table 
A. The mass balances for both conditions show that the amount of total LDH in the 
non-sheared  controls  held  at  21 ± 1ºC  in  a  centrifuge  tube  for  the  duration  of  the 
experiment, did not decrease. As with the disc speed and cell age investigations, any 
changes seen can therefore be fully attributed to processing conditions.  
It also appears that for both low and high cell concentrations the total amount of LDH in 
the  retentate  pre-processing  is  in  good  agreement  with  the  total  amount  of  LDH 148 
 
collected  post-processing  in  both  the  retentate  and  in  the  permeate,  as  was  also 
previously shown from Tables 3.7.A and 3.7.B. 
3.5.2  Physical impact as measured by trypan blue exclusion 
The plots shown in Figures 3.19 and 3.20 were used to analyze the impact of a low and 
a high cell concentration on cell damage as measured by trypan blue exclusion. The 
results presented for low cell concentration in Figures 3.19 and 3.20 are the same as 
those presented in Figures 3.4 and 3.5 for high disc speed (‘?’ = 10,000 rpm) and are 
reproduced for convenience. Figure 3.19 shows the concentration of total and viable 
cells for pre-processing, control and post-processing samples for low cell concentration 
(Figure 3.19.A) and high cell concentration (Figure 3.19.B). At low cell concentration 
there is a ~15% (p = 0.051) decrease in the population of total cells and lower decrease 
of ~8% (p = 0.167) at high cell concentration. There is also a ~25% decrease in the 
population of viable cells (p = 0.003) at low cell concentration and a lower decrease of 
~8% (p = 0.159) at high cell concentration. The only significant change (p <0.01) noted 
is the ~25% decrease in the concentration of viable cells at low cell concentration.  
Figure  3.20  shows  the  percentage  viability  for  pre-processing,  control  and 
post-processing samples for both cell concentrations. Analysis of this figure shows that 
low cell concentration resulted in a significant ~10% (p = 0.001) drop in percentage 
viability  post-processing  compared  to  a  minimal  and  not  significant  drop  ~1%  in 
percentage  viability  at  high  cell  concentration.  Therefore,  these  results  suggest  that 
operating  at  low  cell  concentration  resulted  in  a  generally  poorer  quality  (lower 
percentage viability) cellular suspension post-processing as measured by trypan blue  149 
 
 
 
Figure  3.19:  Membrane  processing  of  feed  (‘N’  =  10,000  rpm)  HCA2  cells  –  effect  of  cell 
concentration on cell damage shown by total and viable cell concentrations pre and post-processing 
of the cellular suspension as recorded by trypan blue exclusion. Table below shows mean of raw 
data determined by trypan blue exclusion for concentration of total and viable cells. A non-sheared 
control held in a centrifuge tube concurrently, 21 ± 1ºC, for the duration of the experiment was 
used to measure trypan blue pre and post-processing for both low and high cell concentration. To 
note results for low cell concentration presented in this figure are as presented in Figure 3.4 for 
high disc speed. Trypan blue exclusion indicates that processing at low cell concentration resulted 
in ~25% reduction of viable cells compared to ~8% at high cell concentration. Significant changes 
between non-sheared control and post-processing (*p<0.5, **p<0.01, ***p<0.001). Data shown are 
mean values ± 1 s.d. (j = 5; n = 4). 
    
 
Concentration (x106 cells mL-1) ± 1 s.d. (j = 5; n = 4) 
   Total cells  Viable cells 
Concentration   Control  Pre-
processing 
Post-
processing  Control  Pre-
processing 
Post-
processing 
Low  1.98 ± 0.06  2.13 ± 0.07  1.67 ± 0.19  1.94 ± 0.06  2.06 ± 0.09  1.44 ± 0.17 
High  54.0 ± 5.8  47.1 ± 1.8  49.8 ± 2.3  51.8 ± 5.3  45.9 ± 1.4  47.8 ± 2.3 
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 Figure  3.20:  Membrane  processing  of  feed  (‘N’  =  10,000  rpm)  HCA2  cells  –  effect  of  cell 
concentration  on  percentage  viability  of  cellular  suspension  as  determined  by  trypan  blue 
exclusion.  The  figure  shows  percentage  viability  before  and  after  membrane  processing  as 
determined by trypan blue exclusion. Table below shows mean of raw data determined by trypan 
blue exclusion for percentage viability. To note results for low cell concentration presented in this 
figure are as presented in Figure 3.5 for high disc speed.  Trypan blue exclusion indicates that at 
low cell concentration there is a ~10% drop in percentage viability after membrane processing 
compared to no drop after processing at a higher cell concentration. Data shown are mean values ± 
1 s.d. (*p<0.5, **p<0.01, ***p<0.001; j = 5; n = 4). 
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% ± 1 s.d. (j = 5; n = 4) 
   % Viability 
Concentration   Control  Pre-processing  Post-processing 
Low  97.0 ± 0.3  97.1 ± 0.5  86.7 ± 2.1 
High  96.5 ± 0.6  96.1 ± 0.7  95.6 ± 1.0 151 
 
exclusion. The loss of viable cells is due largely to loss of membrane integrity but there 
is some evidence also  for cell destruction (i.e. the proportion of viable cells lost  is 
bigger than the loss of viability). 
3.6  Chapter discussion 
Having processed the human fibroblast cell line under different operating conditions 
using  the  USD  membrane  separation  device,  this  chapter  established  a  level  of 
understanding concerning the type of processing stresses that lead to cell death. The 
design space investigated in this chapter for various bioprocessing factors such as (i) disc 
speed, (ii) cell age and (iii) cell concentration (viscosity) assess extreme processing 
conditions with the aim of identifying a window of operation for the production and 
recovery of high quality human cells.  
For  the  first  condition  investigated,  i.e.  disc  speed  (shear  rate),  both  physical  and 
biological characterization of the cells were carried out. Investigation confirmed that the 
decrease  in  the  proportion  of  intracellular  LDH  remaining  in  the  USD  membrane 
separation device throughout operation was higher at high disc speed than at low disc 
(~30% compared to ~8%). Trypan blue exclusion also revealed a higher decrease in the 
population of viable cells at high disc speed than at low disc speed (~25% compared to 
no  drop).  Moreover,  high  disc  speed  resulted  in  a  significant  drop  of  ~10%  in 
percentage viability post-processing compared to no drop at a low disc speed.  Rate 
constants for cell damage were calculated to further assess the impact of disc speed on 
cell damage as measured by the two analytical techniques described. Both techniques 152 
 
indicated that damage at higher disc speeds occurs five times faster than at low disc 
speed. Moreover, LDH release is twice as sensitive as trypan blue exclusion data.  
Preliminary  studies  were  also  performed  to  evaluate  CQAs  including  morphology, 
growth profiles and specific growth rates as well as cell death induction. Morphological 
analysis of cells in suspension revealed the appearance of elongated and ‘blebby’ cells 
immediately post-processing, most of which disappear after a 2 hour hold. The observed 
trend was more apparent when operating at high disc speed than at low disc speed. 
Literature reveals that ‘blebbing’ can be indicative of programmed cell death but can 
also  can  resolve  itself  once  the  actin  cytoskeleton  is  restored  (Kumar  et  al.  2007). 
Assessment of the growth curves indicated that both processed samples retained the 
ability  to  grow  and  proliferate  after  being  exposed  to  shear  for  60  minutes.  Both 
displayed very similar profiles  over the course  of the initial  48 hours of the study, 
exhibiting  a  lower  rate  of  growth  when  compared  to  the  non-processed  control. 
However, by the 72 hour time point, the sample processed at low disc speed proliferated 
at the same rate as the non-sheared control sample, which was not the case for the 
sample processed at high disc speed. The information gathered serves as an indication 
that differences in growth rates exist between samples sheared at varying disc speeds 
although a larger sample and more testing would be required in order to  draw firm 
conclusions. Cell death analysis confirmed increased damage at higher shear rate by the 
appearance  of  apoptotic  and  necrotic  cell  populations.  It  is  therefore  evident  that, 
overall, all findings indicate that harsher operating conditions not only caused more 
damage to the cellular population being processed but also resulted in a generally poorer 
quality  (lower  percentage  viability)  cellular  suspension  post-processing.  Although 153 
 
trypan blue exclusion is a rapid and powerful technique, it does not offer the same level 
of detail as the cell death assay which can offer useful insight into the quality of cells 
post-processing. 
The  second  operating  condition  investigated  was  cell  age  prior  to  processing,  i.e. 
processing of fresh cells versus cells held for 24 hours. On the one hand, LDH data 
indicated that ageing the cells led to an overall weaker cellular population, twice as 
susceptible to shear forces during processing (~15% compared to ~8%). On the other 
hand, trypan blue data indicated that both fresh cells and those aged for 24 hours have 
comparable results with a small (< 2%) and insignificant drop in cell viability. The 
difference may be due to the difference in sensitivity of both measurements and the 
small magnitudes of damage measured. 
The  third  and  final  parameter  investigated  in  this  chapter  was  low  and  high  cell 
concentrations (~2x106 and ~50x106 cells mL-1). At low concentration there is ~25% 
cell loss as recorded both by LDH release and loss of viable cells as measured by trypan 
blue  exclusion.  The  majority  of  this  loss  is  most  likely  due  to  loss  of  membrane 
integrity but there is some evidence to suggest that a proportion of the loss may be due 
to total cell destruction. At high concentration there is ~17% cell loss as recorded by 
LDH  release  but  losses  as  measured  by  cell  counts  (total  or  viable)  appear  to  be 
significantly less (maximum ~10%). However, when considering the errors measured 
for LDH release, a constant proportion of cells appear to have been recovered at both 
concentrations. It should however be noted that the absolute level of damage recorded is 154 
 
significantly more at higher cell concentration (i.e. the total cells lost as opposed to the 
proportion of cells lost).  
The findings of the investigation of the processing variables using the HCA2 cell line 
led  to  the  desire  to  gain  more  understanding  on  the  translation  to  other  clinically 
relevant  cell  lines.  The  following  chapter  will  utilize  the  analytical  techniques 
developed in this chapter for the evaluation of neural stem cells and prostate carcinoma 
cells. 
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Chapter 4.  The physical impact of processing on loss of intact 
cells for CTX0E03 and P4E6 cell lines 
4.1  Introduction 
Understanding and defining the mechanical properties of various candidate cell lines 
may facilitate the design of robust bioprocessing steps, allowing not only the generation 
of  cells  of  reproducible  quality  and  efficacy,  but  also  rejecting  inappropriate  cell 
candidates prior to the clinical manufacturing stage (Acosta-Martinez et al. 2010). USD 
tools may be used at early discovery stage to gain an indication of the properties of 
different cell lines (Acosta-Martinez et al. 2010; Delahaye 2013).  
The methods developed with the human fibroblast candidates are  evaluated for two 
other whole cell therapies; a neural stem cell line (CTX0E03) and one of three cell lines 
in  a  prostate  cancer  whole  cell  therapy  (P4E6  cell  line).  The  CTX0E03  cell  line, 
currently  undergoing  Phase  II  clinical  trials  for  the  treatment  of  debilitated  stroke 
victims, was kindly provided by ReNeuron Group plc. The P4E6 cell line is a prostate 
carcinoma  cell  line  derived  from  an  early  prostate  cancer  biopsy  and  was  kindly 
provided  by  Onyvax  Ltd.  The  effect  on  cell  damage  of  the  same  three  processing 
parameters  as  previously  studied  (disc  speed,  cell  ageing  and  cell  concentration)  is 
investigated in this chapter for the two cell lines above described. For the CTX0E03 cell 
line, both  LDH and trypan blue measurements  are shown. For P4E6 cell line, only 
trypan blue analysis is given. This is because the experiments carried out with the P4E6 
cells were prior to the ones with the HCA2 cells used to develop and optimize the LDH 
measurements and therefore the LDH data collected for P4E6 cell line is considered 
insufficient for analysis (no transmission measurements available).   156 
 
4.2  Effect of disc speed on CTX0E03 and P4E6 cell lines 
The impact of low and high disc speeds (6,000 and 10,000 rpm respectively) using 
CTX0E03 and P4E6 cell lines was investigated in a similar fashion to HCA2 cell line. 
However,  unlike  the  five  runs  carried  out  for  the  HCA2  cell  line,  for  each  of  the 
CTX0E03 and P4E6 cell lines three repeats for each condition were carried out. 
4.2.1  Physical impact as measured by LDH release  
Tables 4.1.A and 4.1.B summarize some of the key performance data for the two sets of 
runs for low and high disc speeds respectively. Each run, A to C, was from a new batch 
of cells prepared using the same method.  
Column 2 presents the measured transmission of LDH through the membrane at the end 
of each of the 60 minutes shear runs. These are the transmission values that are used for 
calculations. The mean value for LDH transmission is significantly lower at the low 
disc speed (0.78 ± 0.03 compared with 0.87 ± 0.04) probably due to the lower shear rate 
over  the  membrane  surface.  These  values  are  similar  to  the  transmission  values 
measured with the HCA2 cells at low and high disc speeds (0.78 ± 0.02 and 0.88 ± 0.04 
respectively; Table 3.4). 
Column 3 demonstrates the stability of LDH over the period of the membrane study for 
each run. For both low and high disc speed there is a small and probably insignificant 
drop of ~3 and ~8% respectively. Hence, the cells are considered stable for the length of 
the run (as for HCA2 fibroblasts, Table 3.4). 
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Column 4 shows the total amount of LDH (extracellular and intracellular) measured - 
i.e. permeate plus retentate – and it is compared with total  LDH at the start of the 
experiment.  This  helps  to  check  whether  all  LDH  is  recovered  (none  is  stuck  to 
membrane) and none is lost through denaturation. For both disc speeds there is a small, 
but not statistically significant, loss of LDH (~2% and ~6% respectively) which might 
be trapped in the membrane. 
Finally, column 5 is a second measure of accountability for LDH comparing the total in 
the retentate and permeate to the control cells for the duration of the experiment. In this 
case for both disc speeds there is no loss of LDH, averaging 1.02 ± 0.10 and 1.02 ± 0.06 
for low and high disc speed respectively. 
Overall, it can be seen from Tables 4.1.A and 4.1.B that the averages are representative 
of  the  runs.  The  average  values  of  the  repeats  were  used  to  produce  Figure  4.1  to 
analyze the impact of low and high disc speed on cell damage as measured by LDH 
release for the CTX0E03 cell line. Processing at low and high disc speeds caused a 
decrease  of  ~50  –  60%  after  60  minutes  in  each  case.  These  results  suggest  that 
CTX0E03 cells are more shear sensitive than HCA2 cells. In Chapter 3 Section 3.3, it 
was shown that for the HCA2 fibroblasts the proportion of intracellular LDH remaining 
with time decreased ~8% at a low disc speed and by ~30% at a high disc speed. 
Moreover, these findings also suggest that the damage caused to this particular cell line 
is mainly dependent on the experience of being exposed to shear forces and the time of 
exposure and less so by the magnitude of the shear forces. Previous studies conducted by 
Acosta-Martinez (2011) somehow reinforce CTX0E03 cells being damaged mainly by  158 
 
A.                                     6,000 rpm ± 1 s.e. (j = 3; n = 4) 
1. 
 
Run (‘?’) 
2. 
 
‘𝑻(?󵑭)’ 
3. 
 
‘?/?’ 
4. 
 
‘(? + ?)/?’ 
5. 
 
‘(? + ?)/?’ 
A  0.77 ± 0.03  1.11 ± 0.01  1.17 ± 0.02  1.05 ± 0.02 
B  0.73 ± 0.10  1.02 ± 0.02  0.85 ± 0.03  0.83 ± 0.03 
C  0.84 ± 0.07  0.80 ± 0.01  0.94 ± 0.01  1.17 ± 0.01 
Average  0.78 ± 0.03  0.97 ± 0.09  0.98 ± 0.10  1.02 ± 0.10 
 
B.                           10,000 rpm ± 1 s.e. (j = 3; n = 4) 
A  0.92 ± 0.03  0.82 ± 0.02  0.88 ± 0.01  1.07 ± 0.01 
B  0.88 ± 0.05  0.99 ± 0.02  1.08 ± 6.43  1.09 ± 0.00 
C  0.79 ± 0.12  0.96 ± 0.02  0.86 ± 0.01  0.89 ± 0.01 
Average  0.87 ± 0.04  0.92 ± 0.05  0.94 ± 0.07  1.02 ± 0.06 
 
Table 4.1: Membrane processing of feed (0 hour cell ageing) CTX0E03 cells – effect of (A) 6,000 
and (B) 10,000 rpm on cell damage as recorded by release of LDH. (C) Shows a box diagram of the 
USD membrane separation device including all process streams. From left to right columns show; 
(1) run; (2) transmission coefficient; (3) ratio of internal LDH in the control to the internal LDH 
pre-processing in the retentate to evaluate stability of LDH in the cells without processing (where 1 
equals  to  no  loss  in  LDH  activity);  (4)  ratio  of  the  sum  of  the  total  LDH  in  the  retentate  
post-processing and permeate streams to the total LDH in the retentate pre-processing, to evaluate 
the mass balance agreement (where 1 equals to complete agreement, i.e. all LDH mass is accounted 
for); (5) ratio of the sum of the total LDH in the retentate post-processing and permeate streams to 
the total LDH in the control, to evaluate the mass balance agreement assuming the processed cells 
change as with control (j  = 3; n = 4). 159 
 
 
B. 
LDH µU ± 1 s.e. (j = 3; n = 4) 
Disc speed  6,000 rpm 
Sample  Notation  Total 
(‘LDH_TOT’) 
Extracellular 
 (‘LDH_EXT’) 
Predicted 
internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  17.16 ± 0.97  1.26 ± 0.22  15.89 ± 0.75 
Control  (b) ‘?(60) = [?](60) × ??’  16.60 ± 1.20  1.12 ± 0.38  15.48 ± 1.36 
Post-processing  (c)  ‘?(60) = [?](60) × ??’  6.99 ± 1.72  0.88 ± 0.21  6.11 ± 1.92 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  9.70 ± 1.11       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’  
16.69 ± 0.68  10.58 ± 1.32  6.11 ± 1.92 
C.  Disc speed  10,000 rpm 
Sample  Notation  Total 
(‘LDH_TOT’) 
Extracellular 
 (‘LDH_EXT’) 
Predicted 
internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  12.96 ± 1.03  0.91 ± 0.37  12.05 ± 0.66 
Control  (b) ‘?(60) = [?](60) × ??’  12.06 ± 1.50  0.95 ± 0.41  11.12 ± 1.24 
Post-processing  (c)  ‘?(60) = [?](60) × ??’  4.44 ± 0.48  1.01 ± 0.40  3.43 ± 0.73 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  7.71 ± 1.16       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’  
12.15 ± 1.24  8.72 ± 1.54  3.43 ± 0.73 
Figure 4.1: Membrane processing of feed (0 hour cell ageing) CTX0E03 cells – effect of disc speed 
on (A) cell damage as recorded by release of LDH. Tables (B) and (C) show mean LDH data for all 
streams including both external and total measurements at 6,000 rpm and 10,000 rpm (‘γ’ = 44,000 
and 116,000 s-1 respectively). A non-sheared control held in a centrifuge tube concurrently, 21± 1ºC, 
for the duration of the experiment was used to measure LDH pre and post-processing. Figure (A) 
shows the proportion of intracellular LDH remaining (‘ɷ’, Eq 3.8), for 6,000 rpm (○) and 10,000 
rpm (▲) at a concentration of ~1.5x106 total cells mL-1. Both disc speeds resulted in a ~50-60 % 
reduction of viable cells as measured by LDH release. Data shown are mean values ±1s.e. (j=3;n=4).   
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exposure  to  shear  forces  rather  than  by  the  magnitude  of  these  forces.  His  studies 
describe a controlled flow through an USD capillary device where cells are exposed to 
several defined hydrodynamic stresses. He  concluded that the variable with the largest 
impact on the final cell integrity of the CTX0E03 population was the number of passes 
through a capillary device. For other cell lines in his study (prostate cancer OnyCap23 and 
P4E6 cell lines), flow rate and length of the capillary had had the largest impact on cell 
integrity.  For  Acosta-Martinez  (2011),  this  finding  suggested  that  CTX0E03  cells  were 
therefore mainly affected by the experience of being exposed to an elongational stress event 
and less so by the time spent inside the capillary or the magnitude of this stress.  
From Figure 4.1, Tables B and C show the average values for the three runs of the 
amount of total, extracellular and internal LDH in each of the process streams for low 
and high disc speeds respectively. For both disc speed conditions, the mass balances 
show that the amount of total LDH in the non-sheared controls held at 21 ± 1ºC in a 
centrifuge tube for the duration of the experiment, within experimental error can be 
considered as stable (low disc speed shows ~6% loss of LDH which is not statistically 
significant and can be attributed to experimental error).  
Moreover, for both disc speeds the total mass of LDH collected in the permeate plus the 
total amount collected in the retentate post-processing is in agreement with the total 
amount pre-processing as was shown from Tables 4.1.A and 4.1.B.   161 
 
4.2.2  Physical impact as measured by trypan blue exclusion 
The plots in this section show the impact of low and high disc speed on cell damage as 
measured  by  trypan  blue  exclusion  for  CTX0E03  (Figures  4.2  and  4.3)  and  P4E6 
(Figures 4.4 and 4.5) cell lines. 
Figure  4.2  shows  the  average  concentration  of  total  and  viable  CTX0E03  cells  as 
measured by trypan blue exclusion for the three repeats at each of both disc speeds. 
Analysis of this figure shows that there is a significant decrease in the population of 
viable cells of ~42% (p = 0.002) at a low disc speed and ~47% (p = 0.001) at high disc 
speed. Figure 4.3 shows the percentage viability of CTX0E03 cells for pre-processing, 
control and post-processing samples for both disc speeds. From this figure it can be 
seen that there is a significant drop in the percentage viability at both low and high disc 
speeds of ~17% (p = 0.01) and ~14% (p = 0.001) respectively. Therefore, these results 
suggest that comparable amounts of cell damage were observed at both disc speeds.  
Processing for 60 minutes caused in both cases a high proportion of viable cells lost as 
well as a generally poor quality (low percentage viability of ~76%) cellular suspension 
post-processing. At both disc speeds there is ~50% cell loss as recorded both by LDH 
release  and  loss  of  viable  cells.  The  loss  of  viable  cells  is  due  largely  to  loss  of 
membrane  integrity  but  there  is  some  evidence  for  both  cell  destruction  (i.e.  the 
proportion of viable cells lost is bigger than the loss of viability). 
   162 
 
 
 Figure 4.2: Membrane processing of feed (0 hour cell ageing) CTX0E03 cells – effect of disc speed 
on cell damage shown by total and viable cell concentrations pre and post-processing of the cellular 
suspension as recorded by trypan blue exclusion. Table below shows mean of raw data determined 
by trypan blue exclusion for concentration of total and viable cells. A non-sheared control held in a 
centrifuge tube concurrently, 21 ± 1ºC, for the duration of the experiment was used to measure 
trypan blue pre and post-processing for both 6,000 and 10,000 rpm (‘γ’ = 44,000 and 116,000 s-1 
respectively).  Trypan  blue  exclusion  indicates  that  processing  at  both  low  and  high  disc  speed 
resulted in ~50% reduction of viable cells. Significant changes between non-sheared control and 
post-processing (*p<0.5, **p<0.01, ***p<0.001). Data shown are mean values ± 1 s.d. (j = 3; n =4).    
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Pre-
processing  Control  Post-
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6,000  1.46 ± 0.09  1.66 ± 0.12  1.24 ± 0.04  1.32 ± 0.05  1.55 ± 0.05  0.90 ± 0.02 
10,000  1.64 ± 0.10  1.80 ± 0.21  1.14 ± 0.24  1.50 ± 0.06  1.67 ± 0.15  0.88 ± 0.14 163 
 
 
 Figure 4.3: Membrane processing of feed (0 hour cell ageing) CTX0E03 cells – effect of disc speed 
on percentage viability of the cellular suspension as recorded by trypan blue exclusion. Table below 
shows  mean  of  raw  data  determined  by  trypan  blue  exclusion  for  percentage  viability.  A 
non-sheared  control  held  in  a  centrifuge  tube  concurrently,  21  ±  1ºC,  for  the  duration  of  the 
experiment was used to measure trypan blue pre and post-processing for both 6,000 and 10,000 
rpm (‘γ’ = 44,000 and 116,000 s-1 respectively). Trypan blue exclusion indicates that processing 
resulted in a significant drop in percentage viability compared to the pre-processed sample, both at 
low disc speed (~17% drop, p = 0.01) and high disc speed (~14% drop, p = 0.001). Significant 
changes between non-sheared control and post-processing (*p<0.5, **p<0.01, ***p<0.001). Data 
shown are mean values ± 1 s.d. (j = 3; n = 4). 
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   % ± 1 s.d. (j = 3; n = 4) 
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(rpm) 
Pre-
processing  Control  Post-
processing 
6,000  91.6 ± 0.1  91.6 ± 0.4  74.3 ± 2.4 
10,000  92.6 ± 1.1  92.2 ± 0.5  78.4 ± 0.4 164 
 
Figure 4.4 shows the average concentration of P4E6 total and viable cells as measured 
by trypan blue exclusion for the three repeats at each of both disc speeds. At low disc 
speed  there  is  a  significant  decrease  in  the  population  of  viable  cells  of  ~18% 
(p = 0.001) and ~41% (p = 4.05x10-5) at high disc speed. Moreover, from Figure 4.5 
which shows the percentage viability as measured by trypan blue exclusion, there is a 
non-significant drop in the percentage viability of ~1% (p = 0.263) at low disc speed 
and a low, yet significant, ~3% (p = 0.008) drop at high disc speed.  
Therefore, these results indicate that harsher operating conditions resulted mainly in a 
higher proportion of cells lysed after 60 minutes of operation and to a lesser extent in a 
drop in percentage viability of the cellular suspension post-processing. However, unlike 
for the HCA2 cell line, significant cell damage for P4E6 cells was also observed at low 
disc speed, indicating P4E6 cells are more shear sensitive than HCA2 fibroblasts but 
less than CTX0E03. 
4.3  Effect of cell age on CTX0E03 and P4E6 cell lines 
The impact of cell age, using fresh cells and cells aged for 24 hours, on the two cell 
lines (CTX0E03 and P4E6) was investigated in a similar fashion to HCA2 cell line. 
Three repeats for each condition were carried out for each cell line.  
For the CTX0E03 cell line, both LDH release and trypan blue exclusion measurements 
will be shown, whereas for P4E6 cell line, only trypan blue analysis will be given. This 
is because the experiments carried out with the P4E6 cells were completed before the 
protocol for balancing using LDH analysis had been established.   165 
 
 
 
 
 
 Figure 4.4: Membrane processing of feed (0 hour cell ageing) P4E6 cells – effect of disc speed on 
cell damage shown by total and viable cell concentrations pre and post-processing of the cellular 
suspension as recorded by trypan blue exclusion. Table below shows mean of raw data determined 
by trypan blue exclusion for concentration of total and viable cells. A non-sheared control held in a 
centrifuge tube concurrently, 21 ± 1ºC, for the duration of the experiment was used to measure 
trypan blue pre and post-processing for both 6,000 and 10,000 rpm (‘γ’ = 44,000 and 116,000 s-1 
respectively). Trypan blue exclusion indicates that processing at low disc speed resulted in ~18% 
reduction  of  viable  cells  whereas  high  disc  speed  resulted  in  a  ~41%  reduction  of  viable  cells. 
Significant  changes  between  non-sheared  control  and  post-processing  (*p<0.5,**p<0.01, 
***p<0.001). Data shown are mean values ± 1 s.d. (j = 3; n = 4). 
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Pre-
processing  Control  Post-
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6,000  1.36 ± 0.07  1.82 ± 0.03  1.50 ± 0.05  1.38 ± 0.01  1.76 ± 0.05  1.44 ± 0.05 
10,000  2.39 ± 0.18  2.62 ± 0.13  1.60 ± 0.05  2.35 ± 0.12  2.51 ± 0.11  1.49 ± 0.06 166 
 
 
Figure 4.5: Membrane processing of feed (0 hour cell ageing) P4E6 cells – effect of disc speed on 
percentage viability of the cellular suspension as recorded by trypan blue exclusion. Table below 
shows  mean  of  raw  data  determined  by  trypan  blue  exclusion  for  percentage  viability.  A 
non-sheared  control  held  in  a  centrifuge  tube  concurrently,  21  ±  1ºC,  for  the  duration  of  the 
experiment was used to measure trypan blue pre and post-processing for both 6,000 and 10,000 
rpm (‘γ’ = 44,000 and 116,000 s-1 respectively). Trypan blue exclusion indicates that processing 
resulted  in  a  small  but  significant  drop  in  percentage  viability  at  high  disc  speed  (~3%  drop, 
p = 0.008)  and  a  low  but  not  significant  change  at  low  disc  speed  (~1%).  Significant  changes 
between non-sheared control and post-processing (*p<0.5, **p<0.01, ***p<0.001). Data shown are 
mean values ± 1 s.d. (j = 3; n = 4). 
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% ± 1 s.d. (j = 3; n = 4) 
   % Viability 
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(rpm) 
Pre-
processing  Control  Post-
processing 
6,000  95.3 ± 1.8  96.4 ± 0.4  95.5 ± 0.7 
10,000  96.4 ± 0.6  96.0 ± 0.5  93.0 ± 0.6 167 
 
4.3.1  Physical impact as measured by LDH release 
Tables 4.2.A and 4.2.B summarize the key performance data for the runs for fresh cells 
(aged 0 hours) and cells aged for 24 hours. The results presented in Table 4.2.A are the 
same as those presented in Table 4.1.A and are reproduced for convenience. Each run, 
A to C, was from a new batch of cells prepared using the same method. For each cell 
preparation, enough cells were prepared to run two experiments, one with fresh cells 
and another with cells aged for 24 hours at 21 ± 1˚C.  
Column 2 presents the measured transmission of LDH through the membrane at the end 
of each of the 60 minutes shear runs. These are the transmission values that are used for 
calculations. An average value of 0.78 ± 0.03 transmission is observed when using fresh 
cells and 0.93 ± 0.03 for cells aged for 24 hours.  
Column 3 examines the stability of LDH over the period of the membrane study for 
each run. For both 0 and 24 hours cell ageing cases, there is a small and probably 
insignificant drop (~3% and ~6% respectively). Hence, the cells are considered as stable 
for the duration of the experiment (as for HCA2 fibroblasts Table 3.6).  
Column 4 examines the total amount of LDH (extracellular and intracellular) measured 
- i.e. permeate plus retentate – and it is compared with total LDH at the start of the 
experiment.  This  helps  to  check  whether  all  LDH  is  recovered  (none  is  stuck  to 
membrane) and none is lost through denaturation. For fresh cells there is no loss of 
LDH with an average value of 0.98 ± 0.10 whereas for cells aged for 24 hours, there is a 168 
 
significant loss of ~12% (p = 0.009) of LDH which might be due to entrapment in the 
membrane. 
Finally, column 5 is a second measure of accountability for LDH comparing the total in 
the retentate and permeate to the control cells for the duration of the experiment. For the 
aged cells there is a small, but not statistically significant, loss of LDH of ~6% and 
there was no loss showed for fresh cells. 
Overall, it can be seen from Tables 4.2.A and 4.2.B that the averages are representative 
of the runs. Therefore, the average values of the repeats were used to produce Figure 
4.6.A together with Tables B and C. The results in Figure 4.6, Table A are the same as 
those presented in Figure 4.1, Table A. Ageing over 24 hours was held the same way 
and under the same conditions as the control during the membrane study. This resulted 
in a ~12% (p = 0.033) loss of stability from total LDH in the control at 0 hours to the 
same control at 24 hours (Figure 4.6, 16.60 ± 1.20 from Table B to 14.62 ± 1.73 from 
Table C). However, by statistical analysis, this loss is classified as not significant. 
Figure  4.6  shows  the  proportion  of  intracellular  LDH  remaining  with  time  for  the 
CTX0E03 cell line. From this figure, both 0 and 24 hours cell age caused a decrease of 
~50 – 60% after 60 minutes of processing. These findings suggests that the damage 
caused to this particular cell line is dependent on the experience of being exposed to shear 
forces and the time of exposure and less so by cell ageing or pre-processing hold times. 
Previous studies conducted by Delahaye (2013) reinforce this finding. He investigated 
the  effect  of  resuspension  method  after  centrifugation  on  percentage  loss  of  intact 
CTX0E03 cells with pre-process hold times of 5 and 120 minutes. His findings suggest  169 
 
A.                                     0 hours ± 1 s.e. (j = 3; n = 4) 
1. 
 
Run (‘?’) 
2. 
 
‘𝑻(?󵑭)’ 
3. 
 
‘?/?’ 
4. 
 
‘(? + ?)/?’ 
5. 
 
‘(? + ?)/?’ 
A  0.77 ± 0.03  1.11 ± 0.01  1.17 ± 0.02  1.05 ± 0.02 
B  0.73 ± 0.10   1.02 ± 0.02  0.85 ± 0.03  0.83 ± 0.03 
C  0.84 ± 0.07  0.80 ± 0.01  0.94 ± 0.01  1.17 ± 0.01 
Average  0.78 ± 0.03  0.97 ± 0.09  0.98 ± 0.10  1.02 ± 0.10 
 
B.                           24 hours ± 1 s.e. (j = 3; n = 4) 
A  0.88 ± 0.02  0.82 ± 0.02  0.84 ± 0.03  1.02 ± 0.03 
B  0.98 ± 0.12  0.97 ± 0.01  0.89 ± 0.02  0.91 ± 0.02 
C  0.94 ± 0.11  1.03 ± 0.02  0.91 ± 0.03  0.88 ± 0.03 
Average  0.93 ± 0.03  0.94 ± 0.06  0.88 ± 0.02  0.94 ± 0.04 
 
Table 4.2: Membrane processing of feed (‘N’ = 6,000 rpm, ‘γ’ = 44,000 s-1) CTX0E03 cells – effect of 
(A) 0 and (B) 24 hours cell age on cell damage as recorded by release of LDH. To note results 
presented in Table 4.2.A are as presented in Table 4.1.A. Box diagram (C) of the USD membrane 
separation device shows process streams. From left to right columns show; (1) run; (2) transmission 
coefficient;  (3)  ratio of  internal  LDH  in  the  control  to  the  internal  LDH  pre-processing  in  the 
retentate to evaluate stability of LDH in the cells without processing (where 1 equals to no loss in 
LDH activity); (4) ratio of the sum of the total LDH in the retentate  post-processing and permeate 
streams to the total LDH in the retentate pre-processing, to evaluate the mass balance agreement 
(where 1 equals to complete agreement, i.e. all LDH mass is accounted for); (5) ratio of the sum of 
the  total  LDH  in  the  retentate  post-processing  and  permeate  streams  to  the  total  LDH  in  the 
control,  to  evaluate  the  mass  balance  agreement  assuming  the  processed  cells  change  as  with 
control (j = 3; n = 4). 170 
 
 
Figure 4.6: Membrane processing of feed (‘N’ = 6,000 rpm, ‘γ’ = 44,000 s-1) CTX0E03 cells – effect 
of cell ageing on (A) cell damage as recorded by release of LDH. Tables (B) and (C) show mean 
LDH data for all streams including both external and total measurements at 0 and 24 hours cell age 
respectively. To note results presented in Figure 4.6 (Table B) are as presented in Figure 4.1 (Table 
B). A non-sheared control held in a centrifuge tube concurrently, 21 ± 1ºC, for the duration of the 
experiment was used to measure LDH pre and post-processing. Figure (A) shows the proportion of 
intracellular LDH remaining (‘ɷ’, Eq 3.8), for 0 (○) and 24 (▲) hours at ~1.5x106 cells mL-1. Both 
conditions resulted in a ~50 - 60 % reduction of viable cells as measured by release of LDH. Data 
shown are mean values ± 1 s.e. (j = 3; n = 4).   
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Time (min)
0 hrs 24 hrs A.
B. 
LDH µU ± 1 s.e. (j = 3; n = 4) 
Cell ageing (hrs)  0 
Sample  Notation  Total 
(‘LDH_TOT’) 
External 
(‘LDH_EXT’) 
Predicted 
internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  17.16 ± 0.97  1.26 ± 0.22  15.89 ± 0.75 
Control  (b) ‘?(60) = [?](60) × ??’  16.60 ± 1.20  1.12 ± 0.38  15.48 ± 1.36 
Post-processing  (c)  ‘?(60) = [?](60) × ??’  6.99 ± 1.72  0.88 ± 0.21  6.11 ± 1.92 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  9.70 ± 1.11       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’  
16.69 ± 0.68  10.58 ± 1.32  6.11 ± 1.92 
C.  Cell ageing (hrs)  24 
Sample  Notation  Total 
(‘LDH_TOT’) 
External 
(‘LDH_EXT’) 
Predicted 
internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  15.43 ± 0.95  1.60 ± 0.20  13.83 ± 0.78 
Control  (b) ‘?(60) = [?](60) × ??’  14.62 ± 1.73  1.87 ± 0.41  12.75 ± 1.55 
Post-processing  (c)  ‘?(60) = [?](60) × ??’  4.47 ± 0.41  0.86 ± 0.10  3.60 ± 0.33 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  9.08 ± 1.30       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’  
13.55 ± 1.08  9.95 ± 1.28  3.60 ± 0.33 171 
 
that  applying  a  constant  shear  environment  using  automatic  resuspension  caused 
equivalent loss independent of pre-process hold times.   
From Figure 4.6, Tables B and C show the average values for the three runs of the 
amount of total, extracellular and internal LDH in each of the process streams for 0 and 
24 hours cell age respectively. The mass balances show that the amount of total LDH in 
the non-sheared controls held at 21 ± 1ºC in a centrifuge tube for the duration of the 
experiment, did not decrease for either fresh cells or aged cells. However,  the total 
amount of LDH in the retentate pre-processing decreased by ~3% for fresh cells and 
~12% for aged cells for 24 hours as was shown from Tables 4.2. 
4.3.2  Physical impact as measured by trypan blue exclusion 
The plots in this section show the impact of 0 and 24 hours cell age on cell damage as 
measured by trypan blue exclusion for the CTX0E03 (Figures 4.7 and 4.8) and P4E6 
(Figures 4.9 and 4.10) cell lines. The results presented for the fresh cells (i.e. 0 hours 
cell ageing) for the CTX0E03 cell line in Figures 4.7 and 4.8 are the same as those 
presented  in  Figures  4.2  and  4.3  for  low  disc  speed  (‘?’  =  6,000  rpm)  and  are 
reproduced for convenience. The results presented for the fresh cells (i.e. 0 hours cell 
ageing) for the P4E6 cell line in Figures 4.9 and 4.10 are the same as those presented in 
Figures  4.4  and  4.5  for  low  disc  speed  (‘?’  =  6,000  rpm)  and  are  reproduced  for 
convenience. 
Figure  4.7  shows  the  average  concentration  of  total  and  viable  CTX0E03  cells  as 
measured by trypan blue exclusion for the three repeats at each of both conditions. 172 
 
Analysis of this figure shows that there is a significant decrease in the population of 
viable cells for both fresh cells and cells aged for 24 hours (~42% with p = 0.002 and 
~57%  with  p = 0.006  respectively).  Figure  4.8  shows  the  percentage  viability  of 
CTX0E03  cells  for  pre-processing,  control  and  post-processing  samples  for  both 
conditions. There is a significant drop in the percentage viability at both 0 and 24 hours 
cell ageing of ~17% (p = 0.005) and ~23% (p = 0.001) respectively is observed. These 
results suggest that 24 hours cell ageing has led to higher amounts of cell damage and 
slightly worse quality of cells (lower percentage viability) post-processing.  
Figure 4.9 shows the average concentration of total and viable P4E6 cells as measured 
by  trypan  blue  exclusion  for  the  three  repeats  at  each  of  both  cell  age  conditions. 
Analysis of this figure shows that there is a significant decrease in the population of 
viable cells of ~18% (p = 0.001) at 0 hours cell ageing and probably insignificant ~5% 
(p  =  0.103)  decrease  at  24  hours  cell  ageing.  However,  when  comparing  the 
concentration of total and viable cells from 0 to 24 hours for both the control and the 
pre-processed samples, there is an evident and statistically significant drop from 0 to 24 
hours  for  all  samples.  For  example,  the  viable  cell  concentration  for  the  control 
decreases  by  ~16%  (p = 0.005)  from  0  to  24  hours.  Similarly,  the  total  cell 
concentrations for the controls from 0 to 24 hours cell ageing decreases by ~22% (p = 
0.003).  It  may  be  that  by  holding  the  cellular  suspension  for  24  hours,  a  weaker 
population of cells was eradicated prior to processing and after 24 hours hold. This 
weaker population may have been the one damaged during processing at 0 hours cell 
ageing, which would explain no cell damage after processing for the 24 hours cell age.  173 
 
 
 
 
Figure 4.7: Membrane processing of feed (‘?’ = 6,000 rpm, ‘𝜸’ = 44,000 s-1) CTX0E03 cells – effect 
of cell age on cell damage as shown by total and viable cell concentrations pre and post-processing. 
Table below shows mean of raw data determined by trypan blue exclusion for concentration of 
total and viable cells for pre and post-processing as well as a non-sheared control. To note results 
for 0 hours cell age (fresh cells) presented in this figure are as presented in Figure 4.2 for low disc 
speed.  A non-sheared control held in a centrifuge tube concurrently, 21 ± 1ºC, for the duration of 
the experiment was used to measure trypan blue exclusion pre and post-processing for 0 and 24 
hours cell age. Trypan blue exclusion indicates that there is a significant drop in the concentration 
of viable cells after processing at both a 0 and 24 hours cell ageing of ~42% (p = 0.002) and ~57% 
(p = 0.006)  respectively.  Significant  changes  between  non-sheared  control  and  post-processing 
(*p<0.5, **p<0.01, ***p<0.001). Data shown are mean values ± 1 s.d. (j = 3; n = 4). 
 
Concentration (x106 cells mL-1) ± 1 s.d. (j = 3; n = 4) 
   Total cells (‘TB_TOT’)  Viable cells (‘TB_VC’) 
Cell 
ageing 
(hrs) 
Pre-
processing  Control  Post-
processing 
Pre-
processing  Control  Post-
processing 
0  1.46 ± 0.09  1.66 ± 0.12  1.24 ± 0.04  1.32 ± 0.05  1.55 ± 0.05  0.90 ± 0.02 
24  1.30 ± 0.31  1.85 ± 0.24  0.91 ± 0.07  1.17 ± 0.28  1.36 ± 0.23  0.59 ± 0.11 
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Figure 4.8: Membrane processing of feed (‘?’ = 6,000 rpm, ‘𝜸’ = 44,000 s-1) CTX0E03 cells – effect 
of cell age on the percentage viability of cellular suspension as recorded by trypan blue exclusion. 
Table below shows mean of raw data determined by trypan blue exclusion for percentage viability. 
To note results for 0 hours cell ageing (fresh cells) presented in this figure are as presented in 
Figure 4.3 for low disc speed. A non-sheared control held in a centrifuge tube concurrently, 21 ± 
1ºC, for the duration of the experiment was used to measure trypan blue pre and post-processing 
for 0 and 24 hours cell ageing. Trypan blue exclusion shows a drop in percentage viability post-
processing for both fresh cells and cells aged for 24 hours. Significant changes between non-sheared 
control and post-processing (*p<0.5, **p<0.01, ***p<0.001). Data shown are mean values ± 1 s.d. (j 
= 3; n = 4). 
   % ± 1 s.d. 
   % Viability (j = 3; n = 4) 
Cell ageing 
(hrs)  Pre-processing  Control  Post-processing 
0  91.6 ± 0.1  91.6 ± 0.4  74.3 ± 2.4 
24  90.5 ± 0.6  91.5 ± 0.5  68.5 ± 1.2 
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Therefore, the overall effect of ageing the cells prior to processing yielded the equal 
amounts of damage as for fresh cells. 
Figure 4.10 shows the percentage viability for both conditions. There is no significant 
drop in the percentage viability for either 0 hours (~1% with p = 0.131) or 24 hours 
(~1% with p = 0.050) cell age.  
4.4  Effect of cell concentration on CTX0E03 and P4E6 cell lines 
The impact of low and high cell concentrations (fresh cells, ‘?’ = 10,000 rpm) using 
CTX0E03 and P4E6 cell lines was investigated in a similar fashion to HCA2 cell line. 
As  with  the  previous  sections,  both  LDH  release  and  trypan  blue  exclusion 
measurements will be shown for CTX0E03 cells and only trypan blue analysis for P4E6 
cells. For both cell lines, the viscosity was assumed to be the same as that measured for 
equivalent concentrations for the HCA2 fibroblast. This was based on the fact that when 
in suspension, all three cell lines have the same mean cell diameter of ~15 µm and 
hence the solids volume fraction will be the same for the same cell density. 
For  the  CTX0E03  cells,  three  runs  were  carried  out  at  low  cell  concentration 
(~1.50 x 106 viable cells mL-1) and two runs at high cell concentration (~29.8 x 106 
viable  cells  mL-1).  For  the  P4E6  cells,  three  runs  were  carried  out  at  low  cell 
concentration (~2.35 x 106 viable cells mL-1) and high cell concentration (~36.6 x 106 
viable cells mL-1).  
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Figure 4.9: Membrane processing of feed (‘?’ = 6,000 rpm, ‘𝜸’ = 44,000 s-1) P4E6 cells – effect of 
cell age on cell damage as shown by total and viable cell concentrations pre and post-processing. 
Table below shows mean of raw data determined by trypan blue exclusion for concentration of 
total and viable cells for pre and post-processing as well as a non-sheared control. To note results 
for 0 hours cell ageing presented in this figure are as presented in Figure 4.4 for low disc speed.  A 
non-sheared  control  held  in  a  centrifuge  tube  concurrently,  21  ±  1ºC,  for  the  duration  of  the 
experiment  was  used  to  measure  trypan  blue  pre  and  post-processing  for  0  and  24  hours  cell 
ageing. Trypan blue exclusion indicates that there is a significant drop of ~18% (p = 0.001) in the 
viable population at 0 hours cell ageing. Small drop in concentration of total or viable cells after 
processing with 24 hours cell ageing (~5%), although significant from 0 hours to end of processing 
(~21%). Significant changes between non-sheared control and post-processing (*p<0.5, **p<0.01, 
***p<0.001). Data shown are mean values ± 1 s.d. (j = 3; n = 4). 
 
Concentration (x106 cells mL-1) ± 1 s.d. (j = 3; n = 4) 
   Total cells (‘TB_TOT’)  Viable cells (‘TB_VC’) 
Cell 
ageing 
(hrs) 
Pre-
processing  Control  Post-
processing 
Pre-
processing  Control  Post-
processing 
0  1.36 ± 0.07  1.82 ± 0.03  1.50 ± 0.05  1.38 ± 0.01  1.76 ± 0.05  1.44 ± 0.05 
24  1.02 ± 0.20  1.60 ± 0.24  1.31 ± 0.09  1.00 ± 0.20  1.47 ± 0.05  1.40 ± 0.09 
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Figure 4.10: Membrane processing of feed (‘?’ = 6,000 rpm, ‘𝜸’ = 44,000 s-1) P4E6 cells – effect of 
cell ageing on the percentage viability of cellular suspension as recorded by trypan blue exclusion. 
Table below shows mean of raw data determined by trypan blue exclusion for percentage viability. 
To note results for 0 hours cell age (fresh cells) presented in this figure are as presented in Figure 
4.5 for low disc speed.  A non-sheared control held in a centrifuge tube concurrently, 21 ± 1ºC, for 
the duration of the experiment was used to measure trypan blue pre and post-processing for 0 and 
24 hours cell ageing. Trypan blue exclusion indicates that there is no significant drop in percentage 
viability after processing at a 0 and 24 hours cell ageing. Significant changes between non-sheared 
control and post-processing (*p<0.5, **p<0.01, ***p<0.001). Data shown are mean values ± 1 s.d. (j 
= 3; n = 4). 
 
% ± 1 s.d. (j = 3; n = 4) 
   % Viability 
Cell ageing 
(hrs) 
Pre-
processing  Control  Post-
processing 
0  95.3 ± 1.8  96.4 ± 0.4  95.5 ± 0.7 
24  97.0 ± 1.1  96.2 ± 3.7  95.6 ± 0.5 
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4.4.1  Physical impact as measured by LDH release 
Tables 4.3.A and 4.3.B summarize key performance data for the two sets of runs for the 
CTX0E03 cell line. The results presented in Table 4.3.A are the same as those presented 
in  Table  4.1.B  and  are  reproduced  for  convenience.  Table  4.3.B  presents  the  key 
performance data for high cell concentration. In both cases, each run, A to C and A to B 
respectively, was from a new batch of cells prepared using the same method.  
Column 2 presents the measured transmission of LDH through the membrane at the end 
of each of the 60 minutes shear runs. These are the transmission values that are used for 
calculations.  The  mean  value  for  LDH  transmission  is  lower  at  the  high  cell 
concentration (0.75 ± 0.04 compared with 0.87 ± 0.04) probably due to the lower shear 
rate over the membrane surface or due to the greater level of membrane fouling species. 
The average transmission value at high cell concentration (‘N’ = 10,000 rpm) is similar 
to  the  average  transmission  value  at  low  cell  concentration  and  low  disc  speed 
(‘N’ = 6,000 rpm) of 0.78 ± 0.03. This might be a reflection of the similarity of the 
average  shear  rates  (14,000  s-1  and  13,000  s-1  respectively,  based  on  the  viscosity 
measurements  for the HCA2 cells  at  30x106 and 2x106 cells  mL-1 of 1.64x10-3  and 
1.02x10-3 Pa s respectively). 
Column 3 examines the stability of LDH over the period of the membrane study for 
each run. For low concentration there is a small (~ 8%) but probably insignificant drop 
(p = 0.325) and there is essentially no drop for high cell concentration (~1% decrease 
with p = 0.474). Hence for both cases, the LDH levels are considered stable for the 
length of the run. 179 
 
Column 4 examines the total amount of LDH (extracellular and intracellular) measured 
- i.e. permeate plus retentate – and it is compared with total LDH at the start of the 
experiment. This helps to check whether all LDH is recovered (e.g. none is stuck to 
membrane)  and  none  is  lost  through  denaturation.  For  both  low  and  high  cell 
concentration there is a small, but not statistically significant, loss of ~5 - 6% (p = 0.321 
and p = 0.375 respectively) of LDH which might be due to entrapment in the membrane 
or may fall within experimental error.  
Finally, column 5 is a second measure of accountability for LDH comparing the total in 
the retentate and permeate to the control cells for the duration of the experiment. For 
low cell concentrations there is no loss and for high cell concentration there is a small 
but probably insignificant loss of LDH (~4% with p = 0.380). 
Overall, it can be seen from Tables 4.3.A and 4.3.B that the averages are representative 
of the runs. The average values of the repeats were used to produce Figure 4.11 to 
analyze the impact of low and high cell concentration on cell damage as measured by 
LDH release for the CTX0E03 cell line. The results in Figure 4.11 (Table B) are the 
same as those presented in Figure 4.1 (Table C). The trends in this figure show that at a 
high cell concentration, more cells are damaged than at a low concentration. However, 
the proportion of intracellular LDH remaining has decreased ~50 ± 10.5% for low cell 
concentration and ~22 ± 8.8% for high cell concentration. Unlike with the HCA2 cells, 
taking into consideration the experimental errors, the values obtained for the decrease 
for both cell concentrations do not overlap. Therefore the proportion of intact cells  
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A.                    Low cell concentration ± 1 s.e. (j = 3; n = 4) 
1. 
 
Run (‘?’) 
2. 
 
‘𝑻(?󵑭)’ 
3. 
 
‘?/?’ 
4. 
 
‘(? + ?)/?’ 
5. 
 
‘(? + ?)/?’ 
A  0.92 ± 0.03  0.82 ± 0.02  0.88 ± 0.01  1.07 ± 0.01 
B  0.88 ± 0.05  0.99 ± 0.02  1.08 ± 6.43  1.09 ± 0.00 
C  0.79 ± 0.12  0.96 ± 0.02  0.86 ± 0.01  0.89 ± 0.01 
Average  0.87 ± 0.04  0.92 ± 0.05  0.94 ± 0.07  1.02 ± 0.06 
 
B.                High cell concentration ± 1 s.e. (j = 2; n = 4) 
A  0.80 ± 0.02  1.02 ± 0.08  0.97 ± 0.05  0.95 ± 0.05 
B  0.71 ± 0.09  0.96 ± 0.02  0.94 ± 0.01  0.97 ± 0.01 
Average  0.75 ± 0.04  0.99 ± 0.03  0.95 ± 0.01  0.96 ± 0.01 
 
Table 4.3: Membrane processing of feed (‘N’ = 10,000 rpm) CTX0E03 cells – effect of (A) low and 
(B) high cell concentration on cell damage as recorded by release of LDH. To note results presented 
in Table 4.3.A are as presented in Table 4.1.B. Box diagram (C) of the USD membrane separation 
device  showing  process  streams.  From  left  to  right  columns  show;  (1)  run;  (2)  transmission 
coefficient;  (3)  ratio of  internal  LDH  in  the  control  to  the  internal  LDH  pre-processing  in  the 
retentate to evaluate stability of LDH in the cells without processing (where 1 equals to no loss in 
LDH activity); (4) ratio of the sum of the total LDH in the retentate  post-processing and permeate 
streams to the total LDH in the retentate pre-processing, to evaluate the mass balance agreement 
(where 1 equals to complete agreement, i.e. all LDH mass is accounted for); (5) ratio of the sum of 
the  total  LDH  in  the  retentate  post-processing  and  permeate  streams  to  the  total  LDH  in  the 
control,  to  evaluate  the  mass  balance  agreement  assuming  the  processed  cells  change  as  with 
control.  181 
 
   
B.  
  
LDH µU ± 1 s.d. (j = 3; n = 4) 
Cell concentration  2x106 cells mL-1 
Sample  Notation 
Measured 
total 
(‘LDH_TOT’) 
Measured 
external 
(‘LDH_EXT’) 
Predicted 
internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  12.96 ± 1.03  0.91 ± 0.37  12.05 ± 0.66 
Control  (b) ‘?(60) = [?](60) × ??’  12.06 ± 1.50  0.95 ± 0.41  11.12 ± 1.24 
Post-processing  (c)  ‘?(60) = [?](60) × ??’  4.44 ± 0.48  1.01 ± 0.40  3.43 ± 0.73 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  7.71 ± 1.16       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’  
12.15 ± 1.24  8.72 ± 1.54  3.43 ± 0.73 
Figure 4.11: Membrane processing of feed (0 hours cell ageing, ‘N’ = 10,000 rpm) CTX0E03 cells – 
effect of cell concentration on cell damage as recorded by (A) release of LDH. Tables (B) and (C) 
show mean LDH data for all streams including both external and total measurements.  To note 
results presented in Figure 4.11 (Table B) are as presented in Figure 4.1 (Table C). A non-sheared 
control held in a centrifuge tube concurrently, 21 ± 1ºC, for the duration of the experiment was 
used to measure LDH before and after processing. Figure (A) shows the proportion of intracellular 
LDH remaining (‘𝝎’, Eq 3.8), for low (~1.50 x 106 cells mL-1, ○) and high (~29.77 x 106 cells mL-
1,▲)  concentrations.  LDH  release  indicates  that  after  membrane  processing  at  higher 
concentration, less proportional damage is seen, suggesting that a higher cell concentration has a 
protective effect on cells. Data shown are mean values ± 1 s.d. (j = 3 and j = 2; n = 4).   
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 C.  Cell concentration  30x106 cells mL-1 (j = 2; n = 4) 
Sample  Notation 
Measured 
total 
(‘LDH_TOT’) 
Measured 
external 
(‘LDH_EXT’) 
Predicted 
internal 
(‘LDH_INT’) 
Pre-processing  (a) ‘?(0) = [?](0) × ??’  270.4 ± 22.9  7.2 ± 0.3  263.2 ± 23.2 
Control  (b) ‘?(60) = [?](60) × ??’  267.8 ± 16.5  5.3 ± 0.6  262.5 ± 17.1 
Post-processing  (c)  ‘?(60) = [?](60) × ??’  183.7 ± 25.2  3.6 ± 0.1  180.2 ± 25.1 
Permeate  (d) ‘ ∑ ?𝐿??(∆𝑡𝑖) 𝑖
𝑖=1 ’  57.2 ± 6.7       
Post-processing 
+ Permeate 
(c) + (d) ‘ [?](60) × ?? +
∑ ([?]𝐿??(∆𝑡𝑖) × ? × ∆𝑡𝑖) 𝑖
𝑖=1 ’  
241.0 ± 31.9  60.8 ± 6.8  180.2 ± 25.1 182 
 
remaining  in  the  USD  device  appears  to  change  with  cell  concentration  for  the 
CTX0E03 cells.  
It was previously shown for this cell line that the proportion of cells damaged appeared 
to be independent of disc speed and therefore shear rate. This observation together with 
the lower proportion of LDH lost at high cell concentration suggest that there may be a 
protective effect with increasing concentration.  
4.4.2  Physical impact as measured by trypan blue exclusion 
The plots in this section show the impact of low and high cell concentration on cell 
damage as measured by trypan blue exclusion for CTX0E03 (Figures 4.12 and 4.13) 
and  P4E6  (Figures  4.14  and  4.15)  cell  lines.  The  results  presented  low  cell 
concentration for the CTX0E03 cell line in Figures 4.12 and 4.13 are the same as those 
presented  in  Figures  4.2  and  4.3  for  high  disc  speed  (‘?’  =  10,000  rpm)  and  are 
reproduced for convenience. The results presented for low cell concentration for the 
P4E6 cell line in Figures 4.14 and 4.15 are the same as those presented in Figures 4.4 
and 4.5 for high disc speed (‘?’ = 10,000 rpm) and are reproduced for convenience. 
Figure 4.12 shows the concentration of total and viable cells for pre-processing, control 
and post-processing samples for low cell concentration (Figure 4.12.A) and high cell 
concentration (Figure 4.12.B). At low cell concentration there is a ~37% (p = 0.099) 
decrease in the population of total cells and lower decrease of ~31% (p = 0.023) at high 
cell concentration. There is also a ~47% (p = 0.061) decrease in the population of viable 
cells at low cell concentration and a lower decrease of ~36% (p = 0.043) at high cell 183 
 
concentration.  Even  though  none  of  these  decreases  is  statistically  significant,  it  is 
evident that there is a decrease for both conditions and both cell populations.  
Figure  4.13  shows  the  percentage  viability  for  pre-processing,  control  and 
post-processing samples for both cell concentrations. Analysis of this figure shows that 
low cell concentration resulted in a significant ~14% (p = 0.001) drop in percentage 
viability  post-processing  compared  to  an  insignificant  ~5%  (p  =  0.333)  drop  in 
percentage  viability  at  high  cell  concentration.  Therefore,  these  results  suggest  that 
operating  at  low  cell  concentration  resulted  in  a  generally  poorer  quality  (lower 
percentage viability) cellular suspension post-processing as measured by trypan blue 
exclusion.  
At low cell concentration there is ~50% cell loss as recorded by both LDH release and 
loss of viable cells as measured by trypan blue exclusion. This loss is probably due to a 
combination of loss of membrane integrity and total cell destruction.  
Figure  4.14  shows  the  same  plots  but  focusing  on  the  P4E6  cell  line.  At  low  cell 
concentration there is a ~39% (p = 0.099) decrease in the population of total cells and a 
decrease of ~60% (p = 1.7x10-5) at high cell concentration. There is also a significant 
decrease  in  the  population  of  viable  cells  at  both  low  and  high  cell  concentrations 
(~41% with p = 4.1x10-5 and ~75% with p = 0.001 respectively), more so at higher cell 
concentration.  
Figure  4.15  shows  the  percentage  viability  for  pre-processing,  control  and 
post-processing samples for both cell concentrations. Analysis of this figure shows that 184 
 
operating at both low and high cell concentration resulted in significant drops in the 
percentage viability. The drop at low cell concentration was small compared to that at 
high cell concentration (~3% with p = 0.005 and ~35% with p = 2.0x10-5 respectively). 
Therefore,  unlike  the  CTX0E03,  these  results  suggest  that  operating  at  high  cell 
concentration resulted in a generally poorer quality (lower percentage viability) cellular 
suspension post-processing as measured by trypan blue exclusion.   
4.5  Chapter discussion 
The USD membrane separation methods and analytical techniques developed for the 
HCA2 cell line in Chapter 3 were evaluated for a prostate carcinoma cell line (P4E6) 
and a neural stem cell line (CTX0E03). The findings for these two clinically relevant 
cell  lines  aid  in  the  characterization  of  the  physical  impact  of  USD  membrane 
separation as well as in understanding the cell line specificity of bioprocessing. The 
variables investigated were the same as those presented in Chapter 3; disc speed, cell 
age  and  cell  concentration  (viscosity).  The  assessment  of  the  impact  of  processing 
conditions on cell damage was measured by LDH release (for the CTX0E03 cell line 
only) and by trypan blue exclusion (for both cell lines). 
4.5.1  CTX0E03 discussion 
Assessment of the impact of disc speed on cell damage for the CTX0E03 cell line was 
measured  by  the  release  of  LDH  and  trypan  blue  exclusion.  LDH  release  showed 
similar trends and amounts of damage for both low and high disc speed (~50 – 60% 
damage). Trypan blue  exclusion also  revealed similar decrease in  the population  of 
viable cells for both conditions (~40 – 50% decrease). The variability for the CTX0E03    185 
 
 
Figure  4.12:  Membrane  processing  of  feed  (‘N’  =  10,000  rpm)  CTX0E03  cells  –  effect  of  cell 
concentration on cell damage shown by total and viable cell concentrations pre and post-processing 
of the cellular suspension as recorded by trypan blue exclusion. Table below shows mean of raw 
data determined by trypan blue exclusion for concentration of total and viable cells. To note results 
for low cell concentration presented in this figure are as presented in Figure 4.2 for high disc speed.  
A non-sheared control held in a centrifuge tube concurrently, 21 ± 1ºC, for the duration of the 
experiment was used to measure trypan blue pre and post-processing for both low and high cell 
concentration. Trypan blue exclusion indicates that processing at low cell concentration resulted in 
~47% reduction of viable cells compared to ~36% at high cell concentration. Significant changes 
between non-sheared control and post-processing (*p<0.5, **p<0.01, ***p<0.001). Data shown are 
mean values ± 1 s.d. (j = 3 and j = 2; n = 4). 
 
Concentration (x106 cells mL-1) ± 1 s.d.  
(j = 3 and j = 2; n = 4) 
   Total cells (‘TB_TOT’) 
Concentration  Pre-
processing  Control  Post-
processing 
Low  1.64 ± 0.10  1.80 ± 0.21  1.14 ± 0.24 
High  32.7 ± 2.4  35.9 ± 0.2  24.7 ± 2.4 
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Viable cells (‘TB_VC’) 
Concentration  Pre-
processing  Control  Post-
processing 
Low  1.50 ± 0.06  1.67 ± 0.21  0.88 ± 0.20 
High  29.8 ± 2.2  33.0 ± 0.6  21.1 ± 3.6 
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Figure  4.13:  Membrane  processing  of  feed  (‘N’  =  10,000  rpm)  CTX0E03  cells  –  effect  of  cell 
concentration  on  percentage  viability  of  cellular  suspension  as  determined  by  trypan  blue 
exclusion.  The  figure  shows  percentage  viability  before  and  after  membrane  processing  as 
determined by trypan blue exclusion. Table below shows mean of raw data determined by trypan 
blue exclusion for percentage viability. To note results for low cell concentration presented in this 
figure are as presented in Figure 4.3 for high disc speed. Trypan blue exclusion indicates that at low 
cell  concentration  there  is  a  significant  drop  in  percentage  viability  of  ~14%  (p  =  0.001)  after 
membrane processing compared to a non-significant drop of ~5% (p = 0.333) after processing at a 
higher cell concentration. Data shown are mean values ± 1 s.d. (j = 3 and j = 2; n = 4). 
   % ± 1 s.d. (j = 3 and j = 2; n = 4) 
   % Viability 
Concentration  Pre-
processing  Control  Post-
processing 
Low  92.6 ± 1.1  92.2 ± 0.5  78.4 ± 0.4 
High  91.0 ± 0.04  91.6 ± 2.8  86.5 ± 5.0 
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Figure  4.14:  Membrane  processing  of  feed  (‘N’  =  10,000  rpm)  P4E6  cells  –  effect  of  cell 
concentration on cell damage shown by total and viable cell concentrations pre and post-processing 
of the cellular suspension as recorded by trypan blue exclusion. Table below shows mean of raw 
data determined by trypan blue exclusion for concentration of total and viable cells. To note results 
for low cell concentration presented in this figure are as presented in Figure 4.4 for high disc speed.  
A non-sheared control held in a centrifuge tube concurrently, 21 ± 1ºC, for the duration of the 
experiment was used to measure trypan blue pre and post-processing for both low and high cell 
concentration. Trypan blue exclusion indicates that processing at low cell concentration resulted in 
a significant ~41% (p = 4.1x10-5) reduction of viable cells compared to ~75% (p = 0.001) at high cell 
concentration.  Significant  changes  between  non-sheared  control  and  post-processing  (*p<0.5, 
**p<0.01, ***p<0.001). Data shown are mean values ± 1 s.d. (j = 3; n = 4). 
 
Concentration (x106 cells mL-1) ± 1 s.d.  
(j = 3; n = 4) 
   Total cells (‘TB_TOT’) 
Concentration  Pre-processing  Control  Post-processing 
Low  2.39 ± 0.18  2.62 ± 0.13  1.60 ± 0.05 
High  37.8 ± 1.7  41.1 ± 2.0  16.6 ± 0.2 
 
 
Viable cells (‘TB_VC’) 
Concentration  Pre-processing  Control  Post-processing 
Low  2.35 ± 0.12  2.51 ± 0.11  1.49 ± 0.06 
High  36.6 ± 1.7  40.4 ± 1.8  10.0 ± 0.0 
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Figure  4.15:  Membrane  processing  of  feed  (‘N’  =  10,000  rpm)  P4E6  cells  –  effect  of  cell 
concentration  on  percentage  viability  of  cellular  suspension  as  determined  by  trypan  blue 
exclusion.  The  figure  shows  percentage  viability  before  and  after  membrane  processing  as 
determined by trypan blue exclusion. Table below shows mean of raw data determined by trypan 
blue exclusion for percentage viability. To note results for low cell concentration presented in this 
figure are as presented in Figure 4.5 for high disc speed. Trypan blue exclusion indicates that at low 
cell concentration there is a small but significant drop in percentage viability of ~3% (p = 0.008) 
after membrane processing compared to a significant drop of ~35% (p = 2.0x10-5) after processing 
at  a  higher  cell  concentration.  Significant  changes  between  non-sheared  control  and  post-
processing (*p<0.5, **p<0.01, ***p<0.001). Data shown are mean values ± 1 s.d. (j = 3; n = 4). 
   % ± 1 s.d. (j = 3; n = 4) 
   % Viability 
Concentration  Pre-
processing  Control  Post-
processing 
Low  96.4 ± 0.6  96.0 ± 0.5  93.0 ± 0.6 
High  97.0 ± 0.3  95.8 ± 0.3  60.6 ± 0.2 
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cell line appears to be higher than for the HCA2 cell line. The temperamental nature of 
neural stem cells means that the slightest change in cell culture conditions or handling 
of the cells whilst harvesting, may have a more pronounced impact on cell quality than 
the same change for HCA2 fibroblasts. This combined with the fact that three repeats 
were carried out rather than five, potentially increase the error measured. Nevertheless, 
it is evident from the collected data that cell damage caused to CTX0E03 cells is mainly 
dependent on the experience of being exposed to shear forces and the time of exposure and 
less so by the magnitude of the shear forces as both disc speed conditions exhibited the 
same proportion of intact cells lost during processing. Acosta-Martinez (2011) reached a 
similar conclusion after exposing the same cell line to several passes through a capillary 
device. He observed that the cells were mainly affected by the experience of being 
exposed to the elongational stress event and less so by the magnitude of the stress.  
Like with the disc speed results, both fresh CTX0E03 cells and cells aged for 24 hours 
prior  to  processing  exhibited  equivalent  cell  damage  profiles  as  measured  by  LDH 
release (~50 – 60% damage). Once again, the experience of being exposed to shear and 
time of exposure appear to impact more on cell damage than the variable investigated. 
Delahaye (2013) reported the same observation when investigating pre-centrifugation 
hold times of 5 and 120 minutes for the same cell line. He observed equivalent loss 
profiles  independent  of  pre-process  hold  time.  However,  trypan  blue  exclusion  dye 
indicated a higher loss of viable cells for the sample aged for 24 hours (~60% decrease 
which agrees with the value reported from the LDH release) than for the fresh sample 
(~40% decrease). It also recorded a drop in the percentage viability of ~20% for fresh 
cells and cells aged for 24 hours. 190 
 
Lastly,  the  effect  low  and  high  cell  concentration  was  investigated  (~1.5x106  and 
~30x106 cells mL-1 respectively). Unlike with the HCA2 cells, LDH release indicated 
that at high cell concentration the proportion of CTX0E03 cells damage was less than at 
low cell concentration (~20% compared to ~50% respectively). Trypan blue exclusion 
reinforces the observation that operating at low cell concentration resulted in higher loss 
of  intact  cells  (~35%  compared  to  ~50%)  as  well  as  generally  a  poorer  quality  of 
cellular  material  post-processing  in  terms  of  percentage  viability  (~14%  decrease 
compared to ~5%). 
4.5.2  P4E6 discussion 
Cell damage for the three processing variables for the P4E6 cell line was assessed using 
only trypan blue exclusion. Results suggest that for low and high disc speed, these cells 
behave in a similar manner to HCA2 cells in terms of loss of viable cells. Like with the 
HCA2 fibroblasts, more cell damage was observed at high disc speed than at low disc 
speed  (~40%  compared  to  ~20%).  However,  the  two  cell  lines  differ  in  that  P4E6 
showed low drop in percentage viability for both disc speeds. 
With respect to fresh P4E6 cells versus cells aged for 24 hours, there was no drop in 
percentage viability due to processing. Therefore, trypan blue exclusion data indicated 
that regardless of pre-process hold time for the P4E6 cell line, the overall quality of the 
cellular  population  after  processing  was  unchanged.  However,  two  other  important 
observations must be made. First, there is a ~15% decrease in the population of viable 
cells merely from holding for 24 hours. Second, there is a higher decrease in the viable 
cell population during processing when using fresh cells compared to cells aged for 24 191 
 
hours  (~20%  compared  to  ~5%).  Therefore,  overall  the  extent  of  damage  for  both 
conditions (including the ageing step) is the same (~20%). It may be that there is a 
weaker population of cells that is eradicated prior to processing by holding the cells for 
24  hours.  However,  this  is  not  enough  information  to  form  an  informed  final 
conclusion. 
Lastly, low and high cell concentration was investigated at ~2x106 and ~35x106 cells 
mL-1 for the P4E6 cell line. Opposite to the observations drawn with the CTX0E03 cell 
line, P4E6 cells showed a higher decrease of the population of viable cells at high cell 
concentration than at low cell concentration (~75% compared to ~40%). Moreover, high 
cell concentration resulted in high drop of percentage viability when compared to low 
cell  concentration  (~35%  compared  to  ~3%).  Therefore  unlike  CTX0E03  cells, 
operating  at  high  cell  concentration  when  using  P4E6  cells  resulted  in  generally  a 
poorer quality of the cellular suspension (in terms of percentage viability). 
Overall, this chapter investigated the susceptibility of cell lines to choice of operating 
conditions. It was shown that different cell lines possess different thresholds leading to 
varying amounts of cell damage, making bioprocessing cell line specific. Where disc speed 
and cell age generally varied in the amount of cell damage recorded depending on the cell 
line investigated, remarkable findings were observed with respect to the impact of cell 
concentration. These findings led to the desire to gain more understanding of the effect 
of cell concentration within a 100-fold increment by assessment of cell damage and 
rheological insights, all which will be tackled in the next chapter. 
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Chapter 5.  Effect of cell concentration on loss of intact cells 
during processing 
5.1  Introduction 
In the previous chapters, the impact of processing at low and high cell concentrations on 
cell damage was investigated using three different cell lines. When a cell therapy dose is 
thawed  at  clinic  for  administration,  it  is  expected  to  have  a  minimum  set  of 
requirements, including a final concentration between 10x106 and 100x106 cells mL-1
 
with a specified number of viable cells (Brandenberger et al. 2011; Pattasseril et al. 
2013). However, when cells are harvested upstream, the initial cell concentrations are 
generally  around  1-2x106  cells  mL-1.  Therefore,  the  cellular  suspension  must  be 
concentrated  by  100-fold  to  achieve  adequate  dose  for  administration  which  will 
inevitably have an effect on the properties of the fluid.  
This chapter aims to understand the effect of cell concentration on cell damage in more 
depth by investigating a range of concentrations of viable (i.e. intact) cells fed to the 
USD membrane separation device using the HCA2 fibroblasts. 
5.2  Loss of intact cells with increasing discrete intact cells fed 
The effect of discrete concentration of intact cells fed (referred to as ‘[?]??’) to the USD 
membrane separation device on cell damage using the HCA2 cell line was assessed by 
the release of LDH and trypan blue exclusion. Three repeats each consisting of six 
different concentrations ranging from ~1x106 to ~100x106 cells mL-1 were carried out 
on different occasions. For each of the three repeats, enough cells were prepared for the 
six  different  concentrations.  The  operating  conditions  were  kept  the  same  as  those 193 
 
presented in Chapters 3 and 4 for the cell concentration studies (i.e. ‘Q’ = 0.5 mL min-1, 
‘VR’ = 1.7 mL, ‘N’ = 10,000 rpm, fresh cells, 60 minutes of processing and varying 
shear rates and shear stress according to viscosity of the cellular suspension).  
Tables 5.1 and 5.2 show the trypan blue exclusion data for the three repeats (labelled 1 
to 3) at each of the six concentrations investigated (listed in decreasing order of cell 
concentration from A to F in column 1). Table 5.1 shows the concentrations of total 
cells pre-processing (i.e. fed), control and post-processing (i.e. recovered) respectively 
in columns 2, 3 and 4 or ‘[?]𝑇?𝑇?(0)’, ‘[?]𝑇?𝑇?(60)’ and ‘[?]𝑇?𝑇?(60)’. Intact cell 
concentrations for the three streams are shown in columns 5, 6 and 7 and referred to as 
‘[?]??𝑇?(0)’, ‘[?]??𝑇?(60)’ and  ‘[?]??𝑇?(60)’  respectively. Column  8 in  Table  5.1 
shows the volume fractions given by: 
∅ = ‘[?]𝑇?𝑇?(0)’ × (
4
3𝜋(
𝑑?𝑉
2 )
3
)      Equation 5.1 
where ‘∅’ is the volume fraction, ‘𝑑?𝑉’ is the average diameter of a cell in suspension 
(assumed to be 15 µm for the HCA2 cell line). Assuming cells to be perfect spheres, the 
range of volume fractions varied from 0.002 to 0.210.  
Table  5.2  shows  the  percentage  viabilities  for  the  pre-processing,  control  and 
post-processing  samples  as  measured  by  trypan  blue  exclusion.  The  percentage 
viabilities of HCA2 cells upon harvest tend to lie within 90 and 95%. However, this was 
not  the  case  for  the  second  repeat,  where  the  percentage  viabilities  for  both 
pre-processing and control samples for experiments 2.A to 2.D, lied between 85 and 
90%. Nevertheless, despite the lower percentage viabilities prior to processing, the  194 
 
   Concentration (x106 cells mL-1) 
   Total cells  Viable cells 
1. 
Run  
2. 
Pre-
processing 
3. 
 
Control 
4. 
Post-
processing 
5. 
Pre-
processing 
6. 
 
Control 
7. 
Post-
processing 
8. 
Volume 
fraction 
[?]𝑇?𝑇?(0)  [?]𝑇?𝑇?(60)  [?]𝑇?𝑇?(60)  [?]??𝑇?(0)  [?]??𝑇?(0) [?]??𝑇?(60)  Ø 
1.A  118.91  123.76  123.05  111.29  117.57  110.55  0.210 
1.B  42.71  37.93  31.36  39.28  35.05  27.91  0.075 
1.C  21.39  18.69  13.78  19.79  17.45  11.20  0.038 
1.D  8.23  7.91  8.70  7.71  7.14  7.38  0.015 
1.E  2.13  1.93  2.20  1.99  1.77  1.99  0.004 
1.F  1.29  1.31  1.12  1.19  1.17  0.96  0.002 
2.A  114.40  104.93  56.52  104.49  95.19  35.21  0.202 
2.B  55.12  56.49  49.16  49.80  50.61  43.45  0.097 
2.C  18.01  14.39  15.98  16.15  12.92  14.19  0.032 
2.D  4.93  3.93  3.87  4.31  3.46  3.27  0.009 
2.E  2.32  2.52  1.80  2.06  2.22  1.46  0.004 
2.F  1.35  1.41  1.05  1.17  1.24  0.79  0.002 
3.A  77.46  76.56  80.73  74.14  72.58  75.03  0.137 
3.B  42.42  40.17  46.82  40.09  37.78  44.12  0.075 
3.C  11.08  11.74  10.13  10.36  10.98  8.85  0.020 
3.D  5.25  3.82  4.52  4.79  3.53  4.09  0.009 
3.E  2.48  2.18  2.51  2.30  2.02  2.27  0.004 
3.F  1.09  1.01  0.89  1.01  0.95  0.77  0.002 
   
 
Table  5.1:  Concentration of  total  and  intact (i.e.  viable)  cells  pre-processing,  control  and  post-
processing  (i.e.  recovered)  as  measured  by  trypan  blue  exclusion  and  analyzed  by  automated 
haemocytometer (ViCell XRTM) software. Three repeats, each of the six starting concentrations 
were carried out (‘Q’ = 0.5 mL min-1, ‘VR’ = 1.7 mL, ‘N’ = 10,000 rpm, fresh cells, 60 minutes). 
Volume  fraction  (Ø)  based  on  the  concentration  of  total  cells  fed  (‘[?]𝑻?𝑻?(?)’)  to  the  USD 
membrane device. Some over-counts are evident post-processing due to incorrect cell identification 
by the software as shown in Figure 5.1. 
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      % 
      % Viability 
 1. 
Run    
2. 
Pre-
processing 
3. 
 
Control 
4. 
Post-
processing 
1.A  90.13  94.60  84.33 
1.B  92.23  91.13  89.25 
1.C  94.10  91.15  84.80 
1.D  92.47  92.77  81.15 
1.E  92.87  92.78  88.75 
1.F  93.93  94.73  90.60 
2.A  85.83  88.40  78.15 
2.B  89.63  88.85  79.50 
2.C  88.60  88.10  86.35 
2.D  89.75  89.80  88.80 
2.E  91.00  89.90  88.65 
2.F  91.50  90.45  62.20 
3.A  91.80  94.45  87.13 
3.B  92.47  92.20  89.60 
3.C  92.90  92.03  90.95 
3.D  94.35  94.55  89.60 
3.E  95.20  94.03  95.55 
3.F  95.73  95.93  93.33 
 
Table 5.2: Percentage viability of cells pre-processing, control and post-processing as measured by 
trypan blue exclusion for the three repeats at each of the six starting concentrations as shown in 
Table 5.1 (‘Q’ = 0.5 mL min-1, ‘VR’ = 1.7 mL, ‘N’ = 10,000 rpm, 0 hours cell ageing, 60 minutes).  
Pre-processing and control percentage viabilities for the second repeat, runs A to D, are lower than 
expected for HCA2 cells upon harvest. Moreover, the drop in percentage viability pre-processing to 
post-processing for run 2.F is considerably higher than all other runs at approximately 30%. It is 
presumed that an error in cell preparation must have led the second repeat to a poorer quality of 
cells as a starting point for the experiments.  
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change due to processing itself remained the same as for the other repeats. The only 
exception  was  experiment  2.F,  where  the  pre-processing  and  control  percentage 
viabilities  appear  to  be  within  the  expected  values  (90  to  95%)  but  the  drop  post-
processing was ~30% (significantly higher than any other experiment). This may be due 
to the cells been exposed to the detachment enzyme for a prolonged time during the 
harvesting of the cellular suspension, compromising the quality of the harvested cells. 
Going forward with the analysis in this chapter, all experiments from this repeat will be 
considered but carefully inspected to assess whether or not they should be classified as 
an outlier. 
Figure 5.1 shows an image obtained from the automated haemocytometer for the post-
processed  sample  from  experiment  3.A  (‘[?]??𝑇?(0)’=  77.46x106 cells  mL-1).  This 
image was included to exemplify the method of cell identification used by the software 
provided with the automated haemocytometer. As can be seen, the software identifies 
“viable” (or “intact”) and “non-viable” (or “dead”) cells by placing green and red circles 
respectively. Figures 5.1.A and 5.1.B show the same image analyzed by the software 
using  two  different  settings;  “medium”  and  “none”  declustering  modes.  The 
“declustering” option intends to help in optimization of different cell types to account 
for “sticky cells” and cells in clusters. From the images in Figure 5.1, it is evident that 
when dealing with  elongated cells rather than spherical ones, counts per image can 
halve depending on the setting use (130 in  Figure  5.1.A compared to  67 in  Figure 
5.1.B).  For  example,  with  the  “medium”  declustering  option,  one  elongated  cell  is 
counted as multiple smaller round cells whereas with “none” declustering that same cell 
is counted as one big round cell. This explains why some of the experiments (1.D, 1.E, 197 
 
3.A,  3.B,  3.D  and  3.E)  shown  in  Table  5.1  showed  higher  concentration  of  cells 
post-processing  than  initially  fed  to  the  device.  The  same  problem  was  previously 
encountered  in  Chapter  3,  Section  3.3.4  Cell  morphology,  growth  and  apoptosis 
analysis. In Section 3.3.4, it was identified that the software provided by manufacturer 
of the automated haemocytometer did not have the capabilities to recognize new cell 
populations  and  therefore  could  not  account  for  the  increase  in  the  population  of 
elongated and “blebby” cells post-processing. To over-come this issue, a Matlab script 
for image processing was kindly developed by Nicolas Jaccard and used to re-analyze 
the images provided by the automated haemocytometer. Further analysis and results on 
the  morphology  of  cells  using  the  Matlab  script  will  be  shown  in  Section  5.3  Cell 
morphology analysis.  
To assess the impact on cell damage, the concentration of intact cells fed as measured 
by  trypan  blue  exclusion  using  the  software  from  the  automated  haemocytometer 
(‘[?]𝑇?𝑇?𝑉?????(0)’) is shown in Figure 5.2. ‘[?]𝑇?𝑇?𝑉?????(0)’ was plotted against three 
measurements of intact cells recovered as measured by; (A) trypan blue exclusion using 
automated  haemocytometer  software,  ‘[?]??𝑇?𝑉?????(60)’;  (B)  trypan  blue  exclusion 
using Matlab script, ‘[?]??𝑇???𝑇???(60)’ and (C) LDH release, ‘[?]𝐿????𝑇(60)∗’. A 
common x-axis of ‘[?]??𝑇?𝑉?????(0)’ was chosen to compare all three measurements as 
no issues were encountered with cell counting for the pre-processed samples. Due to the 
large range of concentrations investigated, log scales were used for the x-axis of the 
three plots.  
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Figure 5.1: Software analysis from the automated haemocytometer using (A) “medium” and (B) 
“none”  declustering  modes  for  the  same  image  for  run  3.A  for  the  HCA2  cellular  suspension 
post-processing (‘[?]𝑻?𝑻?????𝑳𝑳(?)’= 77.46x106 cells mL-1, ‘N’ = 10,000 rpm). The software places a 
green  circle  on  “viable”  (or  “intact”)  cells  and  a  red  circle  on  “non-viable”  (or  “dead”)  cells. 
“Medium” declustering mode identified almost twice the number of cells as “none” declustering 
mode.  
   
A.  
“Medium” declustering 
B.  
“None” declustering 
Same cells with different 
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The  concentration  of  intact  cells  recovered  as  measured  by  LDH  release, 
‘[?]𝐿????𝑇(60)∗’, was based on the concentration of internal LDH calculated pre and 
post-processing: 
[?]𝐿????𝑇(60)∗ =  [?]??𝑇?𝑉?????(0) ×
[?]??HINT(60)
[?]??HINT(0)     Equation 5.2 
where ‘[?]𝐿????𝑇(60)∗’ is the concentration of intact cells recovered (in cells mL-1) as  
measured by LDH release, ‘[?]??𝑇?𝑉?????(0)’ is the concentration of intact cells fed (in 
cells  mL-1)  as  measured by trypan blue exclusion using  automated haemocytometer 
software, ‘[?]?????𝑇(60)’ and ‘[?]?????𝑇(0)’ are the predicted concentrations of internal 
LDH  (in  µU  mL-1)  post-processing  (i.e.  in  the  retentate  at  ‘t  =  60  min’)  and  pre-
processing (i.e. in the retentate at ‘t = 0 min’) respectively. The predicted concentration 
of internal LDH is at any given time ‘t’ is given by: 
[?]𝐿????𝑇(𝑡) = [?]𝐿??𝑇?𝑇(𝑡) − [?]𝐿???𝑋𝑇(𝑡)    Equation 5.3 
where ‘[?]???𝑇?𝑇(𝑡)’ and ‘[?]?????𝑇(𝑡)’ are the measured concentrations of total and 
extracellular LDH (in µU mL-1) in the retentate at ‘t’ respectively. 
From the three plots in Figure 5.2, it can be seen that as the concentration of intact cells 
fed into the USD membrane separation device increases, the concentration of cells lost 
during operation also increases. However, also with increasing concentration of intact 
cells fed, a higher concentration of intact cells post-processing is recovered. Those data 
points lying on the parity line (shown as dashed line) indicate that the concentration of 
intact cells recovered is equal to the concentration of intact cells fed. For example, the 
line of best fit for the experimental data in Figure 5.2.A (cell counts carried out using 200 
 
the software provided by the automated haemocytometer) shows a closer fit to the parity 
line than Figures 5.2.B and 5.2.C. However, as was previously mentioned, over-counts 
post-processing were observed in several occasions using this software for analysis. 
Therefore, Figures 5.2.B and 5.2.C (trypan blue exclusion as analyzed by Matlab script 
and LDH release respectively) are the two measurements with the most confidence and 
also appear to have similar coefficients for the lines of best fit for the experimental data. 
The coefficients from these plots suggest that as the concentration of intact cells fed 
increases,  the difference between the intact  cells  recovered and intact  cells  fed will 
increase.  By  inspection  of  the  equations  of  the  lines  of  best  fit  within  range  of 
concentrations  studied,  both  Matlab  analysis  and  LDH  release  expect  20%  higher 
recovery of intact cells at low cell concentration (starting at 60% and 80% respectively). 
This observation suggests that the proportion of intact cells recovered to intact cells fed 
should decrease with increasing concentration.  
Figure 5.3 shows the proportion of ‘[?]??(60)’ to ‘[?]??𝑇?𝑉?????(0)’ for (A) automated 
haemocytometer (ViCell XRTM), (B) Matlab script and (C) LDH release. From all three 
plots,  it  appears  as  if  the  proportion  of  ‘[?]??(60)’  to  ‘[?]??𝑇?𝑉?????(0)’  remained 
constant and was independent of ‘[?]??𝑇?𝑉?????(0)’. The data points that fall outside the 
upper  and  lower  standard  deviation  from  the  average  value  in  Figure  5.3,  were 
considered  as  outliers.  Most  of  these  are  the  runs  from  the  2nd  repeat  with  low 
percentage  viabilities  pre-processing  previously  identified.  As  was  mentioned,  these 
outliers may be due to differences in cell preparation leading to weaker cells at harvest, 
which is reflected in the initial percentage viabilities on Table 5.2. The average  201 
 
 
Figure 5.2: Concentration of intact cells recovered versus concentration of intact cells fed into the 
USD membrane separation device. Analyzed by (A) automated haemocytometer software (ViCell 
XR™) and (B) Matlab script and (C) LDH release. Lines of best fit for all data points as one series 
are  shown.  As  ‘[?]??𝑻?????𝑳𝑳(?)’  increases,  the  concentration  of  cells  lost  during  operation  also 
increases (j = 3; n = 4).   202 
 
 
Figure 5.3: Intact cells fed versus intact cells recovered over intact cells fed. Trypan blue exclusion 
data analyzed by (A) automated haemocytometer software (ViCell XR™), (B) Matlab software and 
(C) LDH release. Proportion of cells recovered over cells fed appears to be independent of the 
changes in cell concentration (and therefore viscosity). Dashed lines show ± 1 s.d. (j = 3; n = 4); 
outliers may be due to change in cell preparation leading to weaker cells.   203 
 
proportion of ‘[?]??(60)’ to ‘[?]??𝑇?𝑉?????(0)’ was 0.85 ± 0.15 for ViCell XMTR, 0.77 
± 0.13 for the Matlab script and 0.60 ± 0.17 for LDH release (Figure 5.3). Due to the 
over-estimation post-processing seen with the ViCell XMTR software, Matlab script is 
the analysis with most confidence out of the two trypan blue exclusion plots.  
Several hypotheses were proposed as to why this proportion appears to be constant. 
Using CFD analysis, it was shown that there is a specific region of high shear, by the 
edges of the rotating disc, in the device. As the concentration of cells fed increases, the 
concentration of cells in this region or volume of high shear also increases, potentially 
leading to higher number of cells damaged. Another possibility to explain the constant 
proportion  of  cells  lost  with  varying  concentration  is  that  there  may  be  an  age 
distribution of the cell population at harvest. If the proportion of older (or younger) cells 
are constant per flask harvested and were the ones most affected by shear, then this 
would  explain  a  constant  proportion  of  cells  being  damaged  independent  of 
concentration. This weaker population of cells within the cellular suspension may not be 
able to withstand the operating conditions due to different elasticity and mechanical 
properties, metabolic needs and in general physiological needs which are characteristic 
of different stages in the cell cycle. 
5.2.1  Average rate of cell damage constants 
Based on the previous findings, cell damage can be described as a first order process 
with respect to the concentration of cells present and the rate constant can be said to be 
unchanged with change in viscosity of the suspension. The average rate constant for the 204 
 
60 minutes of operation for a first order process with respect to the concentration of 
cells present is given by: 
𝑑[?]??(60)
𝑑[?]??𝑉?????(0) = ?[?]??(60)    Equation 5.4 
where ‘k’ is the average rate of cell damage over 60 minutes of operation (h-1). Using 
equation 5.4, the average rate of damage was calculated for all three repeats and each of 
the six concentrations investigated (Table 5.3). Cell damage assessed on LDH release 
showed the fastest average rate constant of 0.29 ± 0.14 h-1 compared to 0.14 ± 0.08 h-1 
for cell damage based on loss of membrane integrity as analyzed using Matlab script. 
The average rate of damage calculated for LDH release is almost twice as fast as the 
one calculated for the Matlab data. This is consistent with prior observations in Chapter 
3, section 3.3.3 where the average rate constants for both low and high disc speeds as 
measured  by  LDH  released  were  twice  as  fast  as  that  measured  by  trypan  blue 
exclusion.  
5.2.2  Cell morphology analysis 
Even though analysis of cell morphology can be a more subjective parameter than for 
example cell population growth rates, it may offer an inexpensive and interesting insight 
into the physical behaviour and appearance of individual cells at an early stage.  
In Section 3.3.4.1 Cell morphology analysis in Chapter 3, examples for each of the cell 
types identified by the Matlab script for image processing were shown (Figure 3.6.D). 
Morphological characteristics such as aspect ratio and intensity were used as building 
blocks to define the different cell types. These included five main types or populations:  205 
 
     
[?]𝐓?_𝐕𝐈?𝐄𝐋𝐋(?) 
(cells mL-1) 
k 
 (h-1) 
 Repeat    
 
LDH  Matlab 
1 
A  1.11E+08  -0.31  -0.08 
B  3.93E+07  -0.42  -0.23 
C  1.98E+07  -0.58  -0.28 
D  7.71E+06  -0.43  -0.12 
E  1.99E+06  -0.15  -0.02 
F  1.19E+06  -0.33  -0.06 
Average  -0.37  -0.13 
        
2 
A  1.04E+08  -0.79  -0.59 
B  4.98E+07  -0.27  -0.17 
C  1.62E+07  -0.16  -0.06 
D  4.31E+06  -0.29  -0.17 
E  2.06E+06  -0.30  -0.17 
F  1.17E+06  -0.38  -0.18 
Average  -0.36  -0.22 
        
3 
A  7.41E+07  -0.15  -0.06 
B  4.01E+07  -0.14  -0.03 
C  1.04E+07  -0.08  -0.17 
D  4.79E+06  -0.09  -0.08 
E  2.30E+06  -0.12  -0.03 
F  1.01E+06  -0.17  -0.08 
Average  -0.12  -0.08 
          Average  -0.29  -0.14 
±  0.14  0.08 
 
Table  5.3:  Average  rate  of  cell  damage  for  the  three  repeats  investigated  at  each  of  the  six 
concentrations of intact cells fed. Measurements include constants for LDH release and trypan blue 
exclusion analyzed using Matlab script. 
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short elongated (SE), long elongated (LE), viable round (VR), non-viable (NV) and 
debris (DEBRIS). In Chapter 3, it was shown that for low and high disc speeds and low 
cell  concentration,  appearance  of  elongated  and  ‘blebby’  cells  was  observed 
immediately  post-processing.  In  this  section,  the  study  of  cell  morphology  aims  to 
provide  a  basic  breakdown  of  cell  appearance  in  suspension  to  draw  a  preliminary 
comparison of the pre-processed to post-processed samples for all cell concentrations. 
Figure 5.4 shows the plots of the proportions for each of the cell populations compared 
to  the  total  cells  for  both  pre  and  post-processing  samples.  This  figure  presents  an 
average of repeats 1 and 3, experiments A to F. The experiments carried out for the 2nd 
repeat were not included in Figure 5.4 due to the elevated proportions of dead cells 
pre-processing (previously addressed and identified as outliers). For all the experiments 
carried  out,  the  pre-processing  samples  follow  a  similar  profile  with  respect  to  the 
proportions  of  each  cell  type.  For  instance,  irrespective  of  concentration,  the  pre-
processing proportion of SE falls within 8-12%, LE between 2-5%, VR between 75-
85% and NV between 5-12%. However, with the post-processing samples, different 
population profiles and ranges for each cell type arise. For example, levels of SE and 
LE appear to be higher post-processing for high concentration experiments (A to C).  
Figure 5.5 summarizes the changes in proportions of each cell population for all six 
concentrations.  It  shows  the  ratio  of  the  proportion  of  each  cell  population  post-
processing to pre-processing. The values below 1 therefore indicate a higher proportion 
of  that  specific  population  prior  to  processing,  whereas  values  over  1  indicate  an 
increase in the proportion of that population due to processing. The main observation  207 
 
 
Figure  5.4: Examples of cell types identified by software for image processing developed using 
Matlab Image Processing Toolbox (MathWorks, Cambridge, UK). Software kindly developed by 
Nicolas Jaccard in the Biochemical Engineering Department at UCL. Plots A to F show decreasing 
concentration  of  intact  cells  fed  to  the  USD  membrane  separation  device.  The  cell  categories 
correspond  to  libraries  created  for  the  Matlab  script.  The  proportion  of  each  cell  type  or 
population was compared to the total cells in the sample for pre-processing (■) and immediately 
post-processing (■) (j = 2; n = 4). 208 
 
 
Figure 5.5: Ratio of the proportions of each cell population post-processing to pre-processing to 
assess the change in cell populations with varying concentrations. Runs A to F represent the six cell 
concentrations studied, where A is the highest cell concentration and F is the lowest one. Values 
below 1 represent a decrease in the proportion of a specific population post-processing and values 
above  1  represent  an  increase.  For  example,  at  the  highest  concentration  investigated,  A,  the 
proportion of SE cells doubles from pre to post-processing and quintupled for LE. 
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from this plot is once again that there is an increase in the population of SE and LE cells 
at the highest cell concentrations. 
5.3  Investigating the effect of viscosity on loss of intact cells 
Preliminary studies were carried out to investigate the effect of viscosity on the loss of 
intact cells. A change in viscosity was achieved by one of two methods; an increase in 
concentration of the cellular suspension or by the addition of dextran to a low cell 
concentration  suspension.  Three  repeats  (‘ ? ’ = 10,000  rpm,  ‘ 𝑡 ’  =  60  min, 
‘ ? ’ = 0.5 mL min-1)  consisting  each  of  three  experiments  (i.e.  one  at  low  cell 
concentration, one at high cell concentration and one at low cell concentration with 
added dextran) were carried out in this section.  
The concentrations of total and viable (intact) cells as well as the percentage viability 
for the three repeats for pre-processing, post-processing and control samples are shown 
in Table 5.4 for all three conditions. The first condition (labelled ‘1’) was performed at 
low cell concentration without the addition of dextran; the second condition (labelled 
‘2’) was performed at high cell concentration without the addition of dextran and the 
third condition (labelled ‘3’) was carried out at low cell concentration with the addition 
of dextran adjusted to match the viscosity of run 2. Runs 2 and 3 should therefore have 
comparable viscosities (hence shear stress values) whereas runs 1 and 3 should have 
comparable initial cell concentrations. All conditions had a non-sheared control held at 
21 ± 1°C for the duration of the experiment to monitor cell quality. The addition of 
dextran did not lead to loss of intact cells or percentage viability as measured by the 
control  (Table  5.4).  It  also  shows  the  measured  viscosity  at  the  highest  shear  rate 210 
 
(760 s-1) for the control samples for each experiment. This was used to measure the 
averaged and maximum shear rates from the plots in Section 1.5.1. From the measured 
viscosity profiles (shown in Section 5.3.1) it is clear that after about a shear rate of 
300 s-1, the viscosity of the cellular suspension remains  unchanged.  The shear  rates 
experienced inside the device are significantly higher than 300 s-1 and therefore it was 
assumed  that  the  viscosity  of  the  cellular  suspension  inside  the  USD  membrane 
separation device would be comparable to that of the control at shear rate 760 s-1.  
Figure 5.6 shows the proportion of intact cells recovered to the proportion of intact cells 
fed for the three conditions studied as measured by (A) trypan blue exclusion data and 
(B) LDH release. Over-counts post-processing measured by the trypan blue exclusion 
data are evident from Figure 5.6.A, with values higher than 1 for the proportion of cells 
recovered  to  cells  fed.  Therefore  no  evident  trend  can  be  withdrawn  from  this 
information. However, the LDH release measurements (Figure 5.6.B) for the proportion 
of intact cells recovered to intact cells fed do provide some information. The low and 
high cell concentration  experiments  without added dextran  yield  a comparable loss, 
whereas the cellular suspension with added dextran yields a slightly lower proportion of 
recovered cells (~45% loss compared to ~35%). It appears that processing at the same 
concentration but higher shear stress leads to more damage observed, indicating that 
shear stress possibly is the cause of damage. However, these are preliminary results and 
more studies need to be carried out to reach a certain conclusion. 
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Total cells mL-1 
(‘[𝐑]𝐓?𝐕𝐈?𝐄𝐋𝐋(?)’) 
Intact cells mL-1 
(‘[?]??????𝑳𝑳(?)’) 
% 
Viability 
Viscosity 
(mPa s) 
Maximum 
shear rate* 
(s-1) 
Maximum 
shear stress* 
(Pa) 
1st  
1  2.29E+06  2.15E+06  93.89  1.02  116,000  116 
2  3.79E+07  3.58E+07  94.46  1.99  88,000  176 
3  3.28E+06  3.22E+06  98.17  1.96  88,000  176 
2nd 
1  2.45E+06  2.39E+06  97.75  1.27  98,000  147 
2  6.54E+07  6.18E+07  94.42  2.66  79,000  237 
3  2.71E+06  2.68E+06  99.01  2.93  79,000  237 
3rd 
1  3.00E+06  2.87E+06  95.67  1.29  98,000  147 
2  4.84E+07  4.48E+07  92.57  2.03  88,000  176 
3  2.72E+06  2.56E+06  94.12  2.51  84,000  210 
 
Table  5.4:  Three  repeats  each  consisting  of  three  scenarios  investigated,  labelled  1  to  3, 
(‘?’ = 10,000 rpm, ‘??’ = 60 min, ‘?’ = 0.5 mL min-1). Table shows the concentration of total and 
viable  (intact)  cells  fed  (‘[?]𝑻?????𝑳𝑳(?)’  and  ‘[?]??????𝑳𝑳(?)’),  percentage  viability,  measured 
viscosity to the nearest half mPa s and maximum shear rate and shear stress obtained from CFD 
simulation plots (Figure 1.5) using viscosity value rounded to the nearest half. For each repeat, the 
scenarios investigated were (1) low concentration without added dextran; (2) high concentration 
without added dextran and (3) low concentration with added dextran to match the viscosity of 
experiment  2.  The  viscosities  shown  are  those  of the control  samples  at  the  highest  shear  rate 
(760 s -1) as measured by the rheometer (j = 3; n = 4). 
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Figure 5.6: Intact cells recovered (‘[?]??(??)’) over intact cells fed (‘[?]??????𝑳𝑳(?)’) for (A) trypan 
blue exclusion as analyzed by ViCell XR™ and Matlab software and (B) as measured by LDH 
release for the three conditions as shown in Table 5.4. An average of the three repeats for each 
condition is shown. Due to over-counts for the trypan blue exclusion data there is no evident trend. 
However, the LDH release data suggests a comparable loss of ~35% for both low and high cell 
concentration without the addition of dextran and a  ~45% loss for low cell concentration with 
added dextran. Error bars show ± 1 s.d. (j = 3; n = 4).   
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5.3.1  Rheological observations 
Figure 5.7 shows the rheological characteristics of the cellular suspensions measured for 
the  2nd  repeat  for  each  of  the  three  conditions  investigated.  For  all  three  repeats, 
rheological profiles of the cell suspension (like the ones shown in Figure  5.7) were 
measured.  For  the  purpose  of  analysis,  only  the  2nd  repeat  is  shown  given  that  the 
observations are the same for the 1st and 3rd repeat with the only difference being, the 
values measured for the apparent viscosity. 
Figure  5.7.A  shows  the  non-sheared  control  and  Figure  5.7.B  shows  the  viscosity 
measurements  for  the  cellular  suspension  post-processing.  For  all  conditions  the 
apparent viscosity was measured using a single up and down shear sweep, ranging from 
19  s-1  to  760  s-1.  For  both  control  and  post-processed  samples,  conditions  1  and  2 
exhibit a pseudoplastic behavior. This means that with increasing shear rate there is a 
clear decrease in the apparent viscosity, which is a characteristic of a shear thinning 
suspension. Condition 3 (also for both control and post-processing samples), behaves 
more like a Newtonian fluid possibly due to the addition of dextran.  
Comparing the apparent viscosities measured for the control samples (Figure 5.7.A) to 
the  post-processing  samples  (Figure  5.7.B),  it  can  be  seen  that  both  low  cell 
concentration  conditions  (1  and  3)  exhibit  no  change  in  the  values  of  apparent 
viscosities measured. However, the high cell concentration sample (condition 2) does 
appear  to  have  higher  apparent  viscosities  throughout  the  range  of  shear  rates 
investigated  for  the  control  sample  compared  to  the  post-processing  sample.  The 
decrease in viscosity from the control to the post-processed sample at high cell  214 
 
 
Figure 5.7: Apparent viscosity of HCA2 cell line for (A) control and (B) post-processing samples 
using a single up and down shear sweep as measured over a range of shear rates in a cone and plate 
rheometer  for  the  2nd  repeat.  Condition  1  (shown  in  green)  has  a  low  cell  concentration  of 
2.39x106 cells mL-1 and no added dextran; condition 2 (shown in red) has a high cell concentration 
of  65.4x106  cells  mL-1  with  no  added  dextran  and  condition  3  (shown  in  blue)  has  a  low  cell 
concentration of 2.71x106 cells mL-1 and added dextran to match the viscosity of condition 2. Inset 
box: cone angular velocity (shear rate) was first stepped up (1, ▲) and then down (2, ×).      
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concentration could be explained by the lysis of cells leaving less number of intact cells 
in the USD membrane separation chamber. Release of nucleic acid material typically 
leads to an increase in viscosity. However, because of the constant washing of the cells 
with hCGM in the chamber, it may be that as cells are broken, the nucleic material is 
being washed out of the chamber leading to a decrease in viscosity with time as the 
number of cells remaining decreases. 
The profiles for all three conditions and both samples (control and post-processing) do 
have one characteristic in common. As the shear rate increases (300 s-1 or more), the 
apparent viscosity becomes fairly constant. Therefore, it was assumed that the apparent 
viscosity of the cellular suspension inside the USD membrane device during processing 
is equivalent to the apparent viscosity measured at 760 s-1 of the control samples for 
each condition.  
5.4  Chapter discussion 
As  part  of  the  manufacturing  of  cell-based  products,  a  concentration  step  of  up  to 
100-fold  may  be  necessary  whilst  maintaining  CQAs.  Such  a  large  concentration 
change will inevitably lead to changes in the properties of the fluid which will impact 
the hydrodynamic conditions experienced during processing.  
This chapter investigated the effect of cell concentration ranging from 1x106 to 100x106 
cells mL-1 using the HCA2 fibroblasts. At a constant disc speed of 10,000 rpm and  
assuming a viscosity equal to that of water (~1 mPa s) for the lowest concentration 
(~1x106 cells mL-1) investigated, the maximum shear rate experienced by the cellular 216 
 
suspension is 116,000 s-1 (shear stress of 116 Pa). On the other hand, the lowest shear 
stress  must  happen  whilst  operating  at  the  same  disc  speed  at  the  highest  cell 
concentration  (~100x106  cells  mL-1).  The  viscosity  of  this  cell  suspension  was  not 
measured due to the amount of material needed for the analysis. However, assuming a 
viscosity  of  at  least  that  measured  for  a  cellular  suspension  of  65.4x106  cells  mL-1 
(~2.66 mPa s, reported in section 5.3.1) the maximum shear rate experienced in the 
USD membrane separation device is 79,000 s-1 (shear stress of 237 Pa). Despite the 
change in the extent of shear forces, the proportion of cells recovered post-processing 
was independent of initial starting cell concentration as measured by LDH release and 
trypan blue exclusion analyzed by both ViCell XRTM and Matlab  (~0.60, ~0.85 and 
~0.77 respectively).  This  means  that cell damage may be described as a first  order 
process with respect to concentration of cells present in the USD membrane separation 
device. Moreover, it also indicates that the first order rate constant is unchanged with 
the change in viscosity of the suspension. The change in extent of shear stress is not as 
significant as the change in extent of shear rate indicating that cell damage may be more 
dependent on shear stress. However, the total cells damaged increased with increasing 
initial starting cell concentration.  
Preliminary  analysis  on  other  CQAs  such  as  average  rate  of  cell  damage,  cell 
morphology and rheological properties of the cellular suspensions were investigated in 
this chapter. The average rates of cell damage indicated that cell damage as measured 
by LDH release happens almost twice as fast as the one calculated for the Matlab data, 
suggesting  that  LDH  may  be  a  more  sensitive  analytical  technique.  Following, 
morphological  analysis  of  the  cell  population  pre  and  post-processing  revealed  an 217 
 
increase in the proportions of short and long elongated due to processing. This increase 
was found to be more evident at the three highest cell concentrations investigated. For 
instance,  the  highest  cell  concentration  investigated  shows  5  times  as  many  long 
elongated cells post-processing than pre-processing. The gathered information is not 
sufficient to establish why the appearance of elongated cells is higher with increasing 
concentration. Lastly, an initial glance at the effect of viscosity on loss of intact cells 
and  the  rheological  properties  were  carried  out.  Dextran  was  added  to  the  cellular 
suspensions  to  mimic  the  viscosity  increase  measured  by  the  increase  in  cell 
concentration.  It appears that processing at the same concentration but higher shear 
stress leads to more damage observed (~45% loss compared to ~35%), indicating that 
shear stress possibly is the cause of damage although a larger sample and more testing 
would be required in order to draw firm conclusions.  
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Chapter 6.  Final words and future work 
6.1  Final words 
This study was undertaken with the aim of characterizing the response of human cell 
lines to membrane-based processing using an ultra scale-down tool that required only 
small amounts of cellular material. This response was measured by assessing both the 
nature and the extent of the physical and, in some cases, biological changes induced 
within the cell populations as a response to the processing environment. Each chapter 
discussion summarized the key findings specific to that section. With these final words, 
the aim is to provide a more generic picture on the findings, what these convey and their 
relevance to the cell therapy bioprocessing industry.    
6.1.1  Cell line comparison 
Three human cell lines used for therapies were tested for cell damage using a combination 
of techniques developed in this thesis. A human fibroblast cell line, a neural stem cell line 
and a prostate cancer cell line. It appears that further studies to evaluate susceptibility to 
processing  and the effect  of  process  change  will be  needed,  especially  for  the  prostate 
cancer cell line which was only assessed for cell damage using trypan blue exclusion.  Yet, 
findings  suggest  that  the  most  robust  cell  lines  to  processing  damage  were  fibroblasts 
followed by prostate carcinoma and neural stem cells with respectively ~0%, ~18% and 
~42% damage at the lowest shear stress (~44 Pa) conditions. For cells aged for 24 hours 
prior to processing, trypan blue exclusion findings also suggest the same order of resistance 
to cell damage with ~2%, ~21% and ~57% damage for fibroblasts, prostate cancer and 
neural stem cells. Table 6.1 summarizes all this information and more on the cell damage 
figures presented in this study for the two main analytical techniques; (i) LDH release and 219 
 
(ii) trypan blue exclusion. It helps to underline the importance of cell line selection at an 
early stage in the development of the processing strategy. 
6.1.2  Kinetics of damage 
The LDH release data curves give a sense of the kinetics of damage for the different 
operating  conditions  and  cell  lines.  Due  to  the  number  of  assumptions  and  the 
complexity of the calculations to account for transmission, modelling of the kinetics of 
damage is not ideal. However, the data curves do give a sense of the kinetics of damage. 
For  the  HCA2  fibroblasts,  the  data  appears  to  show  a  combination  of  first  order 
expressions (i.e. rate of damage is proportional to the variable investigated). Probably 
two fairly evident ones, with a weaker population of cells to start with (faster damage) 
and a more robust remaining cell population. If processing was prolonged, the second 
population may continue to be progressively damaged until there are no cells left in the 
USD membrane separation device. However, this is not a straightforward and certain 
observation  to  test  due to  the number of complications  that this  implies. Prolonged 
processing time may cause cell damage by the introduction of other complications such 
as cell ageing whilst processing or change in the processing medium properties due to 
release of intracellular components.  High cell concentration LDH release curve for the 
HCA2 cells is the only curve for this cell line that exhibits a slightly different damage 
profile. It appears to indicate a zero order process (i.e. the rate of damage is constant). 
However, it may well be that high cell concentration also obeys a series of first order 
equations and the slope observed over the 60 minutes of operation is only the beginning 
of the cell damage curve at high cell concentration (i.e. the population of weaker cells 
that are damage begin with). 220 
 
What was also evident from the kinetics of damage investigation was that LDH release 
appears to be more sensitive to changes in cell damage  than trypan blue exclusion. 
Previous  studies  conducted  by  Lappalainen  et  al.  (1994)  also  observed  differences 
between the sensitivity of these two techniques. They concluded that LDH release is a 
more  sensitive  indicator  of  earlier  damage  to  the  cell  membrane  than  trypan  blue 
exclusion,  which  stains  only  dead  cells.  Diederichs  et  al.  (1979)  investigated  the 
mechanism of release of LDH from isolated skeletal muscle and concluded that cell 
swelling, which is typical of necrotic cells, prior to membrane damage was connected 
with an increased LDH permeability suggesting that LDH can potentially be released 
prior  to  membrane  lesions  and  therefore  can  serve  as  an  indication  of  earlier 
cytotoxicity. 
6.1.3  Relevance of this research to the cell therapy field 
The recovery of human cells for therapy generally has several particular objectives e.g.: 
(i)  the processing of the cells without any alteration of cell functionality. 
(ii) the removal of soluble growth media components, mainly macromolecular. 
(iii) the preparation of suspensions of high cell concentration (especially for tissue 
therapy or for reduced volume administration). 
(iv)   the avoidance of any contamination of the cells. 
These objectives are achieved with skill at bench scale using dead-end centrifugation in 
test tube batches. Here several repeat centrifugation stages might be required to remove 
sufficient soluble components but provided the cells are suspended with care then loss 
of  functionality  can  be  avoided  and  high  concentrations  achieved.  However,  while 221 
 
carrying this out at small scale with skilled operators allows aseptic recovery to be 
achieved, translation to large scale (e.g. 10s of litres) is very challenging.  
The  translation  to  continuous  centrifugation  has  been  attempted  but  is  so  far  not 
successful due to lack of suitable devices. The use of low-stress feed zones and low-
stress discharge mechanisms is feasible but design of small-scale machines to achieve 
this will probably require very expensive engineering. One challenge will be the scale 
of translation from dead end to continuous centrifugation and while some success has 
been achieved, e.g. with mammalian cell recovery, there is a long way to go for cells for 
therapy. 
The development of counter-flow centrifugation (kSep®, from KBI Biopharma Inc.) is 
potentially  ground  breaking.  Here  viable  cells  are  recovered  and  very  effective  cell 
washing takes place in situ. Good concentration is achieved provided the suspension 
remains  flowable.  The  use  of  single  use  equipment  allows  sterile  operation  to  be 
achieved.  
Understanding  the  tolerance  of  cells  in  a  manufacturing  process  can  have  a  major 
impact  on  the  feasibility.  Hence,  adopting  new  and  ground  breaking  manufacturing 
technology for cell therapies can have disadvantages in terms of cost of development, 
regulatory precedent and easily accessible pools of industrial expertise. However, in 
many cases,  already existing technologies prove to be unsuitable and inefficient for 
these types of therapies leading to lengthy and costly manufacturing processes.  
The way forward  explored in  this  thesis  is  the use of cross flow membranes.  Here 
several challenges are posed: 222 
 
(a) the ability to flow cells repeatedly in a recycle loop (via pump, valve, membrane 
etc.) with no damage or change of cell functionality.  
(b) the use of open membrane pores which remain un-fouled which allows soluble 
components to transmit through the membrane easily i.e. to avoid excessive use 
of diafiltration buffer. Here the flow rate needs to remain high which might 
contradict need to achieve (a). 
(c) the  use  of  cascades  of  membrane  sizes  to  achieve  high  levels  of  cell 
concentration without unacceptable loss of suspension in hold up/ recycle loops. 
The USD device used in this study goes some way to allowing these challenges to be 
addressed while still only having a limited number of cells available. Future work will 
require the device to be so designed such that the maximum stress at the tip of the 
rotating disc matches that experienced by cells in a pumped loop. At the same time the 
average  stress  over  the  membrane  surface  must  match  that  for  commercial  scale 
membrane separators. Finally the use of syringe feeding of cells to go from low to high 
concentration must be matched with concentration effects at full scale. It is not likely 
that all of these functions can be mimicked at the same time but the relatively small 
scale of the device will allow multiple experiments to determine critical regimes of 
operation at full scale. 
The USD device used in this study also goes some way in investigating another major 
challenge; cell line selection. The response to processing stress varied significantly with 
choice of cell line and of processing conditions as was previously discussed. Selection 
of the most robust candidates at an early stage by thorough characterization can help 
minimize the cost of development and manufacturing. Moreover, understanding and 223 
 
quantifying the impact of process changes on cell quality at an early stage will allow 
validating a design space for the manufacturing scenario in order to incorporate changes 
without the need to go through validation again.  
6.2  Future work 
This study has formed the basis of a generic characterization of the susceptibility of cell 
lines to processing conditions which may apply during full-scale processing. A number 
of interesting potential avenues of research have arisen due to the wide scope of the unit 
operation. Three main developments could serve as a basis for future research projects. 
Firstly,  the  impact  of  processing  at  increasing  cell  concentrations  was  investigated. 
However, it may be important to establish how continuous concentration of cells into 
the USD membrane separation device rather than discrete analysis compares in terms of 
cell  damage.  With  continuous  concentration,  the  rheological  considerations  become 
ever more complicated as the viscosity increases with cells fed but potentially decreases 
if  cells  are  damaged  and  intracellular  components  are  constantly  washed  away. 
Understanding the impact of constant concentration may lead to important decisions on 
how membrane separation should be operated (fed-batch or continuous modes). 
Secondly, processing in this study was carried out in CGM which is potentially, in 
terms of avoiding cell damage, a relatively good buffer for the cells to be processed in. 
Central to membrane separation is the buffer exchange step and processing the cellular 
suspension in a buffer suitable for storage or administration. The buffer exchange step 
would focus mainly on the removal of contaminants from upstream whereas processing 
in  a  suitable  buffer  for  administration  or  delivery  would  focus  mainly  on  CQAs. 224 
 
Forming both an operational and cost based window of operation of would not only 
increase process knowledge but also would aid in cost estimation. 
Thirdly, the USD tool used in this study has been developed for the characterization of the 
response of human cell lines to membrane-based processing, using just small quantities of 
cells commonly available at the early discovery stage. A direct comparison to larger scale 
TFF systems would be paramount to the development of the tool in order to perform 
experiments more relevant to full-scale processing. 
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HCA2 cell line  Analytical technique to assess cell damage 
Processing condition  LDH release  Trypan blue 
Disc speed 
(rpm) 
6,000  ~8%  ~0% 
10,000  ~30%  ~25% 
Cell ageing 
(hours) 
0 (fresh)  ~8%  ~0% 
24  ~15%  ~2% 
Cell concentration 
(cells mL-1) 
2x106  ~26%  ~25% 
50x106  ~19%  ~8% 
CTX0E03 cell line  Analytical technique to assess cell damage 
Processing condition  LDH release  Trypan blue 
Disc speed 
(rpm) 
6,000  ~50-60%  ~42% 
10,000  ~50-60%  ~47% 
Cell ageing 
(hours) 
0 (fresh)  ~50-60%  ~42% 
24  ~50-60%  ~57% 
Cell concentration 
(cells mL-1) 
2x106  ~50-60%  ~47% 
50x106  ~20%  ~36% 
P4E6 cell line  Analytical technique to assess cell damage 
Processing condition  LDH release  Trypan blue 
Disc speed 
(rpm) 
6,000 
N/A 
~18% 
10,000  ~41% 
Cell ageing 
(hours) 
0 (fresh)  ~18% 
24  ~21% 
Cell concentration 
(cells mL-1) 
2x106  ~41% 
50x106  ~75% 
 
 
Table 6.1: Brief overview of the findings observed within the two main analytical techniques used 
to assess cell damage as measured by decrease of intact cells conducted within this study.    226 
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